Erforschung des hypertrophen Potentials von Oncostatin M auf Ratten-Herzzellen und die Charakterisierung der Rezeptorkomplexe, welche von Ratten-Oncostatin M genutzt werden by Drechsler, Johannes
 
 
Determination of the hypertrophic potential of Oncostatin M 
on rat cardiac cells and the characterisation of the receptor 
complexes utilised by rat Oncostatin M 
 
Erforschung des hypertrophen Potentials von Oncostatin M auf Ratten-
Herzzellen und die Charakterisierung der Rezeptorkomplexe, welche von 
Ratten-Oncostatin M genutzt werden 
 
Doctoral thesis for a doctoral degree 
at the Graduate School of Life Sciences, 
Julius-Maximilians-Universität Würzburg, 
Section Biomedicine 
 
submitted by  
Johannes Drechsler 
 
from 
Würzburg 
 
Würzburg, September 2012 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Submitted on: 11th September 2012 
 
Members of the Promotionskomitee: 
 
Chairperson: Prof. Dr. Thomas Müller 
 
Primary Supervisor: PD Dr. Heike Hermanns 
 
Supervisor (Second): Prof. Dr. Stefan Engelhardt 
 
Supervisor (Third): Prof. Dr. Manfred Lutz 
 
Date of Public Defence: …………………………………………….………… 
 
Date of receipt of Certificates: ………………………………………………. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For my parents 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A man who dares to waste one hour of life has not discovered 
the value of life. – Charles R. Darwin 
 
 
 
 
 
 
 
 
 
 
 
  
   
Table of Contents 
Table of Contents 
 
Table of Contents .................................................................................................................................. 7 
Index of Abbreviations ........................................................................................................................ 11 
1 Introduction ....................................................................................................................................... 14 
1.1 The IL-6-type cytokine family and their appending receptor complexes ..................................... 14 
1.2 Receptor and cross-species specificity of OSM and LIF ............................................................. 17 
1.3 Cell-type specific expression of IL-6 family receptors and trans-signalling ................................. 18 
1.4 IL-6-type cytokine induced signalling pathways .......................................................................... 19 
1.4.1 Activation of the JAK/STAT pathway .................................................................................... 20 
1.4.2 Activation of the MAPK cascade .......................................................................................... 25 
1.4.3 Activation of the PI3K cascade ............................................................................................. 26 
1.4.4 Termination of IL-6-type cytokine induced signalling pathways ........................................... 26 
1.5 The role of IL-6-type cytokines in cardiac remodelling and hypertrophy ..................................... 28 
1.6 C/EBP beta and delta: IL-6 inducing/induced transcription factors ............................................. 32 
1.7 Aims of the study ......................................................................................................................... 34 
2 Materials ............................................................................................................................................ 35 
2.1 Antibodies .................................................................................................................................... 35 
2.1.1 Antibodies for immune fluorescence .................................................................................... 35 
2.1.2 Primary and secondary antibodies for flow cytometry .......................................................... 35 
2.1.3 Antibodies for Western blotting............................................................................................. 36 
2.2 Recombinant cytokines, receptors and other ligands ................................................................. 38 
2.3 Small interfering RNAs (siRNAs) ................................................................................................. 38 
2.4 Plasmids for cloning and generation of stably transfected cells.................................................. 39 
2.5 Oligonucleotide primers for semi quantitative RT-PCR ............................................................... 39 
2.6 Oligonucleotide primers for quantitative real time RT-PCR ........................................................ 40 
2.7 Oligonucleotide primers for cloning rgp130, rOSMR and rLIFR .................................................. 41 
2.8 Sequencing primers ..................................................................................................................... 42 
2.9 Reaction kits ................................................................................................................................ 42 
2.10 Restriction enzymes .................................................................................................................. 43 
2.11 Enzymes .................................................................................................................................... 43 
2.12 Protein and DNA ladder ............................................................................................................. 44 
2.13 Eukaryotic cells .......................................................................................................................... 44 
2.14 E. coli strain for cloning ............................................................................................................. 45 
2.15 Chemicals .................................................................................................................................. 45 
Table of Contents 
2.16 Buffers, solutions and prepared culture media .......................................................................... 47 
2.17 Consumables ............................................................................................................................. 52 
2.18 Laboratory equipment (technical instruments, machines and robotic systems) ....................... 52 
3 Methods ............................................................................................................................................. 55 
3.1 Cell-biological Methods ............................................................................................................... 55 
3.1.1 Cultivation of eukaryotic cell lines ........................................................................................ 55 
3.1.2 Freezing and thawing eukaryotic cells ................................................................................. 55 
3.1.3 Isolation and culture of NRCM and NRCFB ......................................................................... 56 
3.2 Microscopic techniques to determine NRCM cell size ................................................................ 58 
3.2.1 Immune fluorescence staining on NRCM ............................................................................. 58 
3.2.2 Automated measurement of NRCM hypertrophy (hypertrophy assay): High content 
screening (HCS) ............................................................................................................................ 58 
3.3 Molecular biological methods ...................................................................................................... 59 
3.3.1 Proliferation assay using Ba/F3 cells and the WST-1 Cell Proliferation Assay Kit .............. 59 
3.3.2 Rat IL-6 ELISA using the Rat IL-6 Quantikine ELISA Kit ..................................................... 60 
3.3.3 Reverse transcription of rgp130, rOSMR and rLIFR for subsequent cloning ....................... 60 
3.3.4 PCR amplification of long cDNA products (rgp130, rOSMR and rLIFR) .............................. 60 
3.3.5 Horizontal Agarose Gel Electrophoresis (DNA electrophoresis) .......................................... 61 
3.3.6 Purification of separated DNA fragments from agarose gels ............................................... 62 
3.3.7 Digestion of DNA using restriction enzymes ........................................................................ 62 
3.3.8 Ligation of inserts and vector with T4 DNA Ligase .............................................................. 62 
3.3.9 Transformation of ligated vectors into XL10-Gold ................................................................ 63 
3.3.10 Plasmid purification using the QIAGEN Plasmid Mini Kit ................................................... 63 
3.3.11 Plasmid purification using the QIAGEN Plasmid Maxi Kit .................................................. 64 
3.3.12 DNA sequencing ................................................................................................................. 64 
3.3.13 Stable transfection of murine Ba/F3 cells ........................................................................... 64 
3.3.14 Semiquantitative RT-PCR using the QIAGEN OneStep RT-PCR Kit ................................ 65 
3.3.15 Semiquantitative RT-PCR using the Verso 1-Step RT-PCR Kit ......................................... 66 
3.3.16 Quantitative real time RT-PCR (qPCR) .............................................................................. 66 
3.3.17 Cell stimulation and lysis .................................................................................................... 67 
3.3.18 SDS-PAGE (Sodium dodecyl sulfate polyacrylamide gel electrophoresis) ........................ 68 
3.3.19 Semi-dry Western blot ........................................................................................................ 69 
3.3.20 Small interfering RNA (siRNA) transfection ........................................................................ 70 
4 Results ............................................................................................................................................... 71 
4.1 Analysis of IL-6-type cytokine induced hypertrophy .................................................................... 71 
4.1.1 Hypertrophy assay of IL-6-type cytokine treated NRCM ...................................................... 72 
4.1.2 IL-6-type cytokines induce changes of the sarcomeric assembly ........................................ 73 
4.1.3 Time dependent analysis of IL-6-type cytokine induced signalling in NRCM ...................... 74 
4.1.4 Receptor preference of hOSM and mOSM on NRCM ......................................................... 75 
Table of Contents 
4.1.5 Comparison of the IL-6-type cytokine mediated signalling pathways .................................. 77 
4.1.6 Expression of IL-6-type cytokine family receptors on NRCM ............................................... 78 
4.1.7 IL-6R expression levels and IL-6 signalling in rat hepatoma cells – a comparison of IL-6-
non-responsive cells ...................................................................................................................... 80 
4.1.8 IL-6-type cytokines partially induce enhanced transcription of their own cytokine as well as 
receptor genes prolonging their hypertrophic potential and cytoprotection .................................. 82 
4.1.9 The hypertrophic potential of hIL-6/sIL-6R and mOSM seems to be supported by the lower 
induction of feedback inhibition when compared to LIF ................................................................ 84 
4.2 Analysis of IL-6-type cytokine induced signalling in cardiac fibroblasts: Expression of 
hypertrophy supporting targets .......................................................................................................... 86 
4.2.1 Receptor availability and resulting consequences for hOSM and mOSM signalling in 
NRCFB .......................................................................................................................................... 87 
4.2.2 LIF, OSM and IL-6 mediated signalling on NRCFB ............................................................. 88 
4.2.3 Cytokine and cytokine receptor expression by NRCFB in response to OSM and IL-6 trans-
signalling ........................................................................................................................................ 89 
4.2.4 IL-6 and OSM perform cross-talk with the renin-angiotensin system in NRCFB ................. 92 
4.3 Comparison of long time stimulation with hOSM and hIL-6 in NRCM and NRCFB: IL-6 induces 
prolonged C/EBP beta, C/EBP delta, IL-6 expression and signal transduction in NRCFB ............... 93 
4.3.1 The short time kinetics of IL-6 and mOSM in NRCM and NRCFB are similar ..................... 93 
4.3.2 hIL-6/sIL-6R treatment causes prolonged signalling in NRCFB, but not in NRCM .............. 95 
4.3.3 The IL-6 driven induction of the CCAAT/enhancer binding proteins (C/EBP) might be 
responsible for the strong induction of IL-6 and prolonged signalling in NRCFB .......................... 96 
4.4 A comparison of hOSM, mOSM and the recently cloned rOSM: Signalling pathway induction 
and receptor usage ............................................................................................................................ 98 
4.4.1 Rat OSM induces the typical OSM mediated signalling pathways....................................... 99 
4.4.2 Rat OSM is able to initiate cell signalling in rat, human and murine cells .......................... 100 
4.4.3 Rat OSM signals via the LIFR/gp130 (type I) and the OSMR/gp130 (type II) receptor 
complex on rat cells ..................................................................................................................... 101 
4.4.4 Rat OSM on murine cells: Higher preference for the type II OSMR receptor .................... 104 
4.4.5 Rat OSM utilises the type I receptor complex on human cells ........................................... 106 
4.4.6 Confirmation of the rat OSM receptor usage on human cells using stably transfected Ba/F3-
hOSMR/hgp130 cells ................................................................................................................... 108 
4.4.7 Confirmation of the finding that rOSM signals through the rat type I and the rat type II 
receptor complex using stably transfected Ba/F3 cells ............................................................... 109 
5 Discussion....................................................................................................................................... 113 
5.1 Classification of the hypertrophic potential of IL-6-type cytokines ............................................ 113 
5.1.1 Hypertrophic potential of oncostatin M in relation to different heart relevant IL-6-type 
cytokines ...................................................................................................................................... 114 
5.1.2 The analysis of IL-6-type cytokine target genes in NRCM suggests a potential autocrine 
amplification loop ......................................................................................................................... 119 
Table of Contents 
5.1.3 The response of NRCFB to IL-6-type cytokines: a contribution to hypertrophy ................. 121 
5.1.4 Kinetics of IL-6/sIL-6R and mOSM regulated gene expression differs substantially in 
NRCFB ........................................................................................................................................ 125 
5.2 Characterisation of the rat OSM receptor complex ................................................................... 128 
5.2.1 Only rat OSM signals through the rat LIFR/gp130 (type I) and the rat OSMR/gp130 (type II) 
receptor complex ......................................................................................................................... 129 
5.2.2 Rat OSM predominantly signals via the type II receptor complex on murine cells and via the 
type I receptor complex on human cells ...................................................................................... 131 
5.2.3 Possible reasons for the human OSM-like receptor usage by rat OSM ............................ 132 
5.2.4 Consequences of the use of non-human-like OSM model organisms ............................... 134 
6 Future Prospects ............................................................................................................................ 137 
6.1 Analysis of the hypertrophic potential of rat OSM ..................................................................... 137 
6.2 Analysing the influence of AT1α and ACE induction ................................................................. 138 
6.3 Validating the hypertrophic potential of IL-6 in vivo ................................................................... 139 
6.4 Determining the roles of C/EBPs during hypertrophy ............................................................... 140 
6.5 Cloning of a human- and rat-like murine OSM .......................................................................... 141 
7 Summary ......................................................................................................................................... 143 
8 Zusammenfassung ......................................................................................................................... 146 
9 References ...................................................................................................................................... 149 
Acknowledgements ........................................................................................................................... 167 
Danksagungen ................................................................................................................................... 169 
Publications ........................................................................................ Fehler! Textmarke nicht definiert. 
Curriculum Vitae ................................................................................. Fehler! Textmarke nicht definiert. 
Affidavit ............................................................................................... Fehler! Textmarke nicht definiert. 
Eidesstattliche Erklärung .................................................................. Fehler! Textmarke nicht definiert. 
 
 
 
 
Index of Abbreviations 
Index of Abbreviations 
 
A   Absorbance 
ADP   Adenosine diphosphate 
Akt   Protein kinase B (PKB) 
AmpR   Ampicillin resistance 
Approx.  Approximately 
APS   Ammonium persulfate 
ATP   Adenosine triphosphate 
BSA   Bovine serum albumin 
°C   Degree Celsius 
CBM   Cytokine binding module 
CD   Cluster of differentiation 
C/EBP  CCAAT/enhancer binding protein 
CIS   Cytokine inducible SH2 domain containing protein 
CLC   Cardiotrophin-like cytokine 
cm   Centimetre 
CNTF   Ciliary neurotrophic factor 
CT-1   Cardiotrophin-1 
DAPI   4´,6-Diamidino-2-phenylindole 
DMEM  Dulbecco’s Modified Eagle Medium 
DMSO  Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
dNTP   Deoxyribonucleotide triphosphate 
E. coli   Escherichia coli 
ECL   Enhanced chemiluminescence 
EDTA   Ethylenediaminetetraacetic acid 
ELISA   Enzyme linked immunosorbent assay 
ERK   Extracellular signal regulated kinase 
FDU   FastDigest unit 
FCS   Fetal calf serum (also called fetal bovine serum, FBS) 
FERM   Four-point-one protein, ezrin, radixin and moesin 
for   Forward 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GDP   Guanosine diphosphate 
gp   Glycoprotein 
GTP   Guanosine triphosphate 
h   Hour 
h*   Human 
Hepes  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPRT   Hypoxanthine phosphoribosyl-transferase 
HRP   Horseradish peroxidase 
Index of Abbreviations 
HygR   Hygromycin resistance 
IFN   Interferon 
Ig   Immunoglobulin 
IL   Interleukin 
JAK   Janus kinase 
JH   Janus homology domain 
kDa   Kilodalton 
KIR   Kinase inhibitory region 
l   Litre 
LB   Lysogeny broth 
LIF   Leukaemia inhibitory factor 
LPS   Lipopolysaccharide 
M   Molar 
m*   Murine 
MAPK   Mitogen-activated protein kinase 
MAP2K  Mitogen-activated protein kinase kinase 
MAP3K  Mitogen-activated protein kinase kinase kinase 
MEK/MKK  MAP/ERK kinase 
mg   Milligram 
µg   Microgram 
min   Minute 
ml   Millilitre 
µl   Microlitre 
mM   Millimolar 
µM   Micromolar 
mm   Millimetre 
µm   Micrometre 
MMP   Matrix metalloproteinase 
mRNA  Messenger ribonucleic acid 
NeoR   Neomycin resistance 
nM   Nanomolar 
nm   Nanometre 
NRCM  Neonatal rat cardiomyocytes 
NRCFB  Neonatal rat cardiofibroblasts 
OSM   Oncostatin M 
P   Cell passage number 
PAA   Polyacrylamide 
PAGE   Polyacrylamide gel electrophoresis 
PAMP   Pathogen associated molecular pattern 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PE   Phenylephrine 
PIAS   Protein inhibitor of activated STATs 
PKC   Proteinkinase C 
PMSF   Phenylmethylsulfonyl fluoride 
Index of Abbreviations 
pY   Phospho-tyrosine 
R   Receptor 
r*   Rat 
rcf   Relative centrifugal force 
rev   Reverse 
rpm   Revolutions per minute 
RT   Room temperature 
RT-PCR  Reverse transcription PCR 
SDS   Sodium dodecyl sulfate 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sec   Second 
SEM   Standard error of mean 
SH   Src homology domain 
Shc   SH2 and collagen homology domain containing protein 
SHP   SH2 domain containing tyrosine phosphatase 
siRNA   Small interferring RNA 
SOCS   Suppressor of cytokine signalling 
SOS   Son of sevenless 
STAT   Signal transducer and activator of transcription 
TEMED  Tetramethylethylenediamine 
TF   Transcription factor 
TNF   Tumor necrosis factors 
Tris   Tris(hydroxymethyl)aminomethane 
U   Unit 
UV   Ultraviolet 
 
* Letter in front of a gene, mRNA, oligonucleotide or protein defining the species. 
 
 
Introduction 
 
14 
1 Introduction 
1.1 The IL-6-type cytokine family and their appending receptor 
complexes 
 
The family of interleukin-6 (IL-6)-type cytokines represents a group of pleiotropic 
cytokines which share a similar four α-helix bundle architecture1. At present nine 
members of the family are known: IL-6 itself, IL-11, leukaemia inhibitory factor (LIF), 
oncostatin M (OSM), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), 
cardiotrophin-like cytokine (CLC), IL-27 (consisting of p28 and EBI-3) and 
neuropoietin (NP)1-4. In addition to the comparable structure of these polypeptides, 
organised in a bundle consisting of four helices linked with flexible loops, they share 
the common property to bind to glycoprotein 130 (gp130) serving as receptor subunit. 
IL-6-type cytokines play important roles in inflammation and the acute phase 
response5-10. However, they also contribute to various biological processes including 
cardiovascular remodelling, neuronal differentiation, haematopoiesis, cell 
differentiation and proliferation11. Recently IL-35, that consists of p35 and EBI-3, was 
found to bind to gp130-IL-12Rβ2 receptor complexes12. Therefore, the cytokine fulfils 
the criteria to be added to the family of IL-6-type cytokines.  
 
 
Figure 1: The IL-6-type cytokine family and its receptor complexes 
IL-6-type cytokines signal via gp130 homo- or heterodimers. IL-6 and IL-11 use IL-6R/gp130 and IL-
11R/gp130 receptor complexes, respectively, for their signalling. Structural data propose hexameric 
complexes for these two cytokines bound to their receptors. IL-27 utilises a gp130/WSX-1 heterodimer 
for signalling. IL-35 signals via binding of gp130/IL-12Rβ2 complexes. LIF, CT-1, CNTF, NP, CLC and 
OSM signal through gp130/LIFR-heterodimers. The CNTFR (α-receptor for CNTF, NP and CLC) is a 
non-signalling receptor chain lacking intracellular domains. Human OSM can additionally bind to 
gp130/OSMR receptor complexes. The OSMR connects the IL-6-type cytokine family to the closely 
related cytokine IL-31, that signals through OSMR/IL-31R heterodimeric receptor complexes.  
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Due to the heterodimeric organisation of the cytokines, IL-27 and IL-35 appear to 
mark evolutionary bridges between the IL-6 and IL-12 family of cytokines. The IL-6-
type cytokine receptors belong to the haematopoietic receptor superfamily. Referring 
to their architecture, including an extracellular N-terminus and a single 
transmembrane region, they are further classified as type I membrane receptors13. 
Only the CNTF-receptor (CNTFR) does not fulfil this criterion, because it contains a 
glycosylphosphatidylinositol anchor instead of the transmembrane domain14.  
The initialisation step of a target cell signalling cascade, by which cytokine signals 
are transduced from the extra- to the intracellular compartments, is the cytokine 
binding to its receptors. Receptors can directly participate in this signalling process or 
only be involved in the cytokine binding. Therefore, the IL-6-type cytokine receptors 
can be classified into non-signalling receptors (IL-6R(α), IL-11R(α) and CNTFR(α)) 
and the signal-transducing receptor subunits (gp130, LIFR, OSMR, WSX-1 and IL-
12Rβ2)11, 12, 15 (Fig. 1). Initially gp130 was thought to serve exclusively as signalling 
receptor for IL-6 mediated signalling16. Only later it became evident, that this receptor 
functions as a common signalling receptor to many cytokines. Physiologically active 
cytokine/receptor complexes appear to function as trimers, tetramers or hexamers. 
After low affinity binding of IL-6 to its α-receptor, the IL-6Rα, the resulting IL-6/IL-6R 
complex binds to gp130 with high affinity. This interaction causes dimerisation of two 
gp130 molecules resulting in a hexameric complex containing two molecules each of 
gp130, IL-6R and IL-616-20. IL-11 is believed to function in an analogous fashion also 
resulting in a hexameric receptor complex21, 22. For both cytokines the α-receptors 
are not directly involved in the signal transduction. In contrast to IL-6 and IL-11, LIF 
and OSM utilise signalling receptor heterodimers, in which one of the signalling 
chains is represented through gp130. LIF first binds to the LIFR(α) with low 
nanomolar affinity, but no signalling occurs until binding of the initial LIF/LIFR 
complex to gp13023-25. Human OSM that is very closely related to LIF also binds the 
LIFR to form OSM/LIFR/gp130 complexes. But in contrast to LIF the cytokine 
additionally uses OSMR/gp130 heterodimers to induce its signalling cascades. Unlike 
the LIF/LIFR interactions, OSM first binds to gp130 and the resulting OSM-gp130 
complex subsequently interacts with the LIFR or the OSMR. The gp130/LIFR(β) 
complex is classified as type I receptor complex and the gp130/OSMR(β) complex is 
called type II receptor complex26, 27. In this scenario both receptor subunits are able 
to initiate signalling cascades, provided OSMR and LIFR proteins were actually 
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expressed in a particular human cell type. CNTF, CLC and NP bind to yet another α-
receptor, the CNTF-receptor (CNTFR), although signalling occurs via LIFR/gp130 
heterodimers14, 28. However, it was shown recently that the NP induced STAT3 
activation occurs independent of LIFR phosphorylation29. For CT-1 that also binds to 
LIFR/gp130 heterodimers30, a specific α-receptor subunit was proposed several 
years ago31, but no concrete evidence for the existence of the receptor was found 
until now. IL-27 uses a heterodimer consisting of gp130 and the specific receptor 
WSX-1 for inducing its signalling32. IL-31, that is closely related to the IL-6-type 
cytokine family and sometimes even included into this family, binds to heterodimers 
of the specific IL-31-receptor (IL-31R) and the OSMR33, 34.  
Interactions of the cytokines with their cognate receptors appear to follow a similar 
pattern which was first determined for the IL-6 receptor complex. The binding of IL-6-
type cytokines to their receptors is mainly achieved through interaction of the 
cytokine with the cytokine-binding module (CBM) of the receptor. The presence of 
this 200 amino acid encompassing motif defines IL-6-type cytokine receptors as class 
I cytokine receptors. The CBM is characterised by an N-terminal domain of 100 
amino acids including four conserved cysteine residues and a C-terminal domain 
containing a specific WSXWS motif35. Structurally, both domains of the CBM can be 
characterised as FnIII (fibronectin type III)-like domains. Each of the IL-6-type 
cytokine receptors contains at least one CBM. With exception of WSX-1, IL-12Rβ2 
and IL-31R, an additional immunoglobulin (Ig)-like domain is found in all IL-6 family 
receptors which is located N-terminally to the membrane-proximal CBM. In sharp 
contrast to the non-signalling receptors, the signalling receptors possess three 
additional FnIII-like domains located C-terminally of the membrane-proximal CBM1. 
For some IL-6-type cytokines the exact molecular binding mechanisms to their 
cognate receptors were determined within the last two decades. Various 
mutagenesis studies and binding assays identified the interfaces on the surface of 
the IL-6-type cytokines and receptors. For the cytokines these are characterised as 
site I, site II and site III and are the hot spots for the receptor interaction. The site II of 
all IL-6-type cytokines, except IL-27, interacts with the CBM of gp130. The second 
signalling receptor (e.g. gp130, LIFR, OSMR) is interacting with site III of the cytokine 
via its Ig-like domain1, 36-40. The CBM of the non-signalling receptor (e.g. IL-6R) binds 
to the site I of the cytokine1. However, the heterodimeric cytokine IL-27 (composed of 
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p28 and EBI-3) uses its site III for gp130 interaction and site II for WSX-1 binding. 
The site I of p28 is important for interaction with EBI-341, 42.  
 
1.2 Receptor and cross-species specificity of OSM and LIF 
 
OSM was initially described as an IL-6-type cytokine able to inhibit the growth of 
melanoma cells43. Studies within the last decade, however, have shown that OSM 
has pleiotropic properties. The cytokine plays important roles in haematopoietic 
progenitor cell homeostasis44, 45, extrathymic T cell development46, 47, suppression of 
fetal liver haematopoiesis48, 49, liver development50, 51 and regeneration52, 
angiogenesis53 and most notably in inflammatory processes. Various articles 
describe elevated levels of human OSM during arthritis, psoriasis and 
atherosclerosis54-58. Moreover, OSM is capable of inducing inflammatory genes like 
chemokines59-63 or P-selectin64. The human polypeptide is mainly produced by 
activated macrophages, dendritic cells, neutrophils and T-cells43, 58, 65, 66. The 
translated, unprocessed protein is a 252 amino acid long precursor67. The highest 
bioactivity of the protein is found after cleavage of an N-terminal 25 amino acid signal 
peptide and the last 32 amino acids of the C-terminus68.  
During the last two decades the human (hOSM), bovine (bOSM), murine (mOSM) 
and rat OSM (rOSM) orthologs have been cloned51, 69, 70. Comparison of the gene 
organisation of OSM with that of IL-6, LIF and granulocyte-colony stimulatory factor 
indicates evolutionary relation and descent from a common ancestral gene71. In the 
human, the bovine as well as the rodent system the genes encoding OSM and LIF 
are located on the same chromosome as a tight tandem possibly resulting from a 
gene duplication72. Until today only the murine and the human OSM receptor 
complexes have been characterised. Interestingly and in contrast to other IL-6-type 
cytokines the composition of the receptor systems for OSM are different in man and 
mouse. Human OSM is able to bind and signal via two receptor complexes: the type I 
receptor complex (LIFR/gp130 heterodimer) and the type II receptor complex 
(OSMR/gp130 heterodimer)26, 27, 73. This is in sharp contrast to murine OSM which 
only signals via the type II OSMR/gp130 receptor complex, since it lacks high affinity 
binding sites for the LIFR74, 75. Thus, in vivo studies using mice cannot correctly 
address the physiological response to human OSM. Further information was gained 
by studies treating human and murine cells with OSM originating from both species. 
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Thereby it was found that hOSM is able to efficiently induce signalling in murine cells, 
but it exclusively activates the murine LIFR/gp130 (type I) complex74, 75. Hence, 
reconstitution studies using human OSM in mouse models of human diseases only 
mimic the actions of LIF, because no OSMR signalling is involved. On the other 
hand, mOSM is not capable of stimulating human cells, a characteristic shared by 
many other IL-6-type cytokines74. 
Comparable to OSM, LIF is a pleiotropic cytokine expressed by embryonic stem 
cells, megakaryocytes, osteoblasts and neuronal cells76. The LIF-LIFR system is 
identical in both mouse and man23-25. Human and mouse LIFR share 76% amino acid 
identity, while human and murine LIF contain 78% identical amino acids. Despite this 
high degree of homology species specific signalling characteristics can be observed. 
Binding and signalling activity of mouse LIF is highly restricted, since it cannot 
stimulate human cells. Human LIF, on the other hand, is capable of binding the 
human and the murine LIFR/gp130 complex with high affinity36. Impressively, human 
LIF binds to the foreign mouse LIFR with a 100-500-fold higher affinity than murine 
LIF itself36.  
 
1.3 Cell-type specific expression of IL-6 family receptors and trans-
signalling 
 
While the common IL-6-type cytokine signalling receptor subunit, gp130, is 
ubiquitously expressed on most cell types, the distribution of the other IL-6-type 
cytokine associated receptors is much more restricted. This allows an adequate cell 
response and distinct cellular function for most IL-6-type cytokines. However, recently 
an additional mechanism was identified which allows cells to respond to a specific 
cytokine in the absence of a membrane-bound alpha-receptor. This mechanism was 
called ‘trans-signalling’. In contrast to classical signalling which depends on 
membrane-bound receptors, cells normally devoid of receptor subunits (e.g. the IL-
6R) can react to IL-6 molecules in their vicinity when soluble IL-6R is present. The 
soluble IL-6-receptors (sIL-6R) lack a cytoplasmic and transmembrane part, but the 
extracellular portion is comparable to their membrane-bound counterparts. These 
soluble forms can be generated either by alternative splicing or by regulated 
extracellular proteolysis (shedding) of the membrane-anchored receptor1, 77-79. The 
shedding of the IL-6R is mediated through extracellular metalloproteinases. While 
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ADAM17 (a disintegrin and a metalloproteinase 17, also known as tumor necrosis 
factor-α converting enzyme, TACE) mediates induced shedding of the IL-6R, 
ADAM10 accomplishes constitutive shedding of the receptor80. 
Cells expressing gp130 but no IL-11R can be activated by IL-11 combined with 
recombinant soluble IL-11R (sIL-11R)22, 81. In contrast to sIL-6R, however, no 
naturally occurring sIL-11R has been detected so far. A soluble form of the CNTFR82 
might be generated by cleaving the glycosylphosphatidylinositol anchor from the 
peptide part of the receptor. This reaction can be experimentally mediated by addition 
of phosphatidylinositol specific phospholipase C to astrocytes83. Within the last 
decade also soluble forms of WSX-184, gp13078, OSMR85 and the LIFR86, 87 were 
analysed and characterised. However, while the soluble forms of the non-signalling 
receptor subunits (IL-6R, IL-11R and CNTFR) act agonistically and allow trans-
signalling, the soluble forms of gp130 (sgp130)78, 88, OSMR85, LIFR24, 86 and WSX-184 
are able to inhibit the actions of receptor-cytokine-complexes (e.g. sIL-6R-IL-6). 
Furthermore, the correlation between sIL-6R, sgp130 and IL-6 can be understood as 
a natural buffer system. Therefore, under normal conditions sgp130 might buffer the 
trans-signalling capacity of sIL-6R and IL-6 within certain ranges. Interestingly, during 
infections and inflammatory conditions sIL-6R serum levels proportionally increase 
much stronger than IL-6 serum levels89, 90. As only a minor fraction of free IL-6 
dimerises with sIL-6R, this effect might actually increase the pool of active IL-6/sIL-
6R complexes91. Depending on the ratio of sIL-6R and IL-6, the classical IL-6 
signalling can be partially inhibited as well, representing a further role of sgp130, as 
the soluble receptor was previously thought to exclusively antagonise trans-
signalling91.  
 
1.4 IL-6-type cytokine induced signalling pathways 
 
Once the IL-6-type cytokine has bound its receptor subunits (e.g. LIF to LIFR and 
gp130), the signalling transduction to the intracellular milieu occurs. With exception of 
IL-27 and IL-35, all other IL-6-type cytokines signal via homo- or heterodimerisation 
of gp130 with a second gp130, the LIFR or OSMR. Interactions within the 
cytoplasmic regions of the signal transducing chains induced through the 
cytokine/receptor complex formation initiate the intracellular signalling cascades. 
Conformational changes in the receptor chains and the recruitment of additional 
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cellular proteins (e.g. kinases) are the driving forces that allow all following steps. The 
most prominent signalling pathway activated by IL-6 type cytokines is the JAK/STAT 
(Janus kinase/signal transducers and activators of transcription) pathway. The MAPK 
(mitogen-activated protein kinase) cascade leading to activation of ERK1/2 
(extracellular signal-regulated kinase) is the second key pathway. Depending on the 
cell type, the respective IL-6-type cytokine, concentration of the cytokine and the 
expression rates of receptor(s), the PI3K (phosphatidylinositol 3-kinase)/Akt (protein 
kinase B (PKB), encoded by AKT1, AKT2 and AKT3) cascade can also be 
activated11. To avoid overshooting cytokine responses it is necessary to inhibit 
cytokine induced signalling cascades after certain periods of time. To facilitate this 
inhibition, ‘cellular brakes’ are transcribed or their activity is induced. Therefore, the 
SOCS (suppressors of cytokine signalling) and/or the PIAS (protein inhibitors of 
activated STATs) proteins as well as distinct phosphatases are recruited to disable 
the signalling machinery. 
 
1.4.1 Activation of the JAK/STAT pathway  
 
Once the IL-6-type cytokine is bound to its receptors, the signalling machinery is 
started. The first exclusively cytoplasmic proteins that allow signal transduction into 
the cytosol are tyrosine kinases of the JAK (Janus kinase) family. This step is 
essential, because the IL-6-type cytokine family receptors are devoid of an intrinsic 
kinase activity. Unlike receptor tyrosine kinases like the FGFR (fibroblast growth 
factor receptor) or insulin receptors, they need the support of additional kinases for 
the phosphorylation of distinct amino acid residues. In mammalians there are four 
members of the JAK proteins known: JAK1, JAK2, TYK2 ((non-receptor) tyrosine-
protein kinase 2) and JAK392-95 with molecular weights between 120 to 140 kDa. 
JAK1, JAK2 and TYK2 are ubiquitously expressed and all JAK members show an 
extraordinary homology. JAK3 is mainly expressed in haematopoietic cells and 
mutations of JAK3 are therefore associated with severe combined immunodeficiency 
syndrome96, 97.  
The domain architecture of the JAKs is highly unique, because they contain two 
kinase domains in series. This circumstance was crucial for naming these kinases 
after the two-faced Roman god Janus98. While the JH1 (JAK homology domain 1) 
has functional tyrosine kinase activity, the JH2 domain, which is also called 
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pseudokinase domain, is thought to possess no catalytic activity99 (Fig. 2). However, 
it has to be noted that a recent article from Ungureanu and colleagues provides 
evidence, that the pseudokinase domain of JAK2 has catalytic activity and plays an 
important role in the negative regulation of the protein100. The N-terminal FERM (four-
point-one protein, ezrin, radixin and moesin) domain, located between JH4 and JH7, 
is important for the interaction of JAKs with the cytokine receptors and can be found 
in many proteins with membrane proximal localisation, since it is able to bind to 
peptides and phospholipids101. Although the FERM domain is crucial for receptor 
binding, staurosporine induced conformational change of the JAK3 kinase domain is 
able to inhibit binding to the common γ-chain102. This indicates an involvement of the 
kinase domain in receptor binding. The JAKs bind to the box1 and box2 motifs of 
corresponding IL-6-type cytokine receptors (Fig. 3). Mutation of only two proline 
residues in the box1 or deletion of the entire box1 completely abrogates the JAK 
binding to gp130, LIFR or OSMR103-105. The box2 is characterised by various 
hydrophobic amino acids followed by positively charged residues and seems to 
increase the binding affinity of the receptor to the JAKs. Hence, a recombinant gp130 
with a box2 deletion can only be coprecipitated with JAK1, if the kinase was 
overexpressed106. The interbox region between box1 and box2 also participates in 
binding to the JAK proteins. Mutation of Trp666, localised between box1 and box2, 
abrogates JAK binding to gp130105. Experiments investigating the role of the potential 
SH2 domain located between JH3 and JH4 could not identify a classical SH2 domain 
function107.  
 
 
Figure 2: Domain organisation of JAK and STAT proteins 
JAK proteins possess an N-terminal FERM domain that is important for receptor interaction, a putative 
SH2 domain (without classical SH2 function), a pseudokinase domain (without classical catalytic 
activity) and an active tyrosine kinase domain with an important double tyrosine (Y) motif in the 
activation loop. The STAT proteins consist of an N-terminal coiled coil domain, a DNA binding domain 
(important for promoter binding), a linker region, a C-terminal SH2 domain and phosphorylatable 
tyrosine (Y) and serine (S) residues.  
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To initiate the activity of the JAKs, the receptor chains have to dimerise, which is the 
case after cytokine binding. Through dimerisation of the receptors and the induced 
conformational changes, the JAK proteins are brought in close contact and become 
phosphorylated (probably autophosphorylated)98, 101, 108-110. The activated JAKs 
subsequently phosphorylate specific tyrosine residues in the receptor chains. 
Thereby these sites are transformed into docking sites for SH2 domain-containing 
proteins like the SH2 domain-containing protein tyrosine phosphatase (SHP2) or the 
STATs, which recognise these phosphorylated tyrosine residues111.  
 
 
 
Figure 3: The OSMR-gp130-complex: a junction for several signalling pathways 
and networks 
After OSM binding, the receptor chains of gp130 and OSMR dimerise and initiate the JAK dependent 
phosphorylation of the indicated tyrosine residues. The box1 and box2 regions are important for JAK 
recruitment. The STATs, SOCSs and SHP2 are recruited to their respective docking sites (phospho-
tyrosine residues, see above). SHP2 as well as the STATs are subsequently phosphorylated by JAKs. 
While the STATs translocate into the nucleus upon phosphorylation, SHP2 serves as adaptor protein 
for the activation of the Ras-Raf-MAPK cascade. Thus the transcription of various genes is induced or 
repressed. One of the STAT3 induced genes is the feedback inhibitor SOCS3.  
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JAK1, JAK2, TYK2, but not JAK3, can be immunoprecipitated with gp130 and are 
tyrosine phosphorylated in response to IL-6-type cytokine binding112-115. JAK1 
appears to be the most important kinase for IL-6 signalling116. Cells from JAK1 
knockout-mice are no longer responsive to IL-6, LIF, CT-1, OSM or CNTF117, 
indicating the importance of this kinase also for other IL-6-type cytokines.  
After phosphorylation of specific tyrosine residues in the cytoplasmic region of the 
receptors, the STAT proteins are recruited and become tyrosine phosphorylated 
themselves (Fig. 3 and 4). After homo- or heterodimerisation, the STATs translocate 
into the nucleus, where they bind their respective promoter regions to induce specific 
target gene transcription111.  
 
 
Figure 4: IL-6 activates the JAK/STAT pathway and the MAPK cascade 
IL-6 binds to its α-receptor, the IL-6 receptor, thus generating a high affinity complex for gp130. After 
formation of the hexameric receptor complex (homodimerisation of the signalling gp130 chains), two 
major pathways are initiated, the JAK-STAT pathway and the Ras-Raf-MAPK cascade. Before STAT 
dimers can translocate into the nucleus, where they induce IL-6-responsive gene transcription, they 
are recruited to specific phospho-tyrosine residues in gp130 (intracellular) and phosphorylated via 
JAKs. Another protein that is recruited to a specific phospho-tyrosine is the phosphatase SHP2. 
Serving as an adaptor, SHP2 interacts with additional proteins and induces the Ras-Raf-MAPK 
pathways. At the end of the cascade MAPKs like ERK1/2 are phosphorylated resulting in the activation 
of specific transcription factors (TF).  
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In mammals, the STAT family comprises seven genes that code for STAT1, STAT2, 
STAT3, STAT4, STAT5A, STAT5B and STAT6. Depending on the analysed cell 
system, the used cytokine and the applied cytokine concentration, STAT1, STAT3 
and STAT5 can be activated by IL-6-type cytokines118-123. The common STATs that 
are activated by all known IL-6-type cytokines are STAT1 and STAT3 (originally 
termed acute phase response factor, APRF)113. Not all STATs can be recruited to 
each phospho-tyrosine of the IL-6-type cytokine receptors. Today many details of this 
complex regulatory mechanism are known. The tyrosine (Y) residues Y767, Y814, Y905 
and Y915 of gp130 can serve as docking sites for STAT3, while Y905 and Y915 are 
additionally able to recruit STAT1114, 124. STAT1 and STAT3 can be also recruited by 
the OSMR125, 126. Although not all details of the exact phospho-tyrosine binding are 
solved yet, the box1/box2 region seems to be sufficient for the STAT1 activation. 
STAT3 is suggested to interact with Y917 und Y945 of the OSMR. In addition to STAT3 
and STAT1, activation of STAT5 can be observed after OSM induced signalling127. 
The recruitment of STAT5 to the human OSMR is dependent on Y837 and Y839128. The 
tyrosine phosphorylation of the STATs is very important both for their dimerisation 
and translocation. STAT1, STAT3 and STAT5 have similar tyrosine residues located 
at the C-terminus. Phosphorylation occurs at Y701 of STAT1, Y705 of STAT3 and Y694 
of STAT5. Once the STATs are phosphorylated at these sites, they homo- or 
heterodimerise. The SH2 domains play major roles for the dimerisation through 
binding to the newly phosphorylated tyrosine129, 130. After dimerisation STATs are 
able to dock to and regulate specific promoter regions of various genes.  
Besides the well determined tyrosine phosphorylation, STATs can additionally be 
serine (S) phosphorylated in their transactivation domain. The serine phosphorylation 
in STAT1 (S727) can be observed after type I interferon stimulation and is mediated by 
protein kinase C-delta131. In contrast, STAT5A/B serine phosphorylation (STAT5A at 
S726 and STAT5B at S731) observed after erythropoietin treatment is dependent on 
the activity of the MAPKs ERK1/2 (extracellular signal-regulated kinase 1/2) and 
p38132. For STAT3, phosphorylation of S727 has been described133. Interestingly, the 
tyrosine and serine phosphorylations can act synergistically, but also antagonistically. 
In STAT3 for example, the ERK2 induced phosphorylation of S727 decreases the 
transcriptional activity of STAT3134. In spite of other reports showing that for maximal 
transcriptional activity of STAT3 and STAT1 S727 has to be phosphorylated, this 
residue seems not to be important for the DNA binding of the transcription factors135, 
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136. On the other hand, for mitochondrial localisation the serine phosphorylation of 
STAT3 seems to be of major importance137.  
 
1.4.2 Activation of the MAPK cascade 
 
While the JAK/STAT pathway represents the most prominent pathway triggered by 
IL-6-type cytokines, most family members additionally activate the MAPKs ERK1/2 
and some also the SAPK (stress-activated protein kinases), p38 and JNK1/2/3 (c-Jun 
N-terminal kinase)11 (Fig. 3 and 4). This is achieved through receptor recruitment of 
the phosphatase SHP2 which serves as adaptor protein. SHP2 uses its SH2 domains 
to bind to the previously phosphorylated tyrosine residues of gp130 and LIFR138, 139. 
The essential residues for this recruitment are Y759 of gp130 and Y974 of the LIFR114, 
140. In contrast to gp130 and the LIFR, the OSMR does not utilise SHP2 for activating 
the Ras-Raf-MAPK pathway. It has been shown that the adaptor protein Shc (SH2 
and collagen homology domain-containing protein) is recruited to the OSMR via 
tyrosine residue 861141.  
The MAPK cascade is initiated after gp130 becomes tyrosine phosphorylated by JAK 
activity. SHP2 is rapidly recruited to the receptor and afterwards phosphorylation of 
SHP2 occurs in a JAK1 mediated manner142. Phosphorylated SHP2 subsequently 
interacts with the adaptor protein Grb2 (growth factor receptor-bound protein 2)138. 
Grb2 contains a SH2 and a SH3 (Src homology 3) domain, but no catalytic activity. 
Shc that is recruited to the OSMR also binds Grb2 allowing Ras-Raf-MAPK cascade 
initiation141. Grb2 is constitutively associated with the guanine nucleotide exchange 
factor SOS (son of sevenless). SOS thereby migrates from cytoplasm to the plasma 
membrane and is able to exchange GDP to GTP in the GTPase Ras thus activating 
the serine/threonine kinase Raf. Raf, a MAP kinase kinase kinase (MAP3K), 
subsequently activates the dual specificity kinases MEK1/2 (MAP2K)143. As dual 
specificity kinases, MEK1/2 phosphorylate ERK1/2 on an important tyrosine and 
threonine residue. JNK1/2/3 are phosphorylated by the dual specificity kinases 
MKK4/7 and p38 by MKK3/6144. Afterwards ERK1/2, p38 and JNK1/2/3 can modify 
the activity of various transcription factors143.  
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1.4.3 Activation of the PI3K cascade 
 
IL-6-type cytokines are able to activate additional pathways besides the JAK/STAT 
and the MAPK pathway. The most frequently described one is the PI3K cascade.  
This enzyme modifies certain phosphatidylinositides thus inducing the recruitment of 
the serine/threonine kinase Akt/PKB to the cell membrane. Akt itself is 
phosphorylated at T308 by the phosphoinositide dependent kinase-1 (PDK1) and at 
S473 by mTOR (mammalian target of rapamycin)145-147. Typical substrates of Akt are 
forkhead transcription factors (e.g. FOXO1) and the important pro-apoptotic protein 
Bad (Bcl-2/Bcl-XL antagonist). The phosphorylation of Bad results in its cytoplasmic 
retention and is therefore associated with increased/prolonged survival and cell 
growth. In cardiomyocytes, for instance, gp130 signalling mediates the activation of 
this pathway leading to the prevention of apoptosis induced by the cytostatic 
doxorubicin148. Moreover, PI3K is deeply involved in the IL-6 mediated prevention of 
apoptosis which coincides with the upregulation of the anti-apoptotic protein Mcl-1 in 
basal cell carcinoma149 and multiple myeloma cells150-152. Interestingly the PI3K 
activation upon IL-6-type cytokine stimuli is a cell-type specific phenomenon. For 
example, no elevated Akt activation can be observed in IL-6-treated human HepG2 
hepatoma cells153. The exact mechanism by which the PI3K/Akt pathway is activated 
after gp130 dimerisation is not completely clear. After IL-6-type cytokine receptor 
binding, the adaptor protein Gab1 (Grb2-associated binding protein 1) interacts with 
PI3K finally resulting in an activation of Akt139, 154.   
 
1.4.4 Termination of IL-6-type cytokine induced signalling pathways 
 
To prevent an overshoot of cellular responses upon IL-6-type cytokine stimulation, 
various molecular brakes have evolved. The protein tyrosine phosphatases (PTP), for 
example SHP2, represent one side of the signalling suppressing machinery. As 
described above, SHP2 is recruited to phospho-Y759 of the cytoplasmic tail of 
gp130114, 155 or to phospho-Y974 of the LIFR. SHP2 is a ubiquitously expressed 
phosphatase with two N-terminal SH2 domains in series and a catalytic phosphatase 
domain in the C-terminal half of the protein. Based on the crystal structure of SHP2 it 
is assumed that the N-terminal SH2 domain masks the active site of the enzyme and 
thereby inhibits the catalytic activity in the absence of a tyrosine phosphorylated 
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substrate protein. The interaction of the SH2 domains with phosphorylated tyrosine 
motifs of binding partners such as receptors (e.g. gp130) or free cytoplasmic proteins 
(e.g. STAT3) leads to the opening of the protein structure resulting in the restoration 
of enzymatic activity156-159. A further regulatory mechanism of SHP2 is its own 
phosphorylation on amino acids Y542 and Y580 close to the C-terminus of the protein. 
These phospho-tyrosines behave ‘self-reactive’ to the two SH2 domains of SHP2 and 
induce the unmasking of the phosphatase domain by releasing it from the N-terminal 
SH2 domain160. Thus, tyrosine phosphorylated proteins of the gp130/OSMR/LIFR 
induced signalling pathways are potential SHP2 phosphatase substrates. 
Overexpression of dominant-negative SHP2 mutants leads to strongly increased 
gp130, JAK, STAT and SHP2 phosphorylation indicating the harmful potential of a 
lack of functional SHP2161.  
The second important arm of the cellular signal silencing machinery is the induced 
expression of the SOCS proteins. These proteins are indispensable components for 
the termination of the IL-6-type cytokine induced signalling. There are eight members 
of the SOCS family known at present. They are called CIS (cytokine-inducible SH2 
protein) and SOCS1-7. Partially already expressed under basal conditions, their 
expression can be strongly increased through cytokine mediated signalling. Thus 
they act as inducible feedback inhibitors162-164. The SOCS proteins have a central 
SH2 domain and a so called SOCS box at the C-terminus. While CIS and SOCS1 
expression levels are upregulated by the actions of IL-6, LIF and OSM, SOCS3 
transcription is strongly increased after stimulation with IL-6, IL-11, LIF and OSM. IL-
6 and its related cytokines are also able to induce increased levels of SOCS2162, 165-
167. The exact inhibitory mechanisms by which SOCS proteins suppress signalling 
seem to differ within the SOCS family members. Hence, it is not possible to draft one 
mechanistic blueprint for all eight proteins. CIS, for example, was shown to be 
recruited to the erythropoietin receptor (EpoR) and to compete with STAT5 for its 
docking site at the receptor168, 169. The most important SOCS members for inhibiting 
IL-6-type cytokine signalling are SOCS1 and SOCS3, which are structurally closely 
related. Both were shown to directly influence the activity of the Janus kinases thus 
inhibiting phosphorylation of JAKs themselves and consequently of gp130 and 
STATs162, 166. SOCS1 is able to inhibit JAK/STAT signalling by binding to the 
phosphorylated activation loop within the kinase domain of JAKs via its SH2 domain. 
The N-terminal KIR (kinase inhibitory region) domain and the extended SH2 
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subdomain, which is located N-terminally of the SH2 domain, play the crucial role in 
the inhibition process. The KIR of SOCS1 is thought to inhibit the catalytic activity of 
the JAK kinase domain by blocking the substrate binding pocket170. Although SOCS3 
has a comparable KIR domain and is able to bind the JAKs171-173, it appears to mainly 
interact with phospho-tyrosine motifs of activated cytokine receptors, such as gp130, 
the EpoR, the leptin receptor and the granulocyte colony-stimulating factor 
receptor172-179. Referring to IL-6-type cytokine signalling it was discovered that 
SOCS3 binds to the same docking site of gp130 as SHP2, namely phospho-Y759125, 
174. Moreover, SOCS proteins are implicated in the destabilisation of their interacting 
partners. This is achieved by their function as substrate-recruiting component for 
ubiquitin ligases. Thus SOCS proteins are not only affecting the STAT activation, but 
also the amount of functional protein180.  
In addition to these major signalling suppressors, further proteins are described to be 
involved in the inhibition process for gp130 mediated signal transduction. The PIAS 
proteins, for instance, are able to negatively influence cytokine induced signalling. 
The PIAS family comprises 5 members: PIAS1, PIAS3, PIASy, PIASxα and PIASxβ. 
PIASxα and PIASxβ are identical with exception of their C-Termini. In contrast to the 
SOCS proteins, the constitutively expressed PIAS proteins have to be 
phosphorylated before associating with their corresponding STATs. The molecular 
details of the inhibition mechanism of the PIAS proteins are not completely 
understood to date. But it has been shown that PIAS1 specifically interacts with 
STAT1, while PIAS3 interacts with STAT3. PIAS1 and PIAS3 exert their inhibitory 
actions by blocking the DNA binding activity of STATs and thus suppressing the 
STAT mediated transcription181, 182.  
 
1.5 The role of IL-6-type cytokines in cardiac remodelling and 
hypertrophy 
 
Cardiac remodelling is defined as a compensatory reaction of heart tissue to sudden 
physiological or pathophysiological changes resulting from pregnancy, exercise, 
aging or pathophysiological injuries (i.e. myocardial infarction, pressure overload, 
exposure to cardiotoxic agents and infections). It is characterised by modified 
cardiomyocyte size and changes in vasculature, extracellular matrix composition, 
cytoskeleton composition, myosin chains, cardiac energetics, metabolism and 
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inflammatory status. On the cellular level three different processes can contribute to 
cardiac remodelling: Cell growth of cardiomyocytes, apoptosis/necrosis of cardiac 
myocytes and fibrosis (infiltration of interstitial cells). In some situations these 
changes are reversible and also important for compensating transient physiological 
requirements (e.g. pregnancy, adaptive hypertrophy). However, under many 
pathophysiological conditions these alterations proceed and become irreversible 
contributing to an abnormal phenotype and function of the left ventricle and 
subsequently heart failure183, 184. The most frequently studied modification is the 
cardiomyocyte growth (cardiomyocyte hypertrophy). This unique cell type represents 
the major component of the myocardium and is responsible for the contractility of the 
heart tissue. As described above, several conditions can induce a compensatory 
increase of heart muscle weight and size. Since adult cardiomyocytes hardly 
proliferate under such conditions185, they only grow in size to replace inoperable 
tissue parts (e.g. after myocardial infarction) or to compensate altered requirements. 
On the molecular level this reaction is achieved through sarcomeric addition in 
responding cardiomyocytes. Sarcomers represent the contractile units of the muscle 
tissue and can be assembled in parallel or in series. Assembly in series causes 
eccentric hypertrophy (elongation of the cardiac myocyte), while parallel assembly 
leads to concentric hypertrophy (increase of the entire cell diameter)186.  
 
Figure 5: Schematic view of dilated and hypertrophic cardiomyopathy 
Dilated cardiomyopathy (left side) is characterised by stretched muscle fibres leading to enlargement 
of one or two ventricles. The septum and the ventricular walls are thinned and the heart becomes 
insufficient to pump adequate volumes of blood. Often a correlation with a decreased left ventricular 
ejection fraction is observed. Hypertrophic cardiomyopathy (right side) displays thickened ventricular 
walls causing an increased left ventricular ejection fraction. The electrical function of the heart can be 
negatively affected and sudden heart death can be a direct consequence of such alterations. The 
scheme is modified after http://www.cts.usc.edu.  
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One has to distinguish the anatomic and physiological consequences of the two 
kinds of hypertrophies. Concentric hypertrophy is the cellular basis for a thickened 
ventricular wall (hypertrophic cardiomyopathy) that is followed by diastolic 
dysfunction (Fig. 5). Eccentric hypertrophy is attended by dilatation of the ventricle 
(dilated cardiomyopathy) and is associated with systolic dysfunction (Fig. 5). During 
the progression of cardiac hypertrophy a remarkable number of dying myocytes can 
be observed. Apoptosis as well as necrosis play important roles in provoking this 
process187. Fibroblasts are subsequently infiltrating the tissue to replace dead cells 
thus finally decreasing the contractility and flexibility of the heart to an additional 
severe extent188, 189.  
Besides their roles in inflammation, acute phase, neuronal differentiation, 
haematopoiesis etc., IL-6-type cytokines play a role in cardiac hypertrophy, 
remodelling and survival, which is not fully understood. First of all they are 
fundamental for the developing heart. LIF and CT-1 are highly expressed during 
cardiogenesis and contribute to proliferation and survival of embryonic cardiac 
myocytes190. The role of the cytokine family in the adult heart exposed to 
pathogenesis is, however, far more cryptic. On the one hand, various previous 
studies unambiguously demonstrated that IL-6-type cytokines induce cardiac 
hypertrophy, on the other hand it remains unclear if their activity is more protective or 
rather harmful for the adapting heart191-193. From all family members, IL-6, CT-1, LIF, 
OSM and IL-11 have been identified so far to have cardio-remodelling activities. On 
the cellular level, CT-1, IL-6, LIF, IL-11 and OSM mediate eccentric hypertrophy by 
addition of new sarcomeric units in series, as described above194-201. It was also 
shown, that IL-6 serum concentrations are elevated after myocardial infarction202. 
Moreover, increased blood concentrations of IL-6 and sIL-6R were found in patients 
with congestive heart failure, hypertrophic and dilative cardiomyopathy203, 204. 
Furthermore, the severity of left ventricular dysfunction correlates with systemic IL-6 
levels. Therefore, IL-6 may serve as indicator in patients with heart failure and 
myocardial infarction202, 203, 205-208. However, complete genetic ablation of the Il6 gene 
does not influence remodelling, survival, left ventricular function or infarct size in 
mice209. Besides the IL-6 and sIL-6R expression, severity based elevations of LIF 
and soluble gp130 plasma levels were found in heart failure patients210. Another 
study analysing failing hearts of patients suffering from dilative cardiomyopathy, 
however, found all gp130 protein levels and CT-1 expression levels unaltered211. 
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Therefore, this study is in sharp contrast to an article by Zolk and colleagues who 
analysed patients with ischemic and dilative cardiomyopathy. Here, CT-1 levels were 
elevated, while gp130 protein levels were reduced and, even more controversially, 
gp130 mRNA levels were increased212. Podewski and colleagues have also shown 
that expression levels or phosphorylation status of several proteins of the IL-6 and 
LIF signalling pathways including IL-6, LIF, LIFR, JAK1, JAK2, TYK2, gp130, SOCS1 
and SOCS3 are significantly altered in end-stage heart failure211. Furthermore, the 
study indicates that IL-6 levels are impaired in failing hearts, while LIF expression is 
elevated. Because of these rather controversial data and the relatively small number 
of articles dealing with human cardiomyocytes in combination with IL-6-type 
cytokines, it is difficult to correctly address the role of these cytokines during 
hypertrophic development.  
The IL-6-type cytokine induced cardiac remodelling is mainly mediated via three 
major pathways (JAK/STAT, MAPK cascade and PI3K/Akt)11, 191, 213-216. Recent 
publications also demonstrated that ERK5 phosphorylation might play an important 
role in inducing eccentric hypertrophy upon LIF and CT-1 stimulation217, 218. 
Furthermore, metabolic changes upon IL-6-type cytokine signalling are described 
including a switch to anaerobic catabolism219, 220 and the generation of reactive 
oxygen species (ROS)221. The latter seem to have a beneficial role in 
cardioprotection by blocking the IL-6-type cytokine induced STAT3 activity. Indeed, it 
has been suggested for several years that systemically elevated IL-6-type cytokine 
signalling may contribute to the progression of heart failure222. Conversely, a large 
number of experimental work over the last decade has implicated that the signalling 
induced by these cytokines contributes to compensatory hypertrophy, promotes 
cardioprotection and neovascularisation214, 223-226.  
Indeed, STAT3 plays a key role in gp130 mediated cardiac hypertrophy and is 
sufficient to induce cardiomyocyte hypertrophy in vitro227 and in vivo214, when 
overexpressed in heart cells. Moreover, the augmented STAT3 activation induced by 
overexpression of IL-6 and IL-6R without any further stimulus is sufficient to induce 
cardiac hypertrophy in vitro and in vivo199. Besides their functions during pressure 
overload or ischemia induced cardioprotection, the involvement of IL-6-type cytokines 
in inflammatory diseases of the heart should be mentioned. It has been shown that 
heart specific gp130 knockout-mice or mice overexpressing SOCS3 develop an 
elevated susceptibility to viral infections of cardiomyocytes suggesting a role of 
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STAT3 in protecting these cells from viral pathogens by promoting survival228. STAT3 
seems to mediate not only viral-protective effects, but it also plays a role in pathogen-
associated molecular pattern (PAMP) induced myocardial inflammation. Cardiac 
specific deletion of STAT3 negatively influences the sensitivity of myocytes to 
lipopolysaccharide (LPS) induced inflammation. As consequences of this attenuated 
immune status, extensive fibrosis and augmented apoptosis of cardiac myocytes can 
be observed225. However, these beneficial properties of IL-6 and the related 
cytokines can turn into harmful actions over time. Continuous and excessive 
secretion of IL-6 during viral myocarditis can destroy viral clearance and the 
activation of cytokine networks229. To prevent the heart from myocardial injury, a well 
triggered regulation of the gp130 downstream signalling, therefore, is obviously 
essential.  
Driven by the partially beneficial effects, proteins of the gp130-JAK-STAT axis were 
thought to be appropriate targets for pharmaceutical interventions. The treatment with 
combined hIL-6 and sIL-6R, for example, was shown to suppress myocyte apoptosis 
and to limit infarct size after experimental ischemia and subsequent reperfusion230.  
 
1.6 C/EBP beta and delta: IL-6 inducing/induced transcription factors 
 
CCAAT/enhancer binding proteins (C/EBP) represent a well analysed family of 
transcription factors. The six known members (C/EBPα, C/EBPβ, C/EBPγ, C/EBPδ, 
C/EBPε and C/EBPζ) contain a highly conserved C-terminal basic leucine zipper that 
is important for dimerisation and DNA binding231. C/EBPβ was initially described as 
nuclear factor (for) IL-6 (NF-IL-6). It was shown that C/EBPβ expression is inducible 
through IL-6 stimulation and that the transcription factor itself is able to upregulate IL6 
transcription232, 233. Moreover C/EBPβ can form homodimers or heterodimers with 
C/EBPα, δ and γ. The protein specifically binds to promoter regions of immunity- and 
inflammation-associated genes including IL-6 as well as other cytokines and acute-
phase proteins. C/EBPs also play a role in adipocyte differentiation and liver 
regeneration. There are two protein variants of C/EBPβ that are generated through 
alternative translation start sites, the transcriptional active LAP (liver activating 
protein) and the inhibitory LAP antagonising LIP (liver inhibitory protein)231. The ratio 
of both polypeptides can alter and LIP expression has been shown to be increased 
under some conditions, like oncogenic transformation of breast epithelial cells234. In 
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contrast to C/EBPβ, only one transcriptionally active version of C/EBPδ is known. 
Originally called NF-IL6b, C/EBPδ was shown to form heterodimers and to act with 
C/EBPβ synergistically235. Comparable to C/EBPβ, the expression of the transcription 
factor can be induced by multiple stimuli including IFN-γ, IL-1, IL-6, insulin, LPS and 
TNF-α231.  
The IL-6 induced C/EBPβ induction during acute phase response is based on STAT3 
activity and binding to cAMP-response element (CRE)-like sequences236. The 
transcription of C/EBPδ can also be induced by STAT3. Strong upregulation of both 
transcription factors in response to STAT3 was found in growth-arrested mammary 
epithelial cells and the involuting mammary gland237, 238, but also in hepatocytes 
during the acute-phase response239, 240. While STAT3 tyrosine phosphorylation is a 
rather transient event, the thereby initiated C/EBPδ activity can be a state of clearly 
longer duration239, 240. This extremely prolonged and enhanced expression seems to 
be achieved via autoinduction representing a feed forward mechanism that can be 
maintained by the IL-6-STAT3-C/EBPδ axis235, 241-243.  
A further level of C/EBP regulation is the phosphorylation of the transcription factors 
at different serine or threonine residues. For example, the trans-activation potential of 
C/EBPβ can be enhanced by phosphorylation of T235 through an activated MAPK 
pathway244, 245. Moreover, trans-activation can be induced by phosphorylation of S195 
via protein kinase C (PKC)246 or S276 by Ca2+/calmodulin dependent protein kinase247. 
There are also additional phospho-sites in the protein known that are able to 
suppress the DNA-binding activity of C/EBPβ, once they were phosphorylated248. In 
the case of C/EBPδ no phosphorylation sites have been identified so far, but its 
trans-activation potential is decreased in hepatocytes that are treated with 
phosphatase inhibitors (okadaic acid or sodium orthovanadate)249, a condition that, of 
course, alters several other kinase/phosphatase dependent effects in those cells.  
Furthermore, C/EBPs can interact with other transcription factors, such as NF-κB 
(nuclear factor-kappa B), CREB/ATF (cAMP-response-element-binding protein/ 
activating transcription factor) and AP-1 (activator protein 1) indicating that different 
target genes can be induced by altering the composition of transcription factor 
complexes that translocate to specific promoters250-252.  
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1.7 Aims of the study 
 
The study of numerous published articles describing the influence of IL-6-type 
cytokines on the heart highlights one obvious discrepancy: The classification of the 
cytokine family within the context of cardiac disease ranges from protective to 
harmful. The role of these cytokines in the development and persistence of cardiac 
hypertrophy/dilated cardiomyopathy is of central interest, since several members of 
the cytokine family seem to be capable of inducing cardiomyocyte hypertrophy194-201. 
While the hypertrophic potentials of IL-6, CT-1 and LIF were already partly shown, 
the influence of OSM on heart cells (especially cardiomyocytes) has not been 
determined at this stage. Therefore, the present study was designed to compare the 
hypertrophic potentials of heart relevant IL-6-type cytokines, with particular regard to 
OSM. Furthermore, redundant and specific activities of the various IL-6-type 
cytokines should be clarified with focus on their activated signalling pathways and 
selected target genes. Hypertrophy development and persistence is not only 
dependent on cardiomyocytes, but it is supported by the cardiac fibroblasts. 
Therefore, the cellular responses to IL-6-type cytokine stimulation will be evaluated in 
neonatal rat cardiomyocytes (NRCM) as well as neonatal rat cardiac fibroblasts 
(NRCFB). 
Adrenergic pathways and the renin-angiotensin system were described to cross-talk 
with IL-6-type cytokines. The molecular mechanisms, however, are not fully 
understood to date. Hence, as second aim of this thesis the regulation of several 
members of the renin-angiotensin system in response to IL-6-type cytokines will be 
analysed. Vice versa, it will be examined whether α1-adrenergic stimuli (e.g. 
phenylephrine (PE)) or ATII are able to influence/induce the expression of IL-6-type 
cytokines or their receptors. 
Differential activation of signalling pathways and induction of target genes in the 
course of the study prompted us to analyse the receptor usage of mOSM and hOSM 
on NRCM and NRCFB. The central question of this examination was which receptor 
complexes were utilised by mOSM and hOSM on rat cells. Upon availability of 
recombinant rat OSM, the third major aim of this thesis will be the characterisation of 
the receptor complex(es) used by rat OSM on cells of rat origin. In addition, cross-
species activities of rOSM on murine and human cells will complete the comparison 
of the three OSM variants.  
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2 Materials 
2.1 Antibodies 
2.1.1 Antibodies for immune fluorescence 
 
Antibody Epitope species 
Host 
species 
Dilution/final 
concentration Manufacturer 
Alexa488-anti-mouse IgG 
(polyclonal) mouse goat 1:200/10 µg/ml 
Life Technologies 
(Carlsbad, USA) 
α-actinin, sarcomeric 
(monoclonal) mouse mouse 1:1000 
Sigma-Aldrich 
(Taufkirchen) 
 
2.1.2 Primary and secondary antibodies for flow cytometry 
 
Antibody Epitope species 
Host 
species 
Dilution/final 
concentration Manufacturer 
anti-mouse/rat IL-6Rα 
(monoclonal) mouse/rat rat 1:50-1:100 
BioLegend (San Diego, 
USA) 
anti-mouse gp130 
(monoclonal) mouse rat 1:50-1:100 
MBL International 
(Woburn, USA) 
DiacloneTM anti-human 
gp130 (monoclonal) human mouse 1:50-1:100 
Gen-Probe Incorporated 
(San Diego, USA) 
DiacloneTM anti-human IL-
6R (monoclonal) human mouse 1:50-1:100 
Gen-Probe Incorporated 
(San Diego, USA) 
anti-mouse OSMRβ 
(monoclonal)  mouse rat 1:50-1:100 
MBL International 
(Woburn, USA) 
Alexa488-anti-mouse IgG 
(polyclonal) mouse goat 1:200 
Life Technologies 
(Carlsbad, USA) 
Alexa488-anti-rat IgG 
(polyclonal) rat goat 1:200 
Life Technologies 
(Carlsbad, USA) 
R-Phycoerythrin-anti-
mouse IgG (polyclonal) mouse goat 1:200 Dianova (Hamburg) 
R-Phycoerythrin-anti-rat 
IgG (polyclonal) 
mouse goat 1:200 Dianova (Hamburg) 
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2.1.3 Antibodies for Western blotting 
 
Antibody Epitope species 
Host 
species Dilution Manufacturer 
anti-mouse IgG-HRP 
(polyclonal) mouse horse 1:2000-1:3000 Cell Signaling (Frankfurt) 
anti-rabbit IgG-HRP 
(polyclonal) rabbit goat 1:2000-1:3000 Cell Signaling (Frankfurt) 
anti-biotin-HRP  goat 1:3000 Cell Signaling (Frankfurt) 
anti-mouse IgG-HRP 
(polyclonal) mouse rabbit 1:2000-1:3000 DAKO (Hamburg) 
anti-rabbit IgG-HRP 
(polyclonal) rabbit goat 1:2000-1:3000 DAKO (Hamburg) 
anti-goat IgG-HRP 
(polyclonal) goat rabbit 1:2000-1:3000 DAKO (Hamburg) 
anti-mouse OSMRβ 
(polyclonal)  mouse goat 1:500 
R&D Systems (Minneapolis, 
USA) 
anti-human OSMRβ 
(polyclonal)  human goat 1:1000 
R&D Systems (Minneapolis, 
USA) 
anti-human gp130 
(monoclonal) human mouse 1:1000 
R&D Systems (Minneapolis, 
USA) 
anti-murine IL-6R 
(monoclonal) mouse rat 1:500-1:1000 
R&D Systems (Minneapolis, 
USA) 
anti-human LIFR 
(monoclonal) human mouse 1:500-1:1000 
Santa Cruz Biotechnology 
(Heidelberg) 
anti-ph-JAK1 (Y1022/Y1023) 
(polyclonal) human rabbit 1:1000 Cell Signaling (Frankfurt) 
anti-JAK1 (polyclonal) human rabbit 1:1000 Cell Signaling (Frankfurt) 
anti-ph-JAK2 (Y1007/Y1008) 
(monoclonal) human rabbit 1:1000 Cell Signaling (Frankfurt) 
anti-JAK2 (monoclonal) human rabbit 1:1000 Cell Signaling (Frankfurt) 
anti-ph-STAT5 (Y694) 
(monoclonal) mouse mouse 1:1000 Cell Signaling (Frankfurt) 
anti-STAT5 (polyclonal)  rabbit 1:1000 Cell Signaling (Frankfurt) 
anti-ph-STAT5A (Y694) 
(polyclonal) human rabbit 1:1000 
Signalway Antibody 
(Pearland, USA) 
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Antibody Epitope species 
Host 
species Dilution Manufacturer 
anti-STAT5A (polyclonal) human rabbit 1:1000 Signalway Antibody (Pearland, USA) 
anti-ph-STAT3 (Y705) 
(monoclonal) mouse mouse 1:1000 Cell Signaling (Frankfurt) 
anti-STAT3 (monoclonal) mouse rabbit 1:1000 Cell Signaling (Frankfurt) 
anti-STAT3 (polyclonal) mouse rabbit 1:1000 Cell Signaling (Frankfurt) 
anti-STAT3 (monoclonal) mouse mouse 1:1000 Cell Signaling (Frankfurt) 
anti-ph-STAT1 (Y701) 
(polyclonal) human rabbit 1:1000 Cell Signaling (Frankfurt) 
anti-hSTAT1 
(monoclonal) human rabbit 1:1000 Cell Signaling (Frankfurt) 
anti-STAT1 (polyclonal) human rabbit 1:1000 Cell Signaling (Frankfurt) 
anti-ph-ERK1/2 (T202/Y204) 
(monoclonal) human mouse 1:1000 Cell Signaling (Frankfurt) 
anti-ERK1/2 (polyclonal) rat rabbit 1:1000 Cell Signaling (Frankfurt) 
anti-ph-p38 (T180/Y182) 
(monoclonal) human mouse 1:1000 Cell Signaling (Frankfurt) 
anti-p38 (polyclonal) human rabbit 1:1000 Cell Signaling (Frankfurt) 
anti-ph-Akt (S473) 
(polyclonal) mouse rabbit 1:1000 Cell Signaling (Frankfurt) 
anti-Akt (polyclonal) mouse rabbit 1:1000 Cell Signaling (Frankfurt) 
anti-ph-SHP2 (Y542) 
(polyclonal) human rabbit 1:1000 Cell Signaling (Frankfurt) 
anti-SHP2 (monoclonal) human mouse 1:1000 Santa Cruz Biotechnology (Heidelberg) 
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2.2 Recombinant cytokines, receptors and other ligands 
 
Peptide Activity Concentrations Manufacturer/source 
recombinant human IL-6 1x107 U/mg 20-100 ng/ml Peprotech (Rocky Hill, USA) 
recombinant rat IL-6 1x108 U/mg 20-100 ng/ml Peprotech (Rocky Hill, USA) 
recombinant human  
sIL-6Rα  500 ng/ml 
A. Küster und M. Kauffmann 
(Aachen), Weiergraber et al.253 
recombinant human LIF 1x108 U/mg 1-10 ng/ml Sigma-Aldrich (Taufkirchen) 
recombinant human CT-1 1x106 U/mg 10 ng/ml Peprotech (Rocky Hill, USA) 
recombinant human OSM 5x105 U/mg 10-100 ng/ml Peprotech (Rocky Hill, USA) 
recombinant rat OSM  10-100 ng/ml Peprotech (Rocky Hill, USA) 
recombinant murine OSM 5x106 U/mg 10-20 ng/ml R&D Systems (Minneapolis, 
USA) 
Phenylephrine (PE)  50 µM Sigma-Aldrich (Taufkirchen) 
LIF-05  5-50 ng/ml Prof. Dr. J. Heath (Birmingham, UK), Vernallis et al.254 
 
 
2.3 Small interfering RNAs (siRNAs) 
 
siRNA targeting rOSMR ON-TARGETplus SMARTpool from Dharmacon (Chicago, USA), 
purchased from Thermo Fisher Scientific Inc. (Waltham, USA) 
 
siRNA targeting mOSMR ON-TARGETplus SMARTpool from Dharmacon (Chicago, USA), 
purchased from Thermo Fisher Scientific Inc. (Waltham, USA) 
 
siRNA targeting hOSMR Silencer® Select siRNA from Ambion (Austin, USA), purchased 
from Life Technologies (Carlsbad, USA) 
 
nonsilencing control siRNA AllStars Negative Control siRNA from QIAGEN (Hilden, Germany) 
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2.4 Plasmids for cloning and generation of stably transfected cells 
 
pBO Eukaryotic expression vector was derived from pBI (Clontech, Mountain 
View, USA), that contains a tetracycline responsive bidirectional promoter 
and AmpR (ampicillin resistance gene). HygR (hygromycin resistance gene) 
was inserted and both MCS were modified generating restriction sites for 
NotI, PacI, NheI, AgeI and AscI in MCSII and for SbfI, SgrAI, FseI and SwaI 
in MCSI255.  
 
pTet-On® pTet-On® (Clontech, Mountain View, USA) expresses the reverse tet-
responsive transcriptional activator (rtTA) and contains NeoR (neomycin 
resistance gene) and AmpR. The rtTA is induced by doxycycline. 
 
2.5 Oligonucleotide primers for semi quantitative RT-PCR 
 
mRNA Name Sequence (5´→3´) Amplicon length 
hGAPDH h/r GAPDH for h/r GAPDH rev 
TGATGACATCAAGAAGGTGG 
TTACTCCTTGGAGGCCATGT 244 nt 
hOSMR hOSMR for hOSMR rev 
GACACTGCCTTGGGGTGGTC 
CATCTCCAGGTTGGGGTTTC 877 nt 
rGAPDH h/r GAPDH for h/r GAPDH rev 
TGATGACATCAAGAAGGTGG 
TTACTCCTTGGAGGCCATGT 244 nt 
rgp130 rat gp130 for rat gp130 rev 
CATGGTCAACTTGTGGAACCATG 
TCCCACTGACACAGCATGTTC 380 nt 
rgp130 rat gp130 for II rat gp130 rev II 
GTCAGAGTGGGCAACAGAGA 
GTCTTCCATATGAGCCGTGC 573 nt 
rOSMR rat OSMR for II rat OSMR rev II 
ATATACCAGCGCTGGCCAGG 
AATAGTCCGAGTTGGTGCGG 504 nt 
rLIFR rat LIFR for rat LIFR rev 
ACTGACTGAATAGCACGGAC 
TTACTCTGAAAGCCGTTTTGG 380 nt 
rLIFR rat LIFR for II rat LIFR rev II 
GGACCAGATACTTGGCGAGA 
GGTGCGACAATTGGAGCTAA 573 nt 
rIL-6R rat IL-6R for rat IL-6R rev 
TCACAGAGCAGAGAATGGACT 
GTATGGCTGATACCACAAGGT 481 nt 
mGAPDH m GAPDH for m GAPDH rev 
CTACTGGTGTCTTCACCACC 
GTGGCAGTGATGGCATGGAC 259 nt 
mOSMR mOSMR for mOSMR rev 
GGCATCCCGAAGCGAAGTCTT 
GACGTCCTGCGGAGCCTTTG 952 nt 
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2.6 Oligonucleotide primers for quantitative real time RT-PCR 
 
mRNA Name Sequence (5´→3´) Amplicon 
length 
hGAPDH hGAPDH for hGAPDH rev 
AGCCACATCGCTCAGACAC 
GCCCAATACGACCAAATCC 66 nt 
hgp130 hgp130 for 
hgp130 rev 
AGGACCAAAGATGCCTCAAC 
GAATGAAGATCGGGTGGATG 
69 nt 
hOSMR hOSMR72 for hOSMR72 rev 
TGTCTGGAGAATTGTGAGCTTG 
CATGCAGTTTTGATAATGGCTTC 77 nt 
hLIFR hLIFR for 
hLIFR rev 
GGCCCGGAGAAGAGTATGTA 
TCACCACTCCAACAATGACAG 
103 nt 
rGAPDH rGAPDH for rGAPDH rev 
TGGGAAGCTGGTCATCAAC 
GCATCACCCCATTTGATGTT 78 nt 
rgp130 rgp130 for 
rgp130 rev 
TGTGTATGGAATCACCATACTTTCA 
CCCTCATTCACAATGCAACTC 
75 nt 
rOSMR rOSMR for rOSMR rev 
CCTTCATCAAGTGACCTTCCTT 
GTAAAGGCTCCCCCAAGACT 77 nt 
rLIFR rLIFR for II 
rLIFR rev II 
AAGCTAATTCCAAGAAAGAAGTGC 
CACAGCAACATGGTAGGTTGA 
74 nt 
rIL-6R rIL-6R for rIL-6R rev 
CACGAAGGCTGTGATGTTTG 
GGCACCTGGAAGTCACTCTT 66 nt 
rIL-6R* r msIL-6R for 
r msIL-6R rev 
GCCCACATTCCTGGTAGCTGGAGG 
CCCAAGGGATACGGTGGGGGAG 
141 nt 
rOSM rOSM for III rOSM rev III 
TGGCTGCTCCAGCTCTTC 
GAGCGTGTTCAGGTTTTGGT 118 nt 
rLIF rLIF for 
rLIF rev 
TGCCAATGCCCTCTTTATTT 
CCGATACAGCTCGACCAACT 
148 nt 
rIL-6 rIL-6 for III rIL-6 III 
TCTCGAGCCCACCAGGAACGA 
ACTGGCTGGAAGTCTCTTGCGGA 88 nt 
rACE rACE for 
rACE rev 
TCTGCTTCCCCAACAAGACT 
AGGAAGCCAGGATGTTGGT 
69 nt 
rAT1α 
(Agtr1a) 
rAT1A for 
rAT1A rev 
CACCCGATCACCGATCAC 
CAGCCATTTTATACCAATCTCTCA 110 nt 
rSOCS1 rSOCS1 for 
rSOCS1 rev 
CAGCCGACAATGCGATCT 
CGAGGACGAAGACGAGGAC 
77 nt 
rSOCS3  rSOCS3 for rSOCS3 rev 
AATCCAGCCCCAATGGTC 
GGCCTGAGGAAGAAGCCTAT 65 nt 
rC/EBPβ rC/EBP b for 
rC/EBP b rev 
TCTACTACGAGCCCGACTGC 
GGTAGGGGCTGAAGTCGAT 
120 nt 
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mRNA Name Sequence (5´→3´) Amplicon length 
rC/EBPδ rC/EBP d for rC/EBP d rev 
CCTCCGGCAGTTCTTCAA 
CGGTCGTTCGGAGTCTCTAA 105 nt 
rC/EBPδ rC/EBP d for II rC/EBP d rev II 
CATCAGCGTGTGGAGCAG 
GCTGGGCAGCTCTTTGAA 69 nt 
rSTAT3 rSTAT3 for rSTAT3 rev 
CCAGACAGAAGATGCAGCAG 
CTCGCTCACGATGCTCCT 74 nt 
 
*Oligonucleotide primers that exclusively recognise the membrane bound variant of 
the IL-6R, because primers anneal in the corresponding cDNA region of the 
intracellular part of the IL-6R. Thus alternatively spliced sIL-6R is not detected. 
 
 
2.7 Oligonucleotide primers for cloning rgp130, rOSMR and rLIFR 
 
cDNA  Name Site for Sequence (5´→3´) 
Product 
length 
rgp130 
rgp130 
AgeI AgeI 
ATAATACCGGTTGCAAGATGTCCGC
ACTAAGGATCTGG# 2791 nt 
complete 
rgp130 NotI NotI TAATTAATGCGGCCGCGGTCCCTCACTGTGGCATGTAGCCACC# 
rOSMR 
rOSMR SbfI SbfI AATATTCCTGCAGGGCCACCATGGCTTTCTCTGTGGTCCTTCATCAAG# 2925 nt 
complete rOSMR 
FseI FseI 
TAGGTTGGCCGGCCCCTTGGCCTAA
GAAGTCAAGTTGTTCTCCTTC# 
rLIFR 
rLIFR SbfI SbfI AATATTCCTGCAGGCGGACAATGGGAGCTTTCTCATGGTGG# 3323 nt 
complete 
rLIFR FseI FseI TTAATTGGCCGGCCGACCTGGTTAGTCATTTGGTTTGTTCTGG# 
 
#Printed in bold: Restriction sites for the corresponding enzymes. Printed in 
italics/underlined: Start codon or stop codon, respectively 
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2.8 Sequencing primers 
 
Target Name/Orientation Sequence (5´→3´) Position 5´ of 
the ATG 
rgp130 
1rgp130 rev 
2rgp130 for 
3rgp130 for 
4rgp130 for 
TCCAAACCTGAATTGACCCA 
GAAACCCAGCCCACCTCATA 
TCCCAGACTGGCAGCAAGAA 
CATCTCCAGCAGTGAGGAGA 
747 nt 
657 nt 
1397 nt 
2217 nt 
rOSMR 
1rOSMR rev 
2rOSMR for 
3rOSMR for 
4rOSMR for 
5rOSMR for 
GTTGCTCTCCACGGATTGGC  
GTTGGAAGAAGGTTCCAATG 
GTGCGAGTGCCAACCACTTC 
CAGCGACTTCCAGTCTGGCT  
ACACACCGCACCAACTCGGA 
571 nt 
471 nt 
1211 nt 
1941 nt 
2621 nt 
rLIFR 
1rLIFR rev 
2rLIFR for 
3rLIFR for 
4rLIFR for 
5rLIFR for 
TCAGCACTGTGTTGAGTGAC 
CCAATGCCACCTGGGAGGTT 
TGCTCGCAATCCACTGGGCC 
AGCCCTGCCTCCTGGACTGG 
ACCCATCATTGAGGAGGAAA 
571 nt 
491 nt 
1221 nt 
1991 nt 
2841 nt 
 
2.9 Reaction kits 
 
The following reaction kits were used following the manufacturer´s instructions: 
 
Name of the kit Manufacturer 
QIAGEN Plasmid Mini Kit (QIAGEN, Hilden) 
HiSpeed Plasmid Maxi Kit (QIAGEN, Hilden) 
QIAquick Gel Extraction Kit (QIAGEN, Hilden) 
RNeasy Mini Kit, combined with QIAshredder 
and RNase-Free DNase Set (QIAGEN, Hilden) 
QIAGEN OneStep RT-PCR Kit (QIAGEN, Hilden) 
Verso 1-Step RT-PCR Kit Thermo Fisher Scientific Inc. 
(Waltham, USA) 
Transcriptor First Strand cDNA Synthesis Kit Roche (Basel, Switzerland) 
FastStart Universal SYBR Green Master 
(Rox) 
Roche (Basel, Switzerland) 
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Name of the kit Manufacturer 
PCR Extender System 5 PRIME (Hamburg) 
Thermo Scientific Pierce Enhanced 
Chemiluminescence Kit 
Thermo Fisher Scientific Inc. 
(Waltham, USA) 
WST-1 Cell Proliferation Assay Kit (Clontech, Mountain View, USA) 
Rat IL-6 Quantikine ELISA Kit R&D Systems (Minneapolis, USA) 
 
2.10 Restriction enzymes 
 
Restriction endonucleases Recognised palindrome Manufacturer 
FastDigest® AgeI (BshTI) 5´…A
˅ CCGGT…3´ 
3´…TGGCC˄ A…5´ 
Fermentas (St. Leon-Rot) 
FastDigest® NotI 5´…GC
˅ GGCCGC…3´ 
3´…CGCCGG˄ CG…5´ 
Fermentas (St. Leon-Rot) 
SbfI 5´…CCTGCA
˅ GG…3´ 
3´…GG˄ ACGTCC…5´ 
New England Biolabs 
(Ipswich, USA) 
FseI 5´…GGCCGG
˅ CC…3´ 
3´…CC˄ GGCCGG…5´ 
New England Biolabs 
(Ipswich, USA) 
 
2.11 Enzymes 
 
Used enzyme Method Manufacturer 
Difco Trypsin 250 NRCM isolation BD (Heidelberg) 
DNAse NRCM isolation Sigma-Aldrich (Taufkirchen) 
0.05% Trypsin-EDTA 
(1X), Phenol Red Cell Culture GIBCO (Karlsruhe) 
T4 DNA Ligase Ligation New England Biolabs (Ipswich, USA) 
T4 DNA Ligase Ligation Fermentas (St. Leon-Rot) 
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2.12 Protein and DNA ladder 
 
1) Ladder used for SDS-Gels and Western blotting: 
 
-PageRuler™ Plus Prestained Protein Ladder (10-250 kDa) from Fermentas (St. 
Leon-Rot) 
-Biotinylated Protein Ladder (9-200 kDa) from Cell Signaling (Frankfurt) 
 
2) Ladder used for DNA-Agarose-Gels: 
 
-GeneRuler™ 100 bp DNA Ladder (up to 1 kbp) from Fermentas (St. Leon-Rot) 
-GeneRuler™ 1 kb DNA Ladder (up to 10 kbp) from Fermentas (St. Leon-Rot) 
 
2.13 Eukaryotic cells 
 
Ba/F3 Non adherent murine pre-B cell line, cultured in RPMI 
(10% FCS) + 10 ng/ml mIL-3 
Ba/F3 hOSMR/hgp130 Ba/F3 cells expressing hOSMR and hgp130, cultured in 
RPMI (10% FCS) + 10 ng/ml hOSM or mIL-3; the cells 
were a kind gift form Prof. Dr. J. Heath (Birmingham, 
UK)256 
Ba/F3 @164 (pBO-
rOSMR/rgp130)/pTet-On 
Ba/F3 cells expressing the rOSMR and rgp130, selected 
and cultured in RPMI (10% FCS) + 200 ng/ml hygromycin 
B, 200 ng/ml geneticin (G418), 500 ng/ml doxycycline, 10 
ng/ml rOSM 
Ba/F3 @166 (pBO-
rLIFR/rgp130)/pTet-On 
Ba/F3 cells expressing the rLIFR and rgp130, selected 
and cultured in RPMI (10% FCS) + 200 ng/ml hygromycin 
B, 200 ng/ml geneticin (G418), 500 ng/ml doxycycline, 10 
ng/ml hLIF 
JTC-27 Adherent rat hepatoma cells, cultured in RPMI 1640 (10% 
FCS), purchased from the DSMZ (Braunschweig) 
HepG2 Adherent human hepatoma cells, cultured in DMEM (10% 
FCS), purchased from the DSMZ (Braunschweig) 
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Hepa1c1c7 Adherent murine hepatoma cells, cultured in MEMα 
without nucleosides (10% FCS), purchased from Sigma-
Aldrich (Taufkirchen) 
 
All cell lines mentioned were cultured according to the instructions of the supplier at 
5% CO2 and 37°C in water-saturated atmosphere. 
NRCM and NRCFB were isolated from ≤ 24 h old neonatal Sprague Dawley rats 
(Janvier, Saint-Berthevin Cedex, France), as described in the methods section. While 
NRCM were cultured in self-made NRCM culture medium (as described in chapter 
2.16) at 1% CO2 and 37°C in water-saturated atmosphere, NRCFB were cultured 
using Medium 199 (10% FCS) at 5% CO2 and 37°C in water-saturated atmosphere. 
All culture media were purchased from GIBCO (Karlsruhe).  
 
2.14 E. coli strain for cloning 
  
XL10-Gold Ultracompetent Cells from Agilent (Santa Clara, USA) were used for 
cloning.  
 
2.15 Chemicals 
 
Acrylamide solution (30%) - Mix 37, 5:1  AppliChem (Darmstadt) 
Agar       AppliChem (Darmstadt) 
Agarose       Peqlab (Erlangen) 
Aminocaproic acid     AppliChem (Darmstadt) 
Ampicillin       Roth (Karlsruhe) 
Ammonium persulfate (APS)   AppliChem (Darmstadt) 
Aprotinin       AppliChem (Darmstadt) 
Bromodeoxyuridine (BrdU)    Sigma-Aldrich (Taufkirchen) 
Bromophenol blue     AppliChem (Darmstadt) 
Bovine serum albumin (BSA), blotting grade  AppliChem (Darmstadt) 
DharmaFECT 4 Transfection Reagent  Dharmacon (Chicago, USA) 
4´,6-Diamidino-2-phenylindole (DAPI)   AppliChem (Darmstadt) 
Dimethyl sulfoxide (DMSO)   AppliChem (Darmstadt) 
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Disodium hydrogen phosphate (Na2HPO4) AppliChem (Darmstadt) 
Disodium hydrogen phosphate heptahydrate Merck (Darmstadt) 
(Na2HPO4 x 7 H2O)      
Doxycycline      AppliChem (Darmstadt) 
Ethanol      Roth (Karlsruhe) 
Ethanol absolute      AppliChem (Darmstadt) 
Ethidium bromide     AppliChem (Darmstadt) 
Fetal calf serum (FCS)    PAA (Pasching, Austria)  
Fibronectin solution, bovine (1 mg/ml)  PromoCell (Heidelberg) 
Ficoll® 400      AppliChem (Darmstadt) 
Geneticin (G418)     GIBCO (Karlsruhe) 
Glucose       Merck (Darmstadt) 
Glycerol       AppliChem (Darmstadt) 
Glycine       AppliChem (Darmstadt) 
HaltTM Phosphatase Inhibitor Cocktail  Thermo (Waltham, USA) 
HEPES       AppliChem (Darmstadt) 
Hydrogen chloride (HCl)    AppliChem (Darmstadt) 
Hygromycin B     Life Technologies (Carlsbad, USA) 
Isopropyl alcohol      Roth (Karlsruhe) 
Leupeptin      AppliChem (Darmstadt) 
LipofectamineTM 2000    Life Technologies (Carlsbad, USA) 
Magnesium chloride (MgCl2)     AppliChem (Darmstadt) 
Magnesium sulphate (MgSO4)   AppliChem (Darmstadt) 
2-Mercaptoethanol      AppliChem (Darmstadt) 
Methanol      AppliChem (Darmstadt) 
Minimum Essential Eagle (MEM), powder Sigma-Aldrich (Taufkirchen) 
Non-essential amino acids   GIBCO (Karlsruhe) 
Non-fat dry milk powder, blotting grade   AppliChem (Darmstadt) 
Nuclease free H2O     QIAGEN (Hilden) 
N-Z-Amine®      Sigma-Aldrich (Taufkirchen) 
Opti-MEM®      GIBCO (Karlsruhe) 
Paraformaldehyde     AppliChem (Darmstadt) 
Penicillin (5000 U/ml)/Streptomycin (5 mg/ml) GIBCO (Karlsruhe) 
Pepstatin A      Merck (Darmstadt) 
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Phenylmethylsulfonyl fluoride (PMSF)   AppliChem (Darmstadt) 
Potassium chloride (KCl)     AppliChem (Darmstadt) 
Potassium dihydrogen phosphate (KH2PO4)  AppliChem (Darmstadt) 
Sodium acetate     AppliChem (Darmstadt) 
Sodium chloride (NaCl)     AppliChem (Darmstadt) 
Sodium dihydrogen phosphate (NaH2PO4) Roth (Karlsruhe) 
Sodium dodecyl sulfate (SDS)   AppliChem (Darmstadt) 
Sodium fluoride (NaF)     AppliChem (Darmstadt) 
Sodium hydrogen carbonate (NaHCO3)  Sigma-Aldrich (Taufkirchen) 
Sodium hydroxide (NaOH)   AppliChem (Darmstadt) 
Sodium orthovanadate (Na3VO4)   AppliChem (Darmstadt) 
50x TAE buffer     AppliChem (Darmstadt) 
Tetramethylethylenediamine (TEMED)  AppliChem (Darmstadt) 
Triton X-100      AppliChem (Darmstadt) 
Tris(hydroxymethyl)aminomethane (Tris) AppliChem (Darmstadt) 
Trypan blue for Countess®   Life Technologies (Carlsbad, USA) 
Trypan blue      AppliChem (Darmstadt) 
Tryptone      Roth (Karlsruhe) 
Tween 20      AppliChem (Darmstadt) 
Vitamin B12      Sigma-Aldrich (Taufkirchen) 
Xylene cyanol FF     AppliChem (Darmstadt) 
Yeast extract     Roth (Karlsruhe) 
 
 
2.16 Buffers, solutions and prepared culture media 
 
All buffers and solutions were prepared using H2O of Millipore-quality. Solutions, self-
made media and buffers used for cell culture and primary cell extraction/culture were 
sterile-filtered. Heat inactivated FCS was always added to self-made medium after 
sterile filtration.  
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10x PBS: 1.37 M NaCl 
 27 mM KCl 
 100 mM Na2HPO4 
 20 mM KH2PO4 
  pH 7.4 
 
1x PBS: 137 mM NaCl 
 2.7 mM KCl 
 10 mM Na2HPO4 
 2 mM KH2PO4 
  pH 7.4 
 
2x Laemmli sample buffer/lysis buffer: 
 
 125 mM Tris-HCl (pH 6.8) 
 20 % Glycerol 
 10 % 2-Mercaptoethanol 
 4 % SDS 
 0.005  Bromophenol blue 
 
Triton X-100 lysis buffer: 20 mM Tris-HCl pH 7.5 
 150 mM NaCl 
 10 mM NaF 
 1 % Triton X-100 
 
Applied protease and phosphatase inhibitors for Triton X-100 lysis buffer: 
 
Final concentration Inhibitor 
1mM Na3VO4 
1mM PMSF 
5 µg/ml Aprotinin 
5 µg/ml Leupeptin 
3 µg/ml Pepstatin 
10µl/ml HaltTM Phosphatase Inhibitor Cocktail 
 
 
Tris-buffered saline Tween 20 (TBS-T): 
 
 137 mM NaCl 
 20 mM Tris 
 0.1 % Tween 20 
  pH 7.6 
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Running buffer for SDS-PAGE: 25 mM Tris 
 192 mM Glycine 
 35 mM SDS 
 
10% Separating gel:  3% Stacking gel: 
   
5.9 ml H2O (Millipore)  3.4 ml H2O (Millipore) 
5.0 ml 30% Acrylamide solution  830 µl 30% Acrylamide solution 
3.8 ml 1.5 M Tris-HCl (pH 8.8)  630 µl 2.0 M Tris-HCl (pH 6.8) 
150 µl 10% SDS  50 µl 10% SDS 
12 µl TEMED  5 µl TEMED 
75 µl APS  40 µl APS 
 
Anode I buffer for Western blot: 300 mM Tris 
 20 % Methanol 
  pH 10.4 
 
Anode II buffer for Western blot: 25 mM Tris 
 20 % Methanol 
  pH 10.4 
 
Cathode buffer for Western blot: 40 mM Aminocaproic acid 
 20 % Methanol 
    
 
Stripping buffer: 62.5 mM Tris 
 2 % SDS 
 0.78 % 2-Mercaptoethanol (freshly added) 
  pH 6.7 
 
London Stripping buffer: 2 M Glycin 
  pH 2.5 
 
 
6x DNA sample buffer: 15 % Ficoll® 400 
 0.25 % Bromophenol blue 
 0.25 % Xylene cyanol FF 
 
 
Paraformaldehyde (4% solution): 
-20 g PFA solved in 480 ml 1x PBS 
-Solution heated up to 60°C and pH adjusted to pH 7.2 (NaOH) 
-Filled up to 500 ml with 1x PBS 
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10 mM BrdU: 230 mg BrdU 
 74.8 ml H2O (sterile) 
   5 ml aliquots, frozen at -20°C 
 
 
DNase solution: 100 mg DNase 
 50 ml 0.9% NaCl (sterile) 
   2 ml aliquots, frozen at -20°C 
 
Calicum- and bicarbonate free Hanks with HEPES (CBFHH):  
 
NaCl (3 M) 40 ml 
KCl (0.5 M) 10 ml 
MgSO4 x 7 H2O (8.1 M) 10 ml 
KH2PO4 (0.05 M) 10 ml 
Na2HPO4 x 7 H2O (0.03 M) 10 ml 
HEPES 4.76 g 
Glucose 1 g 
 pH 7.3 (NaOH) 
H2O ad 1 l and sterile filtration 
Penicillin/Streptomycin 5 ml 
 Storage at 4°C 
 
Trypsin solution for enzymatic heart digestion:  
 
Difco Trypsin 250 300 mg 
CBFHH 200 ml 
DNase 2 ml 
 Sterile filtration 
 
 
Vitamin B12 solution: 100 mg Vitamin B12 
 50 ml H2O (sterile) 
   2 ml aliquots, frozen at -20°C 
 
 
NRCM basis medium (uncomplete):  
 
MEM (powder) 10.8 g 
Vitamin B12 solution 1 ml 
NaHCO3 350 mg 
H2O ad 1 l 
 pH 7.3 and sterile filtration 
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NRCM culture medium (ready to use):  
 
FCS  0.5 ml – 25 ml (0.1 - 5.0%), 
see methods 
Penicillin/Streptomycin 5 ml 
BrdU solution (10 mM) 5 ml 
NRCM basis medium ad 500 ml 
 
 
Preplating medium:  
 
FCS 25 ml (5%) 
Penicillin/Streptomycin 5 ml 
NRCM basis medium ad 500 ml 
 
Freezing medium:  
 
Respective medium (e.g. DMEM) 40 % 
FCS 50 % 
DMSO 10 % 
 
LB-medium:  
Tryptone 10 g 
Yeast extract 5 g 
NaCl 10 g 
  pH 7.0 
H2O  ad 1 l 
 
LB-agar:  
Agarose 15 g 
LB-Medium  ad 1 l 
 
NZY+-broth:  
N-Z-Amine 10 g 
Yeast extract 5 g 
NaCl 5 g 
  pH 7.5 
H2O  ad 1 l 
 
12.5 ml of 1 M MgCl2, 12.5 ml of 1 M MgSO4 and 10 ml of 2 M glucose were freshly 
added to the NZY+-broth.  
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2.17 Consumables 
 
Consumables as culture plates, dishes, flasks and tubes, disposable pipettes, tips, 15 
or 50 ml tubes, cryotubes, Eppendorf tubes, cell culture pipettes, well plates, filter tips 
and cuvettes were purchased from Sarstedt (Nümbrecht). Syringes, injection needles 
and scalpels were obtained from B. Braun Melsungen AG (Melsungen). Cell strainers 
and 12 well plates were purchased from BD (Heidelberg). Western blot consumables 
as PVDF-membrane and whatman paper were received from Whatman (Kent, UK). 
Medium bottles and filters for sterile filtration and medium storage were obtained from 
Corning Incorporated (Corning, USA). All other used consumables were purchased 
from Hartenstein (Würzburg), Eppendorf (Hamburg), Serva (Heidelberg) or Millipore 
(Billerica, USA).  
 
2.18 Laboratory equipment (technical instruments, machines and robotic 
systems) 
 
Apparatus Manufacturer 
ABI PRISM® 7900HT, real time PCR cycler Life Technologies (Carlsbad, USA) 
Adjustable casting chamber (JustCast) Peqlab (Erlangen) 
Agarose gel electrophoresis chambers Peqlab (Erlangen) 
AxioObserver.Z1, fluorescence microscope Zeiss (Jena) 
Bacteria incubator Memmert (Schwabach) 
Benchtop shakers, magnetic stirrers and 
overhead stirrers Heidolph (Schwabach) 
BioPhotometer plus Eppendorf (Hamburg) 
Benchtop centrifuges Eppendorf (Hamburg) 
Biometra Multigel and Maxigel, protein gel 
electrophoresis systems Analytik Jena (Jena) 
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Apparatus Manufacturer 
Countess®, automated cell counter Life Technologies (Carlsbad, USA) 
FluorChem Q, Western blot Imager PoteinSimple (Santa Clara, USA) 
Freezer and refrigerators Liebherr (Bulle, Switzerland) 
Gel documentation system Herolab (Wiesloch) 
Heraeus HERAcell 240®, cell incubator Thermo Fisher Scientific Inc. (Waltham, USA) 
Heraeus HERAfreeze, -80°C freezer Thermo Fisher Scientific Inc. (Waltham, USA) 
High performance centrifuges (Avanti™ 
J-25 and Avanti™ J-20XP) Beckmann Coulter (Brea, USA) 
Incubator shaker, Kühnershaker ISF-W1 Adolf Kühner AG (Basel, Switzerland) 
Mastercycler® pro, thermal PCR cycler Eppendorf (Hamburg) 
Microwave oven Privileg (Stuttgart) 
Multiskan EX Microplate Photometer Thermo Fisher Scientific Inc. (Waltham, USA) 
NanoPhotometer® P 300 Implen (Westlake Village, USA) 
4D-Nucleofector™ System, 
nucleofection system Lonza (Basel, Switzerland) 
Single channel and multichannel 
pipettes Eppendorf (Hamburg) 
pH sensor, FE20 - FiveEasy™ pH Mettler-Toledo (Giessen) 
Pipetus®, electronic pipette controller Hirschmann Laborgeräte (Eberstadt) 
Power supplies for electrophoresis Consort (Turnhout, Belgium) 
QIAgility, automated pipetting robot QIAGEN (Hilden) 
Materials 
 
54 
Apparatus Manufacturer 
Sterile benches for cell culture, BDK-S 
1200 
BDK Luft- und Reinraumtechnik 
(Sonnenbühl) 
Thermomixer compact/comfort Eppendorf (Hamburg) 
Transmitted light microscope, Leica 
DMIL Leica (Wetzlar) 
Vortex-Genie® 2; vortex mixer Scientific Industries (Bohemia, USA) 
Water bath GFL - Gesellschaft für Labortechnik (Burgwedel) 
Western blot chamber, semi-dry blotting Peqlab (Erlangen) 
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3 Methods 
3.1 Cell-biological Methods 
3.1.1 Cultivation of eukaryotic cell lines 
 
Cells were cultured under water-saturated atmosphere at 5% CO2 and 37°C. All used 
culture media contained 10% FCS. For Ba/F3 (stably transfected with rOSMR/rgp130 
or rLIFR/rgp130) selection, the antibiotics hygromycin B (200 ng/ml) and geneticin 
(G418, 200 ng/ml) were freshly added to the medium. When Ba/F3 cells were 
cultured without mIL-3 (10 ng/ml), they received 500 ng/ml doxycycline to induce the 
expression of the respective receptors, for at least 24 h. When rLIFR/gp130 
expression was initiated, cell proliferation was induced by treatment with 10 ng/ml 
hLIF. When rOSMR/rgp130 expression was initiated, rOSM (10 ng/ml) was added to 
the medium.  
For longer cultivation of cell lines, continuous passaging of confluent or nearly 
confluent cells was performed. Therefore, suspension cells, as Ba/F3 cells, were first 
centrifuged at 1000 rpm, RT for 5 min. Old medium was removed and cells were 
diluted in fresh medium. The cells were then seeded using the respective passage 
ratio (e.g. one 10 cm dish of confluent cells was passaged 1:2, when the cells were 
seeded on two new 10 cm dishes). Adherent cells were washed with sterile PBS and 
treated with Trypsin/EDTA (e.g. 1 ml for a confluent 10 cm dish). To support the 
process of trypsination, cells were incubated in the incubator at 37°C. The time of 
incubation was dependent on the respective cell line (0.5-3 min). To stop the 
enzymatic reaction and to re-culture the cells, medium with 10% FCS was added and 
cells were seeded applying the particular dilution/passage ratio.  
 
3.1.2 Freezing and thawing eukaryotic cells  
 
For long term storage, non-adherent or adherent cells were removed from the cell 
dishes as described above and centrifuged at 1000 rpm (105 rcf), 4°C for 5 min. 
Medium or PBS was discarded and cells were resuspended in 1 ml cold DMSO-
containing freezing medium (see materials, 2.14). Cells were pipetted into cryotubes 
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and a slow freezing process was achieved by using a Cryo-freezing device 
(Hartenstein, Würzburg). The Isopropyl alcohol filled device allows a slow and gentle 
freezing procedure, as it was cooled down with a rate of -1°C/min. After 24 h, the 
cryotubes were transferred to the liquid nitrogen tank for long term storage.  
Thawing cells was performed by first warming the cryotubes in the water bath at 
37°C. The almost thawed cell suspension was diluted using warm medium containing 
10% FCS. The Falcon tubes were centrifuged at 1000 rpm (105 rcf), RT for 5 min, 
medium was discarded and cells were resuspended in the relative volume of 
prewarmed medium.  
 
3.1.3 Isolation and culture of NRCM and NRCFB 
 
One day before preparation NRCM culture medium and CBFHH (see materials, 2.14) 
were freshly prepared and all instruments (e.g. scissors) as well as beakers with 
agitators were autoclaved. Immediately before the neonatal heart excision, the 
trypsin solution was prepared (see materials, 2.14) and four 50 ml Falcon tubes were 
filled each with 7.5 ml FCS. These tubes, the trypsin solution, the preplating medium, 
the NRCM culture medium and the Medium 199 (10% FCS) were prewarmed in the 
water bath. A further 50 ml Falcon tube with 25-30 ml CBFHH was precooled on ice. 
The newborn rat was cleaned with 70% Ethanol, the head was rapidly cut off using 
biopsy scissors and the rat chest was opened utilizing round scissors. The heart was 
excised via tweezers and transferred into the Falcon tube containing cold CBFHH. 
These steps were repeated with all remaining newborn rats (approximately 22-26 
pups, if two pregnant rats were ordered). The hearts together with a portion of 
CBFHH were transferred into a 10 cm dish on ice. Using the pike scissors and small 
tweezers, the atria were cut off and discarded and the ventricular parts of the hearts 
were gently squeezed to remove residual blood. The hearts were cut into small 
pieces and the tissue pieces were divided into two beakers with agitators using 10 ml 
trypsin solution. Then 5 ml of solution were added to each beaker and the tissue 
solution was incubated for 15 min at RT under the sterile bench while stirring. The 
supernatant was carefully removed and discarded. 20 ml new trypsin solution was 
added to each beaker and they were again incubated at RT while stirring for 10 min. 
Using wide-mouth pipettes, cells were pipetted up and down several times and 
transferred into the FCS containing Falcons. This step was repeated until the trypsin 
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solution was used up. The heart cells were subsequently pelleted via centrifugation 
at 800 rcf for 10 min (RT). The supernatants were discarded and the cells were 
suspended in 10 ml (per Falcon) preplating medium. The suspension was filtered into 
a new Falcon tube by use of a cell strainer (40 µm pore size) and 10 ml of the filtrate 
were seeded in a 10 cm culture dish, allowing four 10 cm dishes to be filled. For 
preplating the dishes were incubated for 1 hour in the cell incubator at 1% CO2 and 
37°C under water-saturated atmosphere. During this time period fibroblasts adhered 
to the bottom of the dishes, while cardiac myocytes remained in the supernatant. 
Meanwhile, cell dishes or plates were coated with fibronectin. For this purpose, 
CBFHH containing 10 µl/ml fibronectin solution (10 µg fibronectin per ml CBFHH) 
was added to the dishes or plates (e.g. 2 ml solution for wetting of a 6 cm dish) and 
incubated at RT for at least 15 min. The fibronectin solution was immediately 
removed before seeding NRCM.  
After 1 hour the NRCM containing supernatant was transferred into a new tube. 
NRCFB were vigorously washed with PBS or Medium 199 (twice) and 10 ml Medium 
199 containing 10% FCS was added. NRCFB were incubated at 37°C and 5% CO2.  
After reaching 90% confluency a few days later, the cells were counted (Countess®), 
passaged once at appropriated dilutions and seeded on new plates or dishes. 
The NRCM suspension was mixed well and counted using the Countess® following 
the manufacturer`s instructions. The cells were diluted and the desired amount of 
cells (usually 1.5 - 2.0 x 106 cells per 6 cm dish for protein lysates or RNAs, 4 x 104 
cells per 96 well for the hypertrophy assay) was seeded on fibronectin coated dishes 
or plates. NRCM designated for lysates or RNAs were diluted with medium 
containing 5% FCS and were incubated at 1% CO2 at 37°C for 24 h. After 24 h the 
medium was replaced by NRCM culture medium containing 1% FCS. NRCM 
designated for the 96 well plate based hypertrophy assay were diluted in medium 
containing 1% FCS and incubated at 1% CO2 at 37°C for 24 h. Afterwards the culture 
medium was replaced by NRCM medium containing 0.1% FCS to prevent serum 
based hypertrophic influences. 
All NRCM were processed at day 3 after isolation to ensure reproducibility of the 
performed experiments. The cells were stimulated with the indicated cytokines for the 
indicated time periods.  
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3.2 Microscopic techniques to determine NRCM cell size 
 
3.2.1 Immune fluorescence staining on NRCM 
 
For performing hypertrophy assays with microscopic cell size determination, NRCM 
were seeded on 96 well plates (4.0 x 104 cells/well). 72 h after PE or IL-6-type 
cytokine treatment, supernatants were removed and cells were treated with 100 
µl/well 4% PFA that was added dropwise. The fixation process was performed 
incubating the cells for 5 min on ice. Afterwards cells were washed thrice with PBS. 
The fixed cells were permeabilised with 0.2% Triton X-100 in PBS (100 µl/well) for 5 
min at RT. NRCM were again washed 3 times with PBS. The primary antibody 
staining with the cardiomyocyte specific α-actinin antibody (1:1000 in PBS) was the 
next step of the immune fluorescence staining procedure. The cells were incubated 
for 30 min at 37°C followed by three further washing steps. The secondary antibody 
(Alexa488 conjugated anti-mouse IgG, 1:200 in PBS) was mixed with the DNA 
staining agent DAPI (1:100 dilution of a 20 mg/ml stock solution in PBS). 100 µl of 
the mixture was added to each well and the plates were incubated at 37°C for 30 
min. After 3 additional washing steps, the cells were covered with a 50% Glycerol 
solution (200 µl/well). Afterwards cells were either used for the automated cell size 
measurement described in the next chapter, or for manual fluorescence microscopy 
with the AxioObserver.Z1 (20x objective) microscope.  
 
3.2.2 Automated measurement of NRCM hypertrophy (hypertrophy assay): High 
content screening (HCS) 
 
Cell size analysis was performed using an automated microscopy method acquiring 
determination of cell size and quantity. This method was previously established and 
published by Jentzsch et al.257. Since the working group of Stefan Engelhardt was 
our former lab neighbour, we had access to the original microscopic equipment and 
were kindly instructed by Claudia Jentzsch and Simon Leierseder. The above 
described immune fluorescence method for the staining of NRCM was the cellular 
base of the automated cell size determination. The following microscopic setup was 
used: The AxioObserver.Z1 (10x objective) microscope, a motorised scanning stage 
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(Märzhäuser, Wetzlar), the Retiga™ 4000DC CCD camera (QImaging, Surrey, 
Canada) and the Lumen200 fluorescence illumination unit from Prior (Cambridge, 
UK). Image acquisition was automated utilizing the so-called Journal record mode 
(Makro functions) of the MetaMorph Basic Imaging Software Package (Molecular 
Devices, Sunnyvale, USA). A main journal consisting of three sub journals was 
generated. The first sub journal coordinates the accurate positioning of the 96 well 
plate to the objective, the focusing of the 10x objective and the image acquisition of 
four images per well (the well is separated into four segments). The acquisition was 
performed consecutively for both fluorescence channels. The second sub journal 
coordinates the 384 images (per 96 well plate) from one fluorescence channel and 
copies them to one stack. A third stack is generated by merging both previously 
generated stacks and can be used for later illustrations. The next subjournal 
determines cell size and quantity via the MetaMorph plug-in “Cell Scoring” that was 
adjusted to the expected diameters and fluorescence intensities. This mode was 
terminally applied to the previously generated stacks. 
 
3.3 Molecular biological methods 
 
3.3.1 Proliferation assay using Ba/F3 cells and the WST-1 Cell Proliferation 
Assay Kit 
 
Proliferation assay was performed using stably transfected Ba/F3 cells expressing 
hgp130/hOSMR, a kind gift from Prof. Dr. J. Heath (Birmingham, UK)256. The cells 
were thawed as described above. Cells were cultured in culture flasks in the 
presence of RPMI containing 10% FCS and 10 ng/ml mIL-3. After several days of 
culture cells were counted via the Countess®, diluted in the appropriate amount of 
medium and seeded on a 96 well plate. Cells were seeded at a concentration of 
1x104 cells per 96 well and treated with different concentrations of hOSM or rOSM (0, 
0.0064, 0.032, 0.16, 0.8, 4, 20 and 100 ng/ml) for 48 h (incubation at 37°C and 5% 
CO2 in water-saturated atmosphere). The experiment was performed in triplicates, as 
every experimental group existed thrice. After the incubation period, 10 µl premixed 
WST-1 reagent were added to every well. The cells were incubated for four additional 
hours at 5% CO2 and 37°C. Subsequently the plates were vortexed gently to 
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disperse the reagent, and the absorbance of the wells was measured at 450 nm and 
660 nm (reference wavelength) using the Multiskan EX Microplate Photometer. The 
results of the assay were calculated by subtracting the A660 reference value from the 
A450 value. 
 
3.3.2 Rat IL-6 ELISA using the Rat IL-6 Quantikine ELISA Kit 
 
NRCFB (P1) were seeded at a density of 3x104 cells per 24 well. The cells were 
stimulated for the indicated time and supernatants were collected subsequently. The 
samples were stored at -80°C until use. The rat IL-6 Quantikine ELISA Kit was 
purchased from R&D Systems (Minneapolis, USA) and the experimental protocol 
was performed according to manufacturer`s recommendations. Absorbance was 
measured using the Multiskan EX Microplate Photometer according to the 
recommendation of the Quantikine ELISA protocol.  
 
3.3.3 Reverse transcription of rgp130, rOSMR and rLIFR for subsequent cloning 
 
RNA was isolated from JTC-27 rat hepatoma cells using the RNeasy mini Kit 
according to the manufacturer’s instructions. 5 µg RNA were used for every reverse 
transcription reaction performed with the Transcriptor First Strand cDNA Synthesis 
Kit. The following approach was pipetted: 5 µg RNA (in 50 µl final volume) were 
mixed with 5 µl anchored-oligo(dT)18 primers, 10 µl random hexamer primers, 20 µl 
5x Transcriptor RT reaction buffer, 2.5 µl protector RNase inhibitor, 10 µl dNTP-Mix 
and 2.5 µl Transcriptor reverse transcriptase. The 100 µl samples were gently mixed 
using the pipette. The samples were shortly centrifuged (short spin) and transferred 
to the Eppendorf Mastercycler® pro. The reverse transcription run was performed 
according to the following steps: 60 min at 50°C (reverse transcription) and 5 min at 
85 °C (inactivation). The resulting cDNA samples were subsequently cooled to 4°C.  
 
3.3.4 PCR amplification of long cDNA products (rgp130, rOSMR and rLIFR) 
 
To generate PCR products containing specific restriction enzyme sites, the cDNA 
templates were used to amplify the complete coding sequence of each receptor with 
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specific primers containing restriction sites flanking the start or stop codon (see 2.7) 
and the PCR Extender System. The kit was used according to the manufacturer`s 
instructions and the following pipetting scheme was applied: Mastermix I (total 
volume: 10 µl): 2.0 µl of each primer (10 µM stock), 100-500 ng template cDNA and 
nuclease free H2O, Mastermix II (total volume: 40 µl): 5 µl 10x tuning buffer, 2.5 µl 
dNTP mix (10 mM each), 0.4 µl PCR Extender polymerase mix and 32.1 µl nuclease 
free H2O. Final concentrations were: 400 nM of each primer, 500 µM of each dNTP 
and 2 U polymerase mix in the entire reaction. Both solutions were mixed shortly 
before transferring the resulting mixture to the Mastercycler® pro. The run was 
performed using the following conditions: 2 min initial template denaturation at 94°C, 
45 cycles of template denaturation (20 sec at 94°C), primer annealing (20 sec at 
56°C for rgp130 and rOSMR, 20 sec at 66°C for rLIFR) and product elongation (4 
min at 68°C) followed by a final extension step (6 min at 68°C) and cooling down to 
4°C. After gel extraction (see 3.3.4 and 3.3.5), the products were subsequently 
exposed to restriction enzyme digestion (described in 3.3.6). After additional gel 
extraction, the processed fragments served as inserts for ligation with linearised pBO 
(see 3.3.7).  
 
3.3.5 Horizontal Agarose Gel Electrophoresis (DNA electrophoresis) 
 
DNA fragments were separated according to their size using agarose gel 
electrophoresis. 0.8-1.0% agarose gels were used to separate larger DNA fragments 
(2 kb to ≥ 12 kb), while 1.5-2.0% agarose gels were applied to separate DNA 
fragments up to a size of 1 kb. Gels were produced solving the appropriate amount of 
agarose in 1x TAE buffer (diluted from 50x TAE buffer) and heating the solution 
several times in a microwave. The gel was allowed to cool down for 5 min and 
ethidium bromide (0.3-0.5 µg/ml) was added. Ethidium bromide intercalates between 
both DNA strands thus visualising a DNA band under UV light (λ=312 nm). The 
agarose gel was cast using the adjustable casting chamber and the appropriate 
combs (Peqlab, Erlangen). The DNA samples were diluted with 6x DNA loading 
buffer and the resulting stained samples as well as the appropriate DNA ladder (see 
materials, 2.11) were loaded onto the gel. The electrophoresis chamber was filled 
with 1x TAE buffer and electrophoresis performed at 80-120 V.  
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3.3.6 Purification of separated DNA fragments from agarose gels 
 
To regain PCR products or restricted DNA fragments from an agarose gel, the 
respective gel slice was cut out using a fresh disposable scalpel and purified using 
the QIAquick Gel Extraction Kit according to the instructions of the manufacturer. The 
DNA fragment was eluted with nuclease free H2O and the amount and purity were 
determined using the NanoPhotometer® P 300. PCR products were further used for 
restriction enzyme digestion, whereas already digested and purified DNA fragments 
were ligated to an appropriate vector.  
 
3.3.7 Digestion of DNA using restriction enzymes 
 
The purified inserts as well as the plasmid (pBO) were digested with matching 
restriction enzymes, whose recognition sequences are present in the MCS of pBO 
and the designed receptor primers. The rgp130 amplicon (1.5 ng) and 1.6 ng pBO 
(MCS I) were digested with 1 µl AgeI (1 FDU) and 1 µl NotI (1 FDU) fast digest 
enzymes for 30 minutes at 37°C (total reaction volume was 10 µl including the 
template, the enzymes, 1 µl FD buffer (10x) and nuclease free H2O). The rOSMR 
(1.5 ng), rLIFR (1.5 ng) amplicon and 1.5 ng pBO-rgp130 (MCS II) were digested with 
2 µl SbfI (20 U) for 4 h at 37°C. For the last hour, 5 µl FseI (10 U) was added to the 
solution (total reaction was 50 µl including enzymes, template, 5 µl NEB buffer 4 (5x) 
and nuclease free H2O). The completeness and success of the reaction were 
determined via agarose gel electrophoresis, as described above. The desired 
fragment was subsequently extracted and purified, as described in 3.3.5.  
 
3.3.8 Ligation of inserts and vector with T4 DNA Ligase 
 
Purified AgeI/NotI restricted rgp130 was ligated with purified AgeI/NotI restricted pBO 
using T4 DNA ligase. The following pipetting scheme was used: 2 µl 10x T4 DNA 
ligase buffer, 50 ng vector DNA (6210 bp), 4-8-fold molar excess of insert DNA (e.g. 
135 ng of rgp130 DNA corresponds to a 4 molar excess of insert; rgp130 DNA 
consisted of 2780 bp after digestion), 1 µl T4 DNA ligase and nuclease free water to 
a total volume of 20 µl. A stepwise ligation was performed, because rgp130 was first 
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inserted into pBO. Then the generated vector (pBO-rgp130) was transformed into 
XL10-Gold bacteria and purified with the QIAGEN Plasmid Mini Kit according to the 
manufacturer´s instructions (see next chapters). pBO-rgp130, the rOSMR and the 
rLIFR were subsequently restricted with FseI and SbfI, as described above. The 
resulting fragments were again ligated, thus generating pBO-rgp130-rOSMR (@164) 
and pBO-rgp130-rLIFR (@164). Portions of the ligation mixtures were subsequently 
transformed into XL10-Gold (see 3.3.8).  
 
3.3.9 Transformation of ligated vectors into XL10-Gold  
 
Before transformation, XL10-Gold cells were thawed on ice. Cells were gently mixed 
and aliquoted in prechilled culture tubes (50 µl per transformation). 2 µl β-
mercaptoethanol (provided with the cells) were added to the bacteria solutions, the 
tubes were gently swirled and the cells were incubated on ice for 10 min. During this 
incubation period an additional swirling step was performed every 2 min. 5 or 10 µl of 
the respective ligation product were added to an aliquot of ultracompetent cells and 
the tubes were incubated for 30 min on ice. After this, the tubes were rapidly 
transferred to a water bath (42°C) for 40 sec. Thus, a heat-shock was induced which 
initiated the uptake of the vectors. The cells were incubated on ice for 2 min and 450 
µl of NZY+ (preheated) were added. The culture tubes were transferred to the 
incubator shaker and incubated for 1 h at 37°C at 250 rpm. 250 and 50 µl, 
respectively, of the transformed bacteria were plated on LB agar plates containing 
100 µg/ml ampicillin. The bacteria were incubated over night at 37°C. The next day, 
colonies were counted and used for plasmid purification and determination of correct 
insertion (see 3.3.9).  
 
3.3.10 Plasmid purification using the QIAGEN Plasmid Mini Kit 
 
After bacterial colonies were grown on petri dishes over night, clones were picked 
and inoculated in 4 ml LB-medium (containing 100µg/ml ampicillin) for further over 
night culture in the incubator shaker at 37°C and 225 rpm. 2 ml of these cultures 
were utilised for small scale purification of the plasmid DNA. Cells were pelleted 
through centrifugation at 6000 g for 3 min. Lysis of the bacteria and plasmid isolation 
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were achieved using the QIAGEN Plasmid Mini Kit according to the manufacturer´s 
instructions. The DNA was eluted in 50 µl EB buffer (provided with the kit). The 
correct insertion of the inserts was analysed using appropriate restriction enzymes 
and gel electrophoresis. At last samples were sent to Eurofins MWG (Ebersberg) for 
sequencing the generated finished construct.  
 
3.3.11 Plasmid purification using the QIAGEN Plasmid Maxi Kit 
 
For large scale purification of plasmids, over night cultures were inoculated, as 
described in 3.3.9. For this purpose, 5 ml LB-medium (containing 100 µg/ml 
ampicillin) were inoculated with a swipe of a glycerol stock (mixture of 200 µl bacteria 
culture + 800 µl glycerol, used for long term storage at -80°C) using the inoculation 
loop. After over night culture (as described above), 250 ml LB-medium (containing 
100 µg/ml ampicillin) were inoculated with 1 ml of the first small over night culture. 
Cells were incubated in the incubator shaker over night at 37°C and 225 rpm. The 
next day, bacteria were pelleted through centrifugation at 4°C and 6000 g for 15 min. 
Lysis of the cells and plasmid purification was performed using the HiSpeed Plasmid 
Maxi Kit according to the instructions of the manufacturer. The purified DNA was 
eluted in 1 ml TE buffer provided with the kit.  
 
3.3.12 DNA sequencing 
 
The sequencing of the purified plasmid/construct DNA was performed by Eurofins 
MWG (Ebersberg). For this purpose, 15 µl (per sequencing reaction) of a 75-100 
ng/µl DNA solution and the appropriate sequencing primers were shipped to Eurofins 
MWG. The sequencing data were verified through alignment analysis using the 
GENtle software (Magnus Manske, Köln, http://gentle.magnusmanske.de).  
 
3.3.13 Stable transfection of murine Ba/F3 cells 
 
First, Ba/F3 cells were transfected with the 2.5 µg of the pTet-ON (neo) plasmid 
using the 4D-Nucleofector® according to the manufacturer’s instruction. For 
approximately 2 weeks, positive cells were selected using geneticin (G418 (200 
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ng/ml)) that was freshly added every day together with fresh RPMI medium (10% 
FCS and 10 ng/ml mIL-3). Cells without the neomycin cassette from the pTet-On 
were dying during selection. The remaining neomycin resistant pool of cells was then 
transfected with 2.5 µg of the pBO-rgp130/rLIFR (@166) or the pBO-rgp130/rOSMR 
(@164) plasmid again using the 4D-Nucleofector® according to the manufacturer`s 
instructions. As described above, cells were again selected for several days using 
200 ng/ml hygromycin and 200 ng/ml geneticin (G418). A hygromycin/neomycin-
resistant pool of cells was then used to induce the respective receptor combination 
expression through treatment with 0.5 µg/ml doxycycline. Now the cells were able to 
proliferate in the presence of hLIF (Ba/F3-rgp130/rLIFR) or rOSM (Ba/F3-
rgp130/rOSMR) and in the absence of mIL-3. For Western blot analysis cells were 
treated over night with 0.5 µg/ml doxycycline. The next day, they were stimulated 
with 10 ng/ml hLIF, 20 ng/ml hOSM, mOSM or rOSM for 15 min and lysed 
subsequently.  
 
3.3.14 Semiquantitative RT-PCR using the QIAGEN OneStep RT-PCR Kit 
 
Semiquantitative reverse transcription polymerase chain reaction (RT-PCR) for the 
analysis of mRNA expression was performed using the QIAGEN OneStep RT-PCR 
Kit. Total RNA from transfected and/or stimulated cells was isolated using the 
RNeasy Mini Kit according to the manufacturer's protocol. RNA concentration and 
purity was determined using the Implen NanoPhotometer. Reverse transcription and 
following PCR were performed with 1 µg isolated total RNA, aforementioned 
oligonucleotide primers (material section) and the kit. The following pipetting scheme 
was applied: Mix I: 1 µl of each primer (4 µM, 200 nM final concentration), 4 µl RT-
PCR reaction buffer (5x), 0.8 µl dNTP-Mix (10 mM of each, 400 µM final 
concentration), 0.4 µl nuclease free H2O and 0.8 µl RT-PCR enzyme-mix, Mix II: 1 µg 
RNA was diluted with nuclease free H2O to a final volume of 10 µl. Both solutions 
were gently mixed, shortly centrifuged (short spin) and transferred to the cycler. The 
RT-PCR run was performed on a Mastercycler® pro as follows: reverse transcription 
at 50°C for 30 minutes, 15 minutes initial activation of the HotStartTaq DNA 
polymerase and denaturation of reverse transcriptase at 95°C, 32-35 cycles of 94°C 
for 30 seconds (denaturation), 58°C for 30 seconds (primer annealing) and 72°C for 
1 minute (elongation). The program was finalised by 10 minutes at 72°C (finale 
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elongation). As described above, DNA products were separated via a 1.5% agarose 
gel electrophoresis. DNA bands were detected using ethidium bromide staining. 
3.3.15 Semiquantitative RT-PCR using the Verso 1-Step RT-PCR Kit 
 
RT-PCR analysing the existence of the rat receptor mRNAs in the stably transfected 
Ba/F3 cells (3.3.13) were performed using the Verso 1-Step RT-PCR Kit. Total RNA 
was isolated from Ba/F3 cells (“empty”, rgp130/rOSMR, rgp130/rOSMR + 0.5 µg/ml 
doxycycline (24 h), rgp130/rLIFR, rgp130/rLIFR + 0.5 µg/ml doxycycline (24 h)) using 
the RNeasy Mini Kit according to the instructions of the manufacturer. The following 
pipetting scheme was applied: Mix I (5 µl): 100 ng RNA in 5 µl total volume. Mix II (25 
µl): 1.25 µl of each primer (4 µM, 200 nM final concentration), 12.5 µl Verso 1-Step 
RT-PCR Master Mix (2x), 1.25 µl RT-Enhancer, 3.25 µl nuclease free H2O and 0.5 µl 
RT-PCR enzyme-mix. Mix I and II were gently mixed, shortly centrifuged (short spin) 
and transferred to the cycler. The run was performed on a Mastercycler® pro as 
follows: reverse transcription at 50°C for 15 minutes, 2 minutes initial activation (of 
the Thermo-Start Taq DNA polymerase) and denaturation of reverse transcriptase at 
95°C, 45 cycles of 95°C for 20 seconds (denaturation), 53°C for 30 seconds 
(annealing) and 72°C for 1 minute (elongation). The program was finalised by 72°C 
for 5 minutes (final elongation). DNA products were separated via a 2.0% agarose 
gel. DNA bands were detected using ethidium bromide staining. 
 
3.3.16 Quantitative real time RT-PCR (qPCR)  
 
Quantitative analysis of gene expression was assessed by real time RT-PCR (qPCR) 
analysing the mRNA expression levels. Total RNA was isolated by use of the 
RNeasy Mini Kit and RNase-Free DNase Set according to the manufacturer's 
protocol. An initial reverse transcription PCR was performed using the Transcriptor 
First Strand cDNA Synthesis Kit according to the recommendations of the 
manufacturer. The following pipetting scheme was used: 1 µg RNA (in 10 µl final 
volume) were mixed with 1 µl anchored-oligo(dT)18 primers, 2 µl random hexamer 
primers, 4 µl Transcriptor RT reaction buffer, 0.5 µl Protector RNase inhibitor, 2 µl 
dNTP-Mix and 0.5 µl Transcriptor reverse transcriptase. The 20 µl reactions were 
gently mixed with a pipette. The samples were shortly centrifuged (short spin) and 
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transferred to the Eppendorf Mastercycler® pro. The reverse transcription run was 
performed according to the following steps: 60 min at 50°C (reverse transcription) 
and 5 min at 85 °C (inactivation). The cDNA samples were subsequently cooled to 
4°C. The resulting cDNA was used to perform real time PCR with the FastStart 
Universal Sybr Green Master (Rox), as instructed by the manufacturer. Primers 
applied in qPCR experiments are mentioned in the material section, chapter 2.6 
(Oligonucleotide primer for quantitative real time RT-PCR). Serial dilutions of 
template cDNAs were used to verify primer efficiencies. For each target mRNA to be 
analysed, 5 µl of Sybr Green master mix, 400 nM of each primer (0.4 µl of a 10 µM 
stock), 2.2 µl nuclease free H2O and 2 µl of the respective cDNA were mixed on 384 
well plates in duplicates using the automated liquid handling robot QIAgility. Real 
time PCR was performed on a real time PCR cycler (ABI PRISM 7900HT) under the 
following conditions: initial activation of 10 minutes at 95˚C, followed by 40 cycles of 
15 seconds denaturation at 95˚C, 20 seconds hybridisation at 60˚C, 20 seconds 
elongation at 60˚C  and a final elongation at 65˚C for 15 seconds. The additional 
recording of the melting curves for determining the exclusiveness of the amplicons 
and the right melting temperature consisted of 15 seconds at 95˚C and 15 seconds at 
60˚C (last step of the PCR run). Quantification of target messages was performed by 
applying the mathematical model described by Pfaffl258.  
 
3.3.17 Cell stimulation and lysis 
 
Stimulated and/or transfected cells were lysed for use in SDS-PAGE and Western 
blotting procedure. At first, cells were stimulated with the cytokines mentioned in the 
figure legends, for the indicated times. While hsIL-6R was directly added before 
stimulation with hIL-6, indicated concentrations of the LIFR specific antagonist LIF-05 
were preincubated 30 min before cells were stimulated with additional cytokines. 
After stimulation periods, cells were instantly washed with cold PBS and lysed with 
either Triton X-100 lysis buffer at 4°C (containing 1 mM Na3VO4, 3 µg/ml pepstatin, 1 
mM PMSF, 5 µg/ml aprotinin, 5 µg/ml leupeptin and 10 µl/ml Halt Phosphatase 
Inhibitor Cocktail), or with 1x Laemmli buffer (63 mM Tris HCl, 10% Glycerol, 2% 
SDS, 0.0025% Bromophenol blue and 5% β-mercaptoethanol, pH 6.8) for all protein 
lysates from siRNA transfected cells. After addition of Triton X-100 lysis buffer, 
adherent cells were scraped using a rubber cell scraper. The solution was transferred 
Methods 
 
68 
to an Eppendorf reaction tube and incubated on ice for 30 min. Lysed cells were 
subsequently centrifuged in a cooled Eppendorf centrifuge at 15000 rpm (21130 rcf) 
for 15 min at 4°C. Supernatants were transferred into new 1.5 ml reaction tubes. 
Lysates were stored at -20°C and gently thawed before further use. Prior to loading 
to a protein gel, equal protein portions of the samples were diluted with Laemmli 
buffer and heated for 5 min at 95°C. Cells were centrifuged (short spin) and loaded. 
Cells directly lysed in Laemmli were detached from the plates/dishes utilizing a 
polyethylene cell scraper. After cell lysis, lysates were incubated for 15 min on ice 
and heated at 95°C for 5 min before loading. They were kept at -20°C for long term 
storage.  
 
3.3.18 SDS-PAGE (Sodium dodecyl sulfate polyacrylamide gel electrophoresis) 
 
The separation of polypeptides according to their mass was performed using the 
denaturating SDS-PAGE under reducing conditions, as described by Laemmli259. 
SDS gels were cast applying the above mentioned gel formula (see 2.14) and the 
Biometra Multigel or Maxigel system. First the separating gel was cast between both 
glass plates (provided with the Biometra gel systems) and covered with isopropyl 
alcohol. After polymerisation of the gel, the isopropyl alcohol was discarded and the 
plates were dried. Then the stacking gel was cast and the appropriate comb was 
immediately inserted. After polymerisation of the stacking gel the pockets were 
washed and the gel chamber filled with 1x running buffer. For the experiments 
described in this work, only 10% separation gels and 3% stacking gels were 
produced. After loading the samples, electrophoresis was performed at 25-50 mA 
amperage for 2-3 h. Besides the samples, the PageRuler™ Plus Prestained Protein 
Ladder and the Biotinylated Protein Ladder were loaded to the gel. The anionic part 
of the detergent SDS binds to side chains of proteins after constant distances and 
thus masks the electrical charges of the protein. By addition of SDS, proteins can be 
separated according to their size irrespective of their own charges. Moreover, SDS 
interrupts hydrogen bonds and, in combination with β-mercaptoethanol, denatures 
polypeptides. 
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3.3.19 Semi-dry Western blot 
 
After proteins were separated according to their size via 10% SDS-polyacrylamide 
gel electrophoresis, they were transferred to a PVDF (polyvinylidene fluoride) 
membrane via semi-dry Western blotting. The membrane and 12 layers of whatman 
paper were cut to the required gel size. The PVDF-membrane was activated through 
immersion in 100% methanol for a few seconds. Afterwards the membrane was 
shortly washed in H2O (Millipore) and equilibrated in anode II buffer. Meanwhile, the 
gel was extracted from the glass plates and equilibrated in cathode buffer. The 
whatman papers were equilibrated in the appropriate buffer and the assembly was 
performed according to the following conditions (from the bottom (anode) to the top 
(cathode)): 5 whatman paper soaked in anode I buffer, 2 whatman paper soaked in 
anode II buffer, the PVDF-membrane soaked in anode II buffer, the gel soaked in 
cathode buffer and 5 whatman paper soaked in cathode buffer. The blotting chamber 
was gently closed and electric current was applied. The applied amperage was 
defined as follows: 0.8 x area of the membrane (cm2) = used amperage (mA) (e.g. 50 
cm2 area of the membrane x 0.8 = 40 mA). The procedure was operated for 65 min. 
After protein transfer, membranes were blocked using 10% Western blot grade BSA 
(in TBS-T) for 50 minutes. Membranes were subsequently incubated over night with 
indicated primary antibodies at 4°C on a shaker. The next day, membranes were 
washed thrice for 10 minutes each in 1x TBS-T, incubated with the respective 
horseradish peroxidase (HRP) conjugated second antibody for 1 h at room 
temperature, followed again by three washing steps. Western blot analysis was 
finalised by using an enhanced chemiluminescence Kit according to the 
manufacturer’s instructions. For detecting the chemiluminescence signal, a 
quantitative Western blot imager from ProteinSimple, the FluorChem Q, was used. 
Before washing, blocking and reprobing of the blots to detect the unphosphorylated 
protein loading controls and/or independent α-tubulin detection, the membranes were 
incubated in stripping buffer (at 70°C for 20 min) to remove primary and secondary 
antibodies. When a second phospho-protein was detected on the same membrane, 
the blots were incubated in London stripping buffer supplemented with a point of a 
spatula of SDS. After incubating the membranes for 2 h on a shaker and additional 3 
h without shaking, blots were washed three times, blocked and reprobed with the 
respective antibody. These procedures were performed as described above.  
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3.3.20 Small interfering RNA (siRNA) transfection  
 
For siRNA transfections, JTC-27 cells were seeded on 6 cm plates at a density of 3.0 
x 105 cells/plate, while HepG2 and Hepa1c1c7 were cultured on 6 wells at a density 
of 2.0 x 105 cells/well. After 24 h incubation (37°C, 5% CO2), growth media were 
removed and replaced by Opti-MEM®. DharmaFECT 4 was used as transfection 
reagent for transient JTC-27 transfections and Lipofectamine 2000 was chosen for 
transient HepG2 and Hepa1c1c7 transfections. Both transfection reagents were 
applied according to the manufacturer´s instructions. The respective siRNA as well 
as the transfection reagent were each prediluted in Opti-MEM® without FCS. Then 
both solutions were mixed and incubated for 30 minutes. JTC-27 cells were 
transfected with a final concentration of 100 nM siRNA, whereas HepG2 and 
Hepa1c1c7 were transfected with 50 nM siRNA final concentration. After the 
incubation period the mixtures were added dropwise and cells were incubated for 5 h 
at 37°C and 5% CO2 without serum. After 5 h incubation, Opti-MEM® containing 
excessive FCS for adjustment of a final concentration of 10% FCS was added. Cells 
were incubated for 28 h (Hepa1c1c7) or 48 h (HepG2 and JTC-27). After incubation, 
cells were stimulated as mentioned in the figure legends and further investigated. 
The transfection efficiencies were analysed on RNA level using RT-PCR or qPCR. In 
Hepa1c1c7 and HepG2 cells the protein levels were additionally analysed performing 
Western blots.  
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4 Results 
4.1 Analysis of IL-6-type cytokine induced hypertrophy 
 
Previous studies have indicated that stimulation of the LIFR/gp130 receptor complex 
via LIF196, 217 or CT-1194, 195, 201, 218 as well as of the IL-6R/gp130 receptor complex via 
IL-6199, 260 induces hypertrophy and morphological changes in neonatal rat 
cardiomyocytes (NRCM). One of the central questions in this first part of the thesis 
was, which kind of hypertrophy IL-6-type cytokines induce in comparison to the α1-
adrenergic agonist PE and whether different IL-6-type cytokines act in a comparable 
manner, particularly since for OSM only limited information is available. The currently 
best established model for the analysis of cardiomyocyte hypertrophy uses neonatal 
rat cardiomyocytes. However, not for all IL-6-type cytokines rat recombinant proteins 
were available. Therefore, cross-species activities have to be taken into account. 
Previous publications have demonstrated that human OSM (hOSM) exclusively 
utilises LIFR/gp130 heterodimers (type I receptor complex) on murine cells74, while 
murine OSM (mOSM) utilises the murine type II (OSMR/gp130) receptor complex74, 
75. Moreover, human IL-6 (hIL-6) has been shown to stimulate murine and rat cells as 
potent as murine IL-6261. Human LIF (hLIF) that was used for many studies with cells 
of rat and murine origin has been demonstrated to strongly activate rodent cells by 
utilising the heterodimeric LIFR/gp130 complex23-25, 36. Human Cardiotrophin-1 (hCT-
1) has been shown to stimulate murine and rat cells equally potent as murine CT-
1262. In contrast to all other mentioned IL-6-type cytokines, the murine variant of CT-1 
is also able to signal through the human receptor complex262.  
Therefore, we decided to analyse the hypertrophic potential of hOSM, mOSM, hLIF, 
hIL-6 with and without human soluble IL-6R (hsIL-6R) and of hCT-1. Since IL-6 signal 
transduction is achieved via g130 homodimerisation requiring two IL-6 molecules for 
the activation of one gp130 homodimer18-20, we used the twofold amount of IL-6 (20 
ng/ml) in comparison to all other cytokines (10 ng/ml hOSM, mOSM, hLIF and hCT-
1). The latter cytokines utilise gp130/LIFR heterodimers or gp130/OSMR 
heterodimers, respectively, requiring only one cytokine molecule for the activation of 
one receptor heterodimer23-27, 30, 31. The induced hypertrophic phenotype was 
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determined regarding hypertrophy type and cytokine capacity 72 h after stimulation of 
NRCM via fluorescence microscopy/automated cell size measurement. 
 
4.1.1 Hypertrophy assay of IL-6-type cytokine treated NRCM 
 
Upon isolation of NRCM as described in the methods section, the cells were cultured 
for three days prior to treatment with the mentioned IL-6-type cytokines for 72 h. 
 
Figure 6: Hypertrophic properties of IL-6-type cytokines on NRCM 
NRCM (cultured for three days) were treated for 72 h with 50 µM PE, 50 µM PE + 10 ng/ml mOSM, 10 
ng/ml hLIF, hOSM, mOSM, hCT-1 or 20 ng/ml hIL-6 (± 0.5 µg/ml hsIL-6R). A, Representative 
immunostainings of NRCM using a sarcomere specific α-actinin antibody and DAPI for visualisation of 
nuclei (stimuli as indicated, scale bar: 100 µm, 20x objective). B, The diagram represents cell size 
values corresponding to the immunostainings shown in A. Mean values of four experiments with 
standard error of mean (SEM) are displayed. Statistical significance was calculated against untreated 
NRCM using a two-tailed, paired Student’s t-test, ** p<0.01, *** p<0.001.  
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A clear but differentially strong hypertrophic answer of the analysed NRCM has been 
observed (Fig. 6). While PE predominately mediates a concentric type of hypertrophy 
(cells increase in length and width), all used IL-6-type cytokines induce a more 
eccentric type of hypertrophy (cell length, but not width, is critically increased). 
Human LIF is the strongest inducer of hypertrophy among the tested IL-6-type family 
members and has a hypertrophic potential comparable to PE (induction od twofold 
cell size increase).  
All other IL-6-type cytokines cause 1.4- to 1.8-fold cell size increases (hOSM 1.6-fold, 
mOSM 1.4-fold, hCT-1 1.8-fold and hIL-6/hsIL-6R 1.5-fold cell size enlargement). 
Although hIL-6 together with its soluble α-receptor (trans-signalling) is able to induce 
hypertrophy comparable to mOSM, pure hIL-6 mediates no measureable cell growth 
stimulatory effect providing first evidence for a lack of IL-6R on the NRCM cell 
surface. 
 
4.1.2 IL-6-type cytokines induce changes of the sarcomeric assembly 
 
The fluorescence microscopy was additionally used for analysis of sarcomeric 
changes that are induced by IL-6-type cytokines. Alpha-actinin staining allows optical 
visualisation of the Z-lines of sarcomers. Thus degradation, reorganisation or addition 
of sarcomers can be detected after treatment of NRCM with hypertrophic stimuli.  
The enlarged immunostainings clearly show that PE treated NRCM possess perfectly 
organised Z-lines, and the sarcomeric architecture seems to be retained (Fig. 7, left).  
 
 
 
Figure 7: Partial loss of the Z-line pattern in IL-6-type cytokine treated NRCM 
Detailed section (scale bar: 100 µm, 20x objective) of PE (left) and hIL-6/hsIL-6R (right) treated NRCM 
(for details see Fig. 6) stained with an α-actinin-FITC antibody (green) and DAPI (blue).  
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In contrast, IL-6-type cytokine treated NRCM (e.g. hIL-6/hsIL-6R) show a lack of Z-
lines in some locations (Fig. 7, right, marked by red arrows). In these regions the 
typical T-shaped structure of the sarcomers is interrupted indicating strong 
remodelling of sarcomeric proteins in the contractile units of the cardiomyocytes or 
the cardiac muscle, respectively. 
 
4.1.3 Time dependent analysis of IL-6-type cytokine induced signalling in 
NRCM 
 
One major part of this study is describing the IL-6-type cytokine induced signalling 
pathways in NRCM. To understand the hypertrophic actions and differences in the 
potential of hypertrophy initiation, the known relevant pathways activated in response 
to hLIF, hOSM, mOSM, hCT-1, hIL-6 (with and without hsIL-6R) were analysed in 
detail. Hence, the time kinetics (up to 60 min) of the cytokine mediated 
phosphorylations of STAT3, STAT1 and the MAPK ERK1/2 were analysed in NRCM 
(Fig. 8). pY705-STAT3 and STAT3 are detected at 79, 86 kDa (α and β isoform, 
respectively), pY701-STAT1 and STAT1 at 84, 91 kDa (α and β isoform, 
respectively), pT202-pY204-ERK1 and -ERK2 at 44 and 42 kDa, respectively. 
 
 
Figure 8: IL-6-type cytokines induce phosphorylation of STATs and ERK1/2 in 
NRCM with different strength and duration 
NRCM (cultured for three days) were stimulated for the indicated time periods with 10 ng/ml hOSM, 
hLIF, hCT-1, mOSM, 20 ng/ml hIL-6 or 20 ng/ml hIL-6 + 0.5 µg/ml hsIL-6R. Phosphorylation levels of 
STAT3 (pY705) and STAT1 (pY701) as well as ERK1/2 (pT202/pY204) were detected via Western 
blot analysis. The blots were stripped and reprobed with antibodies recognising the proteins 
irrespective of their activation status (STAT3, STAT1 and ERK1/2). Blots shown are representative for 
three independent experiments. 
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As shown in figure 8, hOSM and hLIF are potent activators of STAT3, STAT1 and 
ERK1/2 phosphorylation. The signalling pathways are activated in a time dependent 
manner with phosphorylation maxima at 15 min past stimulation. 60 min after 
cytokine treatment, the observed pathways are hardly stimulated above basal status. 
While hCT-1 is also able to strongly induce activation of STAT3, only a weak ERK1/2 
and STAT1 phosphorylation can be observed after treatment of NRCM with the 
cytokine. The signalling pathway composition and kinetics induced by mOSM are 
highly comparable to those initiated by hOSM and hLIF. IL-6 on its own is not able to 
induce STAT activation, however a very transient ERK1/2 phosphorylation is 
observed. Nevertheless, IL-6 together with its soluble α-receptor (sIL-6R) induces a 
moderate STAT3 phosphorylation. However, it has to be mentioned that responses to 
hIL-6/hsIL-6R were variable between different experiments regarding the 
phosphorylation intensities. 
 
4.1.4 Receptor preference of hOSM and mOSM on NRCM 
 
Up to now, the receptor usage of mOSM and hOSM on cells of rat origin was not 
definitely clarified. Detailed information from murine cells demonstrated that mOSM, 
unlike hOSM, exclusively signals via the type II OSMR/gp130 receptor complex74. 
Treatment of murine cells with hOSM activates the type I LIFR/gp130 complex, but 
not the type II receptor complex74, 75. To analyse the receptor complexes used by 
hOSM and mOSM on rat cells (NRCM), the cells were pretreated with various 
concentrations of the LIFR specific antagonist LIF-05254 (30 min, indicated 
concentrations) followed by 15 min hOSM or mOSM stimulation (Fig. 9). LIF-05 
pretreatment strongly reduces the hOSM induced activation of various signalling 
pathways (phospho-STAT3, phospho-STAT1, phospho-STAT5 and ERK1/2) in a 
concentration dependent manner (Fig. 9, compare lanes 3-6). For STAT1, STAT5 
and ERK1/2 activation, 5ng/ml LIF-05 were sufficient to completely abolish the hOSM 
mediated activation, while application of 20 ng/ml LIF-05 was required to achieve 
complete inhibition of STAT3 activation (Fig. 9, first panel). In contrast, mOSM 
induced activation of all analysed signalling proteins remains mostly unaffected upon 
LIF-05 pretreatment (Fig. 9, compare lanes 7-10). This strongly suggests that hOSM 
signals via the type I LIFR/gp130 complex on NRCM, as it does on murine cells, and 
that mOSM exclusively utilises the type II OSMR/gp130 complex. Higher 
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concentrations of LIF-05 (≥20 ng/ml) have a weak influence on the mOSM induced 
STAT phosphorylations, however, this might be due to the observation that the basal 
phosphorylation levels of STAT3 and STAT1 are decreased as well by LIF-05 
(compare lanes 1 and 2). In chapter 4.4 the examined receptor preferences of hOSM, 
mOSM and rOSM on rat, murine and human cells will be further described in detail. 
 
 
Figure 9: LIF-05 suppresses hOSM but not mOSM mediated signalling on 
NRCM 
NRCM (cultured for three days) were pretreated with the indicated concentrations of LIF-05. 30 min 
later, cells were stimulated with 10 ng/ml hOSM or mOSM for 15 min. Phosphorylation levels of 
STAT3 (pY705), STAT1 (pY701), STAT5 (pY694), ERK1/2 (pT202/pY204), Akt (pS473) as well as p38 
(pT180/pY182) were detected via Western blot analysis. The blots were stripped and reprobed with 
antibodies recognising the proteins irrespective of their phosphorylation status. Blots shown are 
representative for three independent experiments. 
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4.1.5 Comparison of the IL-6-type cytokine mediated signalling pathways  
 
After determining the signalling peaks of the IL-6-type cytokines in NRCM (Fig. 8) 
and the receptor preferences of hOSM and mOSM on NRCM (Fig. 9), all induced 
signalling pathways were compared 15 min post stimulation, since most pathways 
were found to be stimulated most strongly at this time point. The rationale for these 
experiments was to determine if the strength, lack or presence of one pathway 
correlates with the distinguishable hypertrophic potential of the tested IL-6-type 
cytokines (compare 4.1.1). As mentioned in the introduction, the phosphorylations of 
STAT3, ERK1/2 and Akt are most frequently described to promote cardiomyocyte 
hypertrophy. Because the hypertrophic actions of hCT-1 have already been 
extensively described, we decided to analyse the signalling activities of mOSM, 
hOSM and hIL-6 ± hsIL-6R in comparison to hLIF, which has been the most potent 
hypertrophic cytokine in the hypertrophy assay. OSM was not yet characterised in the 
cardiac context when the presented work was started.  
 
 
 
Figure 10: LIF, hOSM and mOSM are inducers of STAT, MAPK and Akt 
pathways in NRCM 
NRCM (cultured for three days) were stimulated with 10 ng/ml hLIF, hOSM, mOSM or 20 ng/ml hIL-6 ± 
0.5 µg/ml hsIL-6R for 15 min. Phosphorylation levels of STAT3 (pY705), STAT1 (pY701), STAT5 
(pY694), ERK1/2 (pT202/pY204), Akt (pS473) as well as p38 (pT180/pY182) were detected via 
Western blot analysis. The blots were stripped and reprobed with antibodies recognising the proteins 
irrespective of their activation status (STAT3, STAT1, STAT5, ERK1/2, Akt, p38). The detection of α/β-
tubulin served as additional loading control. Phosphorylation signals were quantified by determination 
of chemiluminescence intensities and normalisation to loading controls (strongest signal is set to 
100%). Depicted blots and quantifications are representative for three independent experiments. 
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Human LIF, hOSM, mOSM and hIL-6 in combination with hsIL-6R are capable of 
inducing STAT3 and STAT1 phosphorylation with different intensities (Fig. 10, 
compare lanes 2, 3, 4 and 6 of upper left and middle panel). While LIF additionally 
induces strong STAT5 tyrosine phosphorylation (Fig. 10, upper right panel, lane 2), 
hOSM and mOSM provoke only very weak phosphorylation of STAT5 (lanes 3 and 
4). Moreover, hLIF, hOSM and mOSM cause ERK1/2 phosphorylation, while hIL-
6/hsIL-6R stimulation has only minor influence on the activation of this pathway (Fig. 
10, lower left panel). In addition, distinct phosphorylations of Akt and p38 are 
observed after stimulation of NRCM with hLIF and mOSM, while activation of these 
pathways cannot be detected upon hIL-6 + hsIL-6R (Fig. 10, lower middle and right 
panels). 
 
4.1.6 Expression of IL-6-type cytokine family receptors on NRCM 
 
The differences of hOSM, mOSM and hLIF induced signal intensities in NRCM, 
mainly regarding STAT1, STAT5, ERK1/2, p38 and Akt phosphorylation (Fig. 10), led 
to the question whether the LIFR and the OSMR are expressed in similar amounts. 
Clearly distinguishable expression ratios of the two receptors could explain the 
observed differences in hOSM, mOSM and hLIF signalling strength. We also wanted 
to analyse the IL-6R expression levels, because we did not find any effect of IL-6 on 
its own in NRCM. First, we tried to determine IL-6R, gp130 and OSMR levels on 
NRCM via flow cytometry. For this purpose, we applied a monoclonal rat/mouse 
specific IL-6R antibody (anti-mouse/rat CD126 (IL-6Rα chain), clone D7715A7) from 
BioLegend, a monoclonal mouse specific gp130 antibody (anti-mouse gp130, clone 
RMβ1) and a monoclonal mouse specific OSMR antibody (anti-mouse OSMR, clone 
30-1) from MBL International. Labelled (phycoerythrin- or Alexa488-conjugated) 
secondary antibodies were used to detect the primary antibodies. Since these initial 
stainings failed, we tried to determine gp130 and IL-6R levels again performing flow 
cytometry, using a monoclonal anti-human gp130 antibody (clone B-R3) and a 
monoclonal anti-human IL-6R antibody (B-R6) from DiacloneTM (Gen-Probe 
Incorporated). Furthermore, different antibodes were used to detect whole protein 
levels of IL-6R (monoclonal anti-mouse IL-6R, MAB1830, R&D systems), gp130 
(monoclonal anti-human gp130, MAB228, R&D Systems), LIFR (monoclonal anti-
human LIFR, clone AN-E1, Santa Cruz Biotechnology) and OSMR (polyclonal anti-
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human OSMR, AF4389, R&D systems and polyclonal anti-murine OSMR, AF662, 
R&D systems) via Western blot analysis. Unfortunately, due to the lack of cross-
species reactivity of the tested antibodies, IL-6R, gp130, LIFR and OSMR protein 
levels could not been detected by Western blot analysis or flow cytometry.  
Thus, the mRNA expression of gp130, OSMR, LIFR and IL-6R was analysed 
performing semiquantitative RT-PCR and additionally quantitative real time RT-PCR. 
The results of the RT-PCR clearly show that NRCM express high levels of gp130 and 
OSMR mRNA (Fig. 11A).  
 
 
Figure 11: NRCM express gp130, OSMR and LIFR 
A, NRCM (cultured for three days, untreated or 3 h hLIF (10ng/ml) treated) were lysed and total RNA 
was isolated. Semiquantitative RT-PCR was performed using the OneStep RT-PCR Kit (reverse 
transcription and 30 cycles of denaturation, annealing, elongation, as described in the method section) 
and resulting cDNA was separated by 2% agarose gel electrophoresis. Receptors are represented by 
the upper bands, while the lower bands show GAPDH serving as housekeeping gene. B, Total RNA of 
untreated NRCM (cultured for three days) was isolated and mRNA levels of the indicated receptors 
and GAPDH were determined by quantitative real time RT-PCR (reverse transcription, 40 cycles of 
denaturation, annealing, elongation). Shown are the CT-value means with standard error of mean 
(SEM) of three independent experiments. Lower CT-values correlate with higher mRNA amounts. 
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While the LIFR is strongly expressed (compare LIFR mRNA levels in NRCFB, 
chapter 4.2.1, Fig. 15) too, only very low mRNA levels of the IL-6R are found in 
NRCM (weak bands after 30 PCR cycles) correlating with the unresponsiveness of 
NRCM to pure IL-6 stimulation (see Fig. 10). This would also explain why the IL-6R 
was not detected in flow cytometry using the rat/mouse specific IL-6R antibody from 
BioLegend.  
As shown in figure 11B, the real time RT-PCR results confirm that gp130, OSMR and 
LIFR (gp130 CT: 20.9, OSMR CT: 21.7, LIFR CT: 23.0) mRNAs are highly expressed. 
Since the CT-value (cycle threshold) indicates the PCR cycle number which is 
required for the fluorescent signal to cross the background threshold level, a higher 
CT-value indicates a lower amount of mRNA (i.e. the CT-value is inversely 
proportional to the amount of target mRNA). The IL-6R has been found to pass the 
background fluorescence level five cycles later than gp130 (IL-6R CT: 25.8, gp130 
CT: 20.9). This means that in case of a theoretical mRNA duplication within each 
cycle and comparable oligonucleotide primer efficiencies, the IL-6R is expressed only 
0.03-fold the amount of gp130. Later results of receptor expression in cardiac 
fibroblasts and hepatoma cells will substantiate the suspicion, that IL-6R expression 
is not sufficient to promote IL-6-signalling in the absence of soluble α-receptor in 
NRCM. Hence, in the next chapter the hIL-6 stimulation of the rat hepatoma cell line 
JTC-27 and its IL-6R expression levels are shown as a direct comparison. 
 
4.1.7 IL-6R expression levels and IL-6 signalling in rat hepatoma cells – a 
comparison of IL-6-non-responsive cells 
 
The unresponsiveness of NRCM to stimulation with IL-6 (see chapters 4.1.5 and 
4.1.6) and the correlating low level expression of the IL-6R mRNA elicited the 
question, if other cells from rat origin expressing similar low levels of the IL-6R are 
also not responsive to the cytokine. Therefore the rat hepatoma cell line JTC-27, that 
we also utilised for the characterisation of the rat OSM receptor complexes (chapter 
4.4), was used to determine IL-6R expression levels and the correlating 
responsiveness to hIL-6 (with and without sIL-6R) as well as to rIL-6 stimulation. As 
shown in figure 12, JTC-27 cells are strongly responding to 10 ng/ml hLIF (15 min), a 
feature they share with NRCM. Again, STAT3 is potently phosphorylated at tyrosine 
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705 and the double phospho-motif of ERK1/2 (pT202-pY204) is phosphorylated after 
LIF treatment (Fig. 12A). Neither a concentration of 20 ng/ml nor of 100 ng/ml hIL-6 is  
 
Figure 12: Rat hepatoma cells (JTC-27) exhibit NRCM-like IL-6R expression and 
corresponding IL-6 unresponsiveness to pure IL-6 stimulation 
A, JTC-27 cells were treated with hLIF (10 ng/ml), hIL-6 (20 ng/ml or 100 ng/ml) ± hsIL-6R (0.5 µg/ml) 
or with rIL-6 (20 ng/ml or 100 ng/ml) for 15 min. Phosphorylation levels of STAT3 (pY705) and ERK1/2 
(pT202/pY204) were detected via Western blot analysis. The blots were stripped and reprobed with 
antibodies recognising the proteins irrespective of their activation status. B, RNA from JTC-27 cells 
was isolated and used for real time RT-PCR (reverse transcription, 40 cycles of denaturation, 
annealing, elongation). Using specific primers, IL-6R and gp130 and GAPDH mRNA levels were 
detected. Shown are the CT-value means with standard error of mean (SEM) of three independent 
experiments.  
Results 
 
82 
able to induce a measureable phosphorylation of STAT3 or ERK1/2 (compare lanes 
1, 2, 3 and 4). In contrast, hIL-6 together with hsIL-6R is capable of mediating the 
phosphorylation of STAT3 in a concentration dependent manner, but no distinct 
phosphorylation of ERK1/2 can be observed upon hIL-6/hsIL-6R stimulation (lanes 1, 
5 and 6). 
As a precaution, JTC-27 were also stimulated with 20 and 100 ng/ml rIL-6 to exclude 
the possibility of cross-species problems with human IL-6 on cells of rat origin (lanes 
1, 7 and 8). Comparable to hIL-6 treatment, stimulation of JTC-27 with rIL-6 also 
does not induce any detectable STAT3 or ERK1/2 activation. To analyse the mRNA 
amounts of rIL-6R and rgp130 in the hepatoma cell line, again quantitative real time 
RT-PCR was performed to determine the CT-values of both receptors. As shown in 
figure 12B, similar gp130 and IL-6R expression rates as in NRCM (Fig. 11B) have 
been found. While both receptors elicit later CT-values (IL-6R CT: 28.6 and gp130 CT: 
23.6), the ratio of the rgp130 CT to the IL-6R CT is equal to the ratio of both receptors 
in NRCM. Notably, the gp130 expression levels measured in JTC-27 cells are fully 
sufficient to mediate incoming LIF signals (lane 1 and 2 in Fig. 12A).  
 
4.1.8 IL-6-type cytokines partially induce enhanced transcription of their own 
cytokine as well as receptor genes prolonging their hypertrophic potential and 
cytoprotection 
 
Time course experiments have shown that most of the immediately activated 
signalling pathways following IL-6-type cytokine stimulation are suppressed back to 
basal levels after approximately one hour (Fig. 8). However, for the hypertrophy 
assay NRCM were treated once per day with each tested IL-6-type cytokine. In order 
to determine how the cytokines can maintain their activity over longer time periods 
finally resulting in the observed dramatic phenotypical change of NRCM, we first 
analysed the expression of a number of genes known to be involved in the 
hypertrophic response (angiotensinogen (Agt), renin (Ren1), angiotensin II receptor 1 
alpha (At1α) and angiotensin I converting enzyme (Ace)). No obvious alterations of 
the corresponding mRNA levels were detected. Next the transcriptional regulation of 
OSM, LIF, IL-6 and their receptors (OSMR, LIFR, gp130, IL-6R) following stimulation 
with hLIF, mOSM and hIL-6/hsIL-6R was analysed. No significant alterations of 
gp130, LIFR, IL-6R or OSM mRNA levels are detectable using real time RT-PCR. In 
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contrast, significantly increased transcription of the Osmr gene is found in response 
to mOSM, hLIF and hIL-6R/sIL-6R stimulation (Fig. 13, upper panel). Elevated mRNA 
levels can be detected between 3 h and 24 h post stimulation. OSM itself mediates 
the strongest upregulation of its own receptor (3.7 ± 0.4-fold induction after 24 h 
stimulation). Interestingly, no subsequent decrease of OSMR mRNA levels can be 
observed up to 24 h after NRCM treatment. 
 
 
 
Figure 13: IL-6-type cytokines strongly increase OSMR, IL-6 and LIF expression 
in NRCM 
NRCM (cultured for three days) were treated with 10 ng/ml hLIF, mOSM or 20 ng/ml hIL-6 plus 0.5 
µg/ml hsIL-6R for the indicated time (3 h, 12 h and 24 h). Total RNA from NRCM was isolated, reverse 
transcribed and the resulting cDNA used for real time PCR (40 cycles of denaturation, annealing and 
elongation). Shown are the means (± SEM) of three or more independent experiments. Means 
represent x-fold mRNA increase or decrease, respectively, normalised to GAPDH mRNA levels. 
Statistical significance was calculated using a paired, two-tailed Student’s t-test, * p<0.05, ** p<0.01, 
*** p<0.001. 
 
 
Moreover, a strong increase of IL-6 mRNA levels is observed in response to mOSM 
(5.6 ± 0.4-fold induction after 3 h), hLIF (12.5 ± 2.0-fold induction after 3 h) and hIL-
6/sIL-6R (18.6 ± 3.2-fold mRNA induction after 3h, Fig. 13). Also after 12 and 24 h 
stimulation elevated levels of IL-6 mRNA can be detected indicating a permanent 
effect. Especially between 12 and 24 h no decrease of IL-6 mRNA levels is observed. 
Interestingly, IL-6 induces the strongest transcription of its own gene. While mOSM 
also leads to enhanced Il6 gene transcription, it negatively influences the expression 
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levels of LIF mRNA (Fig. 13, 0.3 ± 0.02 LIF mRNA expression rate compared to 
unstimulated cells, after 24 h). In contrast, hLIF and hIL-6/sIL-6R treatment results in 
a distinct, but transient upregulation of LIF mRNA levels (4.2 ± 0.6-fold LIF mRNA 
upregulation after 3 h LIF and 4.9 ± 0.8 LIF mRNA upregulation after 3 h IL-6/sIL-6R 
stimulation). However, after 24 h only basal expression levels of the cytokine mRNA 
can be detected (Fig. 13). 
 
4.1.9 The hypertrophic potential of hIL-6/sIL-6R and mOSM seems to be 
supported by the lower induction of feedback inhibition when compared to LIF 
 
The discrepancy between the extremely strong initial signalling of hLIF on NRCM 
(Fig. 8 and 10) and the rather intermediate gene induction of Il6, Lif and Osmr 
compared to mOSM and hIL-6/sIL-6R (Fig. 13) is obvious. On the other hand, mOSM 
and hIL-6/sIL-6R are able to deliver an almost equivalent hypertrophic signal to hLIF 
(Fig. 6), although their initial induction of hypertrophic pathways is clearly less potent. 
In detail, hIL-6/sIL-6R treatment causes lower STAT3 and STAT1 phosphorylation 
than hLIF (Fig. 10). Moreover, phosphorylations of ERK1/2 and Akt are not 
detectable in response to hIL-6/sIL-6R stimulation. While mOSM induces ERK1/2 
and Akt phosphorylation equivalent to hLIF, STAT1 and STAT3 are, however, less 
strongly phosphorylated (Fig. 10). Furthermore, hIL-6/sIL-6R induces an increase of 
LIF mRNA levels equivalent to hLIF, and the highest gene induction levels of Il6 are 
also mediated by IL-6 trans-signalling (Fig. 13). The strongest induction of Osmr 
gene transcription is observed after mOSM treatment and the cytokine significantly 
increases IL-6 mRNA levels as well (Fig. 13).  
To solve this enigma, we analysed the induction of SHP2 phosphorylation, SOCS1 
and SOCS3 expression following IL-6-type cytokine treatment. Although operating 
through absolutely different mechanisms, these three proteins represent the most 
important and mostly examined inhibitors of IL-6-type cytokine based signalling. As 
shown in figure 14A, SOCS3 and SOCS1 mRNA levels are increased by the activity 
of all used IL-6-type cytokines. The highest increase of mRNA levels has been found 
1 h after cytokines were applied. As direct targets of STAT3 or STAT1 activity, 
respectively, their expression rate directly correlates with the potency of STAT 
phosphorylation and translocation to the nucleus. Hence, hLIF induces the highest 
expression levels of SOCS3 and SOCS1 (Fig. 14A) by most strongly activating 
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STAT3 and STAT1 (Fig. 14B). The expression of SOCS mRNAs is an extremely 
transient cellular event. This is due to the feedback inhibitory function of the proteins 
and their short-lived mRNAs. Hence the increased transcription is ceased already 
after 3 h cytokine treatment. 24 or 48 h after NRCM stimulation, only marginally 
elevated mRNA levels of SOCS3 and basal SOCS1 levels can be observed. 
 
 
Figure 14: hIL-6/sIL-6R and mOSM mediate less SOCS1 and SOCS3 mRNA 
increase and weaker SHP2 phosphorylation in NRCM than hLIF 
A, NRCM (cultured for three days) were treated with 10 ng/ml mOSM, hLIF or 20 ng/ml hIL-6 plus 0.5 
µg/ml hsIL-6R for the indicated time (1 h, 3 h, 24 h and 48 h). Total RNA from NRCM was isolated and 
used for real time RT-PCR (reverse transcription, 40 cycles of denaturation, annealing and 
elongation). Shown values represent x-fold mRNA increase or decrease, respectively, normalised to 
GAPDH mRNA levels (n=1). B, NRCM (cultured for three days) were stimulated with 10 ng/ml hLIF, 
hOSM, mOSM or 20 ng/ml hIL-6 ± 0.5 µg/ml hsIL-6R for 15 min. Phosphorylation levels of STAT3 
(pY705), STAT1 (pY701), JAK1 (pY1022/pY1023), JAK2 (pY1007/pY1008) and SHP2 (pY542) were 
detected via Western blot analysis. The blots were stripped and reprobed with antibodies recognising 
the proteins irrespective of their activation status. As an additional and independent loading control, 
α/β-tubulin was detected. 
 
 
The JAK1 dependent phosphorylation of SHP2 in response to hLIF, mOSM and hIL-
6/sIL-6R (additional stimuli are hOSM and pure hIL-6) was also analysed and is 
shown in figure 14B. Corresponding to the other phosphorylations, SHP2 activation 
was analysed 15 min after cytokines were applied. Interestingly double tyrosine 
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phosphorylations in the activation loop of the kinase domains of JAK1 and JAK2 are 
only detectable following hLIF stimulation. SHP2 phosphorylation is observed in 
response to all applied cytokines (with the exception of pure IL-6 as explained 
before), but it is obvious that hLIF mediates the strongest phosphorylation of this 
phosphatase. Altogether, it is likely that mOSM and hIL-6/sIL-6R are amplifying the 
observed gene inductions and their hypertrophic potential by weaker induction of 
SOCS3 mRNA, SOCS1 mRNA and SHP2 phosphorylation. Nevertheless, this seems 
to be a rather transient mechanism, because the SOCS3 and SOCS1 mRNA levels 
are very similar at later time points (Fig. 14A). Further experiments analysing the 
signalling at later time points in response to cytokine treatment will substantiate this 
hypothesis (chapter 4.3.2).  
 
4.2 Analysis of IL-6-type cytokine induced signalling in cardiac 
fibroblasts: Expression of hypertrophy supporting targets 
 
While the role of cardiomyocytes in the development and progression of hypertrophic 
diseases like hypertrophic cardiomyopathy was described in countless studies, the 
involvement of the underrepresented cardiac fibroblasts has been started to be 
determined only recently. Doubtless, cardiac myocytes that respond to hypertrophic 
stimuli like adrenergic agonists, IL-6-type cytokines or angiotensin II (ATII) represent 
the main cell type in the heart responsible for morphological changes and thus 
causing cardiac hypertrophy. As described in the introduction, cardiac fibroblasts 
represent a second cell type in the heart that is able to support hypertrophic changes 
of heart tissue, for example by replacing dead cardiomyocytes. While the 
consequences of fibroblast tissue invasion, fibroblast proliferation and progressing 
fibrosis, causing decreased contractility and flexibility of the heart, were shown in 
several articles, cardiac fibroblast based cytokine production and cross talk with 
cardiomyocytes were rarely determined. Therefore, the signalling pathways of IL-6-
type cytokines on neonatal rat cardiac fibroblasts (NRCFB) and the corresponding 
induction of cytokine mRNAs, cytokine receptor mRNAs and additional hypertrophic 
targets were analysed. One of our main goals was to compare receptor availability 
and the resulting receptor preference of the IL-6-type cytokines on NRCFB with those 
of NRCM.  
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4.2.1 Receptor availability and resulting consequences for hOSM and mOSM 
signalling in NRCFB 
 
Synchronously to the experiments in NRCM, the receptor expression levels of gp130, 
OSMR, LIFR and IL-6R and the resulting signalling properties of mOSM, hOSM, hLIF 
and hIL-6 on NRCFB have been determined. As shown in figure 15A, the basal 
receptor CT-values indicate that the expression levels of the IL-6R (CT-value: 26.3 ± 
0.2) are similar to those in NRCM (CT-value: 25.8 ± 0.5) suggesting that classical IL-6 
signalling would also not be supported by these cells. While the CT-value of the 
OSMR (22.8 ± 0.3) in untreated cells is comparable to that observed in NRCM (21.7 
± 0.0), NRCFB clearly express lower levels of the LIFR (CT-value: 26.2 ± 0.2) in 
comparison to NRCM (CT-value: 23.0 ± 0.4).  
 
 
Figure 15: NRCFB are producing high levels of gp130 and OSMR mRNA, while 
IL-6R and LIFR are weakly expressed 
A, Total RNA from untreated NRCFB (P1) was isolated and used for real time RT-PCR (reverse 
transcription, 40 cycles of denaturation, annealing and elongation). Shown are the CT-value means 
with standard error of mean (SEM) of four independent experiments. Lower CT-values correlate with 
higher initial mRNA-amounts. B, NRCFB were pretreated with 20 ng/ml LIF-05 for 30 min and 
afterwards stimulated with 10 ng/ml hOSM or mOSM for further 15 min. Phosphorylation levels of 
STAT3 (pY705), STAT1 (pY701), ERK1/2 (pT202/pY204) and Akt (pS473) were detected via Western 
blot analysis. The blots were stripped and reprobed with respective total protein recognising 
antibodies. Depicted blots are representative for three independent experiments. 
Results 
 
88 
The fibroblasts from cardiac origin show remarkably strong expression of gp130 (CT-
value: 19.3 ± 0.2) that is clearly still higher than in NRCM (CT-value: 20.9 ± 0.3). In 
other words, when GAPDH mRNA would be set to 100%, cells would produce 30% 
gp130 mRNA in comparison. The strong Il6st (encoding for gp130) transcription in 
NRCFB could have a severe influence on the IL-6 trans-signalling. Further indications 
supporting this hypothesis as well as the signalling analysis of the remaining 
cytokines (hLIF, hIL-6 without sIL-6R) are described in chapter 4.2.2. In line with the 
LIFR, OSMR and gp130 real time RT-PCR data (Fig. 15A), hOSM induces extremely 
weak phosphorylation of STAT3, STAT1 and ERK1/2 (Fig. 15B), since NRCFB only 
express low levels of LIFR mRNA. As shown before in NRCM (Fig. 9) and in line with 
results from murine cells74, 75, hOSM is able to exclusively activate LIFR/gp130 
heterodimers (type I receptor complex) on NRCFB. Therefore, hOSM signalling (Fig. 
15B, lanes 2 and 3) is completely abrogated by the antagonist LIF-05, which blocks 
LIFR downstream signalling254. In contrast, mOSM mediated phosphorylations of 
STAT3, STAT1, ERK1/2 and Akt (lanes 4 and 5) remain entirely unaffected by the 
presence of LIF-05. This indicates again that mOSM, unlike hOSM, uses the type II 
receptor complex on rat cells, as it does on murine cells. Final proof for this proposed 
receptor binding of mOSM and hOSM on rat cells will be described in chapter 4.4. 
 
4.2.2 LIF, OSM and IL-6 mediated signalling on NRCFB 
 
To analyse the signalling potentials of hLIF, hOSM, mOSM, hIL-6 (± sIL-6R) in 
NRCFB, the phosphorylation intensities of STAT3, STAT1, STAT5, ERK1/2, Akt and 
p38 were determined 15 min after stimulation. In contrast to the previously described 
signalling of these cytokines in NRCM, NRCFB are only poorly responsive to the 
LIFR utilising cytokines hLIF and hOSM (Fig. 16, lanes 2 and 3 of each panel). 
However, the LIFR agonists hOSM and hLIF are capable of inducing measureable 
phosphorylations of STAT3, STAT1 and ERK1/2, while STAT5, p38 or Akt 
phosphorylations cannot be detected. On the other hand, mOSM strongly induces 
phosphorylations of STAT3, STAT1, STAT5, ERK1/2, Akt and p38 (Fig. 16, lane 3 of 
each panel). As anticipated by the extremely low level of mRNA for the IL-6R (Fig. 
15), hIL-6 on its own (lane 5) provokes no detectable activation of any analysed 
signalling pathway. However, hIL-6 combined with its soluble receptor (sIL-6R) 
mimicking trans-signalling is able to induce potent phosphorylations of STAT3, 
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STAT1 and ERK1/2 (lane 6), while no distinct phosphorylations of p38, Akt or STAT5 
are detected. 
 
 
Figure 16: mOSM and hIL-6/sIL-6 are potent promoters of NRCFB signalling 
NRCFB (P1) were stimulated with 10 ng/ml hLIF, hOSM, mOSM or 20 ng/ml hIL-6 ± 0.5 µg/ml hsIL-6R 
for 15 min. Phosphorylation levels of STAT3 (pY705), STAT1 (pY701), STAT5 (pY694), ERK1/2 
(pT202/pY204), Akt (pS473) as well as p38 (pT180/pY182) were detected via Western blot analysis. 
The blots were stripped and reprobed with antibodies recognising the proteins irrespective of their 
activation status (STAT3, STAT1, STAT5, ERK1/2, Akt, p38 and α/β-tubulin). The shown Western 
blots are representative for three independent experiments. Phosphorylation intensities were 
quantified by chemiluminescence analysis and normalised to loading controls (mOSM signal is set to 
100%).  
 
 
Because LIFR-based signalling in NRCFB was rather weak and OSM as well as IL-6 
are typical cytokines described to elicit fibroblast responses, following experiments in 
NRCFB were carried out as comparisons between mOSM and hIL-6/sIL-6R 
stimulation. 
 
4.2.3 Cytokine and cytokine receptor expression by NRCFB in response to 
OSM and IL-6 trans-signalling 
 
In line with the described experiments from NRCM, NRCFB were stimulated with 
mOSM or hIL-6/sIL-6R for 3 h or 18 h, respectively. The isolated RNA was used to 
perform real time RT-PCR using specific oligonucleotide primers for the detection of 
gp130, IL-6R, OSMR, LIFR, LIF and IL-6 mRNA levels. Furthermore, the mRNA 
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levels of endogenous OSM were analysed, but cytokine induced alterations could not 
be detected (data not shown) and the corresponding CT-values indicated that OSM is 
not produced from NRCFB, neither under basal conditions nor in response to mOSM 
or hIL-6/sIL-6R treatment. 
 
 
Figure 17: IL-6-type cytokines induce upregulation of IL-6R, OSMR, LIFR, LIF 
and IL-6 in NRCFB  
A, NRCFB (P1) were treated with 10 ng/ml mOSM or 20 ng/ml hIL-6 plus 0.5 µg/ml hsIL-6R for the 
indicated time (3 h and 18 h). Afterwards total RNA was isolated and used for real time RT-PCR 
(reverse transcription, 40 cycles of denaturation, annealing, elongation). Shown are means (± SEM) of 
three or more independent experiments. Means represent x-fold mRNA increase or decrease, 
respectively, normalised to GAPDH mRNA levels. Statistical significance was calculated using a 
paired, two-tailed Student’s t-test, * p<0.05, ** p<0.01, *** p<0.001. B, NRCFB (P1) were stimulated as 
described in A for 5 or 20 h, respectively. Rat IL-6 amounts in NRCFB supernatants were determined 
by enzyme-linked immunosorbent assay (ELISA). Values shown are the means (± SEM) of three 
independent experiments. Statistical significance was calculated using a paired, two-tailed Student’s t-
test, * p<0.05, ** p<0.01.  
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As shown in figure 17A, mOSM and hIL-6/sIL-6R stimulations do not increase gp130 
mRNA levels neither after 3 h nor 18 h stimulation, but mOSM contrariwise leads to a 
decrease of gp130 mRNA by approx. 25% after 3 h compared with the initial/basal 
mRNA level (Fig. 17A, upper left diagram). Moreover, IL-6R mRNA regulation in 
response to mOSM treatment cannot be observed (upper right diagram), while hIL-
6/sIL-6R stimulation induces a slight IL-6R mRNA upregulation (2.17 ± 0.10-fold 
induction) that is rather transient and no longer detectable at later time points. 
Analogous to the results in NRCM, the OSMR mRNA levels are strongly, but 
transiently, increased after 3 h mOSM treatment (5.54 ± 1.04-fold induction). 18 h 
after cell treatment a significant increase of the OSMR mRNA cannot be observed 
(middle left diagram). In sharp contrast to the mOSM activity, hIL-6/sIL-6R treatment 
induces a clearly longer upregulation of the OSMR mRNA, that is even more 
elevated after 18 h (6.53 ± 1.17-fold induction after 3 h and 8.83 ± 1.86-fold induction 
after 18 h). 
Moreover, the LIFR mRNA levels are elevated after 3 h stimulation with mOSM or 
hIL-6/sIL-6R (2.07 ± 0.14-fold induction after 3 h mOSM, 1.67 ± 0.14-fold induction 
after 3 h hIL-6/sIL-6R treatment), although no significant increases are detectable 
after 18 h cytokine treatment. While mOSM has no promoting effect on Lif 
transcription, hIL-6/sIL-6R treatment causes a 3.86 ± 0.58-fold increase of LIF mRNA 
levels after 3 h. The measurements for LIF mRNA after 18 h cytokine treatment are 
rather inhomogeneous, and no normal distribution of the values could be achieved 
(variation between 1.0 and 2.76-fold induction). In contrast to the IL-6 expression, 
however, the increased LIF expression seems to be rather transient.  
Treatment with mOSM causes a clear upregulation of IL-6 mRNA levels after 3h 
(15.57 ± 4.33-fold induction), while hIL-6/sIL-6R stimulation mediates an enormous 
increase in Il6 transcription after 3 h (203.56 ± 45.27-fold induction) and after 18 h 
(70.30 ± 12.90-fold induction). Detection of IL-6 protein by ELISA verified that the 
increase in mRNA is indeed translated into protein and furthermore that IL-6 is 
secreted by NRCFB and detectable in the cell supernatant (Fig. 17B). After 5 h 
mOSM or hIL-6/sIL-6R treatement, respectively, significantly increased rIL-6 amounts 
are not measurable. However, 20 h after the cytokines were added, we found rIL-6 
concentrations of 131 (± 7) pg/ml in response to mOSM and of 265 (± 31) pg/ml in 
response to hIL-6/sIL-6R in the supernatants of NRCFB.  
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4.2.4 IL-6 and OSM perform cross-talk with the renin-angiotensin system in 
NRCFB 
 
IL-6-type cytokines are not only able to induce the expression of their receptors or 
other cytokines of their own family, but also to mediate cross-talk with other ligand-
receptor systems. Considering the proposed role of the renin-angiotensin system in 
cardiac hypertrophy and suspecting that it might be a system targeted by IL-6-type 
cytokines, the mRNA expression of angiotensin I converting enzyme (ACE) and 
angiotensin II receptor 1 alpha (AT1α) was analysed following mOSM and hIL-6/sIL-
6R treatment. As shown in figure 18 (left diagram), hIL-6/sIL-6R as well as mOSM 
stimulation induces a clear and significant increase in ACE mRNA levels (3.02 ± 
0.07-fold induction after 3 h mOSM and 1.78 ± 0.24-fold induction after 3 h hIL-6/sIL-
6R treatment). 
 
 
Figure 18: IL-6-type cytokines induce enhanced transcription of Ace and At1α 
NRCFB (P1) were stimulated with 10 ng/ml mOSM or 20 ng/ml hIL-6 plus 0.5 µg/ml hsIL-6R for 3 h or 
18 h, respectively. Afterwards total RNA was isolated and real time RT-PCR (reverse transcription, 40 
cycles of denaturation, annealing, elongation) was performed. Values shown are the means (± SEM) 
of three (3 h values) or four (18 h values), respectively, independent experiments. Means represent x-
fold mRNA induction, normalised to GAPDH mRNA levels. Statistical significance was calculated 
using a paired, two-tailed Student’s t-test, * p<0.05, ** p<0.01, *** p<0.001.  
 
 
In correlation with the strength of promoted transcription at early time points (3 h after 
cytokines were applied), both cytokines also mediate significant ACE mRNA 
increases after 18 h (2.11 ± 0.70-fold induction upon OSM and 1.33 ± 0.02-fold 
induction upon hIL-6/sIL-6R treatment).  
The transcriptional increase of the important angiotensin receptor AT1α (Fig. 18, right 
diagram), which is known to be involved in hypertrophy development263-266, is 
comparable in response to both stimuli (4.88 ± 0.48-fold induction after 3 h OSM 
treatment and 4.56 ± 0.68-fold induction after hIL-6/sIL-6R treatment). Interestingly, 
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as observed before for other targets (Fig. 17A), mOSM stimulation only leads to a 
transient increase in AT1α mRNA levels, whereas exposure of NRCFB to hIL-6/sIL-
6R appears to maintain high AT1α mRNA levels at least up to 18 h (2.80 ± 0.27). 
This observation suggests that a similar mechanism might be responsible for the 
At1α gene induction as observed before for the Osmr and Il6 transcription in NRCFB 
after IL-6 trans-signalling (see Fig. 17A). 
 
4.3 Comparison of long time stimulation with hOSM and hIL-6 in NRCM 
and NRCFB: IL-6 induces prolonged C/EBP beta, C/EBP delta, IL-6 
expression and signal transduction in NRCFB 
 
The comparison of mOSM or hIL-6/sIL-6R induced IL-6 mRNA upregulation in 
NRCFB and NRCM reveals one obvious difference in the response of both primary 
cell types to these cytokines: In NRCM, mOSM as well as hIL-6/sIL-6R induce a 
clear, prolonged and comparable gene transcription resulting in elevated IL-6 mRNA 
levels up to 24 h or even 48 h (data not shown) past stimulation. In NRCFB, a 
completely different response can be observed. On the one hand, the potential of the 
mRNA induction is extremely different (ratio of hIL-6/sIL-6R to mOSM induced IL-6 
mRNA expression is approximately 13:1 after 3 h, while it is 3:1 in NRCM). On the 
other hand, the kinetics of the regulated transcription of the Il6 gene vary for both 
cytokines. While the IL-6/sIL-6R response is prolonged, OSM induces a very 
transient IL-6 mRNA upregulation which is completely shut down after 18 h. Taken 
together, this comparison suggests an additional factor in NRCFB that is activated or 
induced by IL-6, but not by mOSM. However, it is also possible that an already 
produced factor is more strongly activated or induced in NRCFB than in NRCM. In 
the following chapter the kinetics of signalling were analysed for both cytokines, and 
two potential candidate proteins facilitating the enormous IL-6 mRNA induction in 
NRCFB were introduced (C/EBPβ and C/EBPδ).  
 
4.3.1 The short time kinetics of IL-6 and mOSM in NRCM and NRCFB are similar 
 
To exclude the possibility that simple differences in the kinetics of signalling molecule 
activation contribute to the differences in gene transcription initiated by IL-6/sIL-6R or 
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OSM in NRCFB, we first performed short term (1-60 min) stimulations (Fig. 19). As 
previously described (compare sections 4.1.5 and 4.2.2), the hIL-6/sIL-6R stimulation 
is clearly stronger in NRCFB compared to NRCM, when mOSM serves as reference 
(Fig. 19, compare left panel with right panel). 
 
Figure 19: mOSM and hIL-6 induce similar short time kinetics of signalling in 
NRCFB and NRCM 
Left panel of Western blots: NRCFB (P1) were stimulated with 10 ng/ml mOSM or 20 ng/ml hIL-6 plus 
0.5 µg/ml hsIL-6R for the indicated time periods. Right panel of Western blots: NRCM (cultured for 
three days) were treated with 10 ng/ml mOSM or 20 ng/ml hIL-6 plus 0.5 µg/ml hsIL-6R for the 
indicated time periods. Phosphorylation levels of STAT3 (pY705) and STAT1 (pY701) as well as 
ERK1/2 (pT202/pY204) were detected via Western blot analysis. The blots were stripped and 
reprobed with antibodies recognising the proteins irrespective of their activation status (STAT3, STAT1 
and ERK1/2). The Western blots shown are representative for three independent experiments. 
 
 
As shown in the left Western blot panels representing mOSM and hIL-6/sIL-6R 
signalling kinetics on NRCFB, STAT3 and STAT1 phosphorylation is clearly induced 
via both cytokines. In contrast, a potent ERK1/2 phosphorylation is exclusively 
observed following mOSM treatment. The maxima of phosphorylations are reached 
after 15 min (quantification not shown), even though the 5 min, 15 min and 30 min 
values in NRCFB are rather similar. Interestingly, the signalling in NRCFB seems to 
be prolonged compared to NRCM, since strong STAT phosphorylations are still 
clearly detectable after 30 and 60 min. In contrast to this, after 60 min of cytokine 
treatment only small fractions of the initial STAT phosphorylations are detectable in 
NRCM (Fig. 19, right Western blots), when compared with the 15 min values. Thus, 
the short time kinetics cannot explain, why hIL-6/sIL-6R induces IL-6 mRNA 
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expression comparable to mOSM in NRCM, while it enforces much stronger and 
prolonged IL-6 mRNA upregulation in NRCFB. Furthermore, it is intriguing that Il6 
gene induction is rather constitutive in NRCM following treatment with either cytokine, 
although signalling pathways are mostly inhibited already after 60 min.  
 
4.3.2 hIL-6/sIL-6R treatment causes prolonged signalling in NRCFB, but not in 
NRCM 
 
To corroborate whether the trend towards prolonged STAT activation in NRCFB (Fig. 
19, left panel) extends to increased phosphorylation levels even after several hours 
or days past stimulation, long time kinetics were performed. Therefore, NRCFB and 
NRCM were stimulated with mOSM or hIL-6/hsIL-6R for 3 h, 6 h, 12 h, 24 h and 48 h.  
 
Figure 20: IL-6 signalling is clearly more prolonged in NRCFB than in NRCM 
Left panel of Western blots: NRCFB (P1) were stimulated with 10 ng/ml mOSM or 20 ng/ml hIL-6 plus 
0.5 µg/ml hsIL-6R for the indicated times. Right panel of Western blots: NRCM (cultured for three 
days) were treated with 10 ng/ml mOSM or 20 ng/ml hIL-6 plus 0.5 µg/ml hsIL-6R for the indicated 
duartions. Phosphorylation levels of STAT3 (pY705) and STAT1 (pY701) as well as ERK1/2 
(pT202/pY204) were detected via Western blot analysis. The blots were stripped and reprobed with 
antibodies recognising the proteins irrespective of their activation status (STAT3, STAT1 and ERK1/2). 
Depicted blots are representative for three independent experiments. 
 
 
The resulting Western blots are shown in figure 20. Again, the phosphorylation status 
of STAT3, STAT1 and ERK1/2 was used as readout for IL-6-type cytokine signalling. 
In NRCFB, STAT1 and STAT3 phosphorylations in response to OSM and IL-6/sIL-6R 
can still be detected even 3-6 h after stimulation. However, while OSM induced 
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signalling is mainly ceased between 6 and 12 h past stimulation, IL-6/sIL-6R induced 
STAT1 and STAT3 phosphorylations are maintained for at least 48 h (Fig. 20, left 
panel). This observation correlates with the prolonged Il6 gene induction that was 
observed only in response to IL-6/sIL-6R stimulation (Fig. 17A). Aside from the 
induced ERK phosphorylation and the Lif transcription, this was the most significant 
difference we observed analysing these two cytokines on NRCFB. In NRCM, 
however, no increased phosphorylation of STATs was detectable at any time point 
between 3 h and 48 h (Fig. 20, right panel). 
 
4.3.3 The IL-6 driven induction of the CCAAT/enhancer binding proteins 
(C/EBP) might be responsible for the strong induction of IL-6 and prolonged 
signalling in NRCFB 
 
To identify potential proteins involved in the prolonged lL-6 expression in NRCFB, we 
decided to analyse the important IL-6 associated transcription factors C/EBPβ and 
C/EBPδ. C/EBPβ and δ are potent inducers of IL-6 expression231-233. On the other 
hand, as already described in the introduction, their expression is directly inducible by 
IL-6 treatment232, 239-241. To corroborate a potential involvement of these transcription 
factors in Il6 transcription in NRCFB and NRCM, freshly isolated cells were 
stimulated for the same time periods as before with mOSM or hIL-6/shIL-6R (3 h, 12 
h and 24 h for NRCM, 3 h and 18 h for NRCFB). Total RNA was isolated and mRNA 
levels of C/EBPβ, C/EBPδ and IL-6 were detected by quantitative real time RT-PCR 
(Fig. 21). Indeed, the induced C/EBP mRNA levels in NRCM are rather low (Fig. 21A, 
upper and middle diagram; approximately 1.8-fold C/EBPβ and 2.1-fold C/EBPδ 
mRNA increase after 3 h hIL-6/sIL-6R stimulation) compared with those observed in 
NRCFB (Fig. 21B, upper and middle diagram; 3.9-fold C/EBPβ and 14.9-fold C/EBPδ 
mRNA increase after 3 h hIL-6/sIL-6R treatment). However, particularly upon OSM 
stimulation the induction of both C/EBP mRNAs appears to be preserved for at least 
24 h which correlates well with the weak, but persistent transcription of Il6 in NRCM 
(Fig. 21A). Altogether, in NRCM mOSM, hLIF or hIL-6/sIL-6R induce very similar 
mRNA amounts of IL-6 and both C/EBPs.  
Vice versa, in NRCFB the type of stimulus determines the fate of C/EBP and IL-6 
expression. The Cebpd transcription following 3 h mOSM stimulation is potently 
elevated (7.4 ± 1.0-fold mRNA induction). Furthermore, C/EBP β expression is 
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weakly induced in response to 3 h mOSM stimulation (1.7 ± 0.2-fold mRNA 
induction), but only basal levels remain at later time points.  
 
 
 
Figure 21: Enhanced C/EBPβ and δ mRNA expression in response to IL-6 
correlates with the increased transcription of Il6 
A, NRCM (cultured for three days) were treated with 10 ng/ml mOSM, hLIF or 20 ng/ml hIL-6 plus 0.5 
µg/ml hsIL-6R for the indicated time periods (3 h, 12 h and 24 h). Total RNA was isolated and used for 
real time RT-PCR (reverse transcription, 40 cycles of denaturation, annealing and elongation). Shown 
are means (± SEM) of three or more independent experiments. Means represent x-fold mRNA 
increase or decrease, respectively, normalised to GAPDH mRNA levels. B, NRCFB (P1) were 
stimulated with 10 ng/ml mOSM or 20 ng/ml hIL-6 plus 0.5 µg/ml hsIL-6R for 3 h or 18 h. Afterwards 
total RNA was isolated and real time RT-PCR (reverse transcription, 40 cycles of denaturation, 
annealing and elongation) was performed. Shown are means (± SEM) of three or more independent 
experiments. Means represent x-fold mRNA inductions, normalised to GAPDH mRNA levels. 
Statistical significance was calculated using a paired, two-tailed Student’s t-test, * p<0.05, ** p<0.01, 
*** p<0.001.  
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The nearly basal values of both C/EBPs after 18 h mOSM treatment are in line with 
the completely decreased IL-6 expression. In contrast, in response to hIL-6/sIL-6R 
treatment a stronger and more prolonged induction of C/EBP β (3.9 ± 0.3 after 3 h 
treatment, 3.0 ± 0.3 after 18 h treatment) and C/EBP δ (14.9 ± 1.1 after 3 h 
treatment, 7.8 ± 0.6 after 18 h treatment) transcription can be observed. This strongly 
corresponds to the much more prominent induction of Il6 transcription in response to 
IL-6/sIL-6R stimulation after 3 h (203.6 ± 45.3-fold induction) and 18 h (70.3 ± 12.9-
fold increase). 
 
4.4 A comparison of hOSM, mOSM and the recently cloned rOSM: 
Signalling pathway induction and receptor usage 
 
Several studies from the last two decades have clearly shown that human and 
murine OSM signal in a different manner. While human OSM uses two receptor 
complexes on human cells, the type I (gp130/LIFR) or the type II (gp130/OSMR) 
receptor complex 26, 73, murine OSM exclusively signals via the type II receptor 
complex in murine cells74, 75. In addition, it has been determined that human OSM 
activates only the type I receptor complex (LIFR/gp130) in mouse cells. However, 
murine OSM absolutely fails to activate signal transduction in human cells74. In 
chapters 4.1 - 4.3 the receptor preferences of mOSM and hOSM on cells from rat 
origin (NRCFB and NRCM) were described. These experiments indicated that hOSM 
and mOSM appear to use the same receptor complexes on rat cells as on murine 
cells. None of both cytokines is therefore able to correctly mimic the situation on 
human cells treated with hOSM. On the other hand, it could not be excluded that the 
OSMs of murine and rat origin share the same receptor preferences.  
Since OSM from rat origin was not available in the past, an analysis of the receptor 
usage and induced signalling pathways was not performed previously. The most 
important question in this context has been, if the rat homologue equals the human 
or the murine cytokine. Therefore, an approach has been chosen, by which the 
receptor usage and the induced signalling pathways of human, murine and the 
recently available rat OSM were analysed in hepatoma cells from rat (JTC-27), 
human (HepG2) and murine (Hepa1c1c7) origin. All three cell lines express gp130, 
LIFR and OSMR (data not shown) and are capable of being stimulated by 
LIFR/gp130 and OSMR/gp130 activation.  
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4.4.1 Rat OSM induces the typical OSM mediated signalling pathways 
 
To analyse the signalling capacities of the recently cloned rOSM, JTC-27 rat 
hepatoma cells were stimulated with 10, 20, 50, 100 and 200 ng/ml cytokine for 15 
min. 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: rOSM induces phosphorylation of STAT3, STAT1, STAT5, ERK1/2, 
p38 and Akt 
JTC-27 cells were treated with 10, 20, 50, 100 or 200 ng/ml rOSM for 15 min. Phosphorylation levels 
of STAT3 (pY705), STAT1 (pY701), STAT5 (pY694), ERK1/2 (pT202/pY204), p38 (pT180/pY182) and 
Akt (pS473) were detected via Western blot analysis. The blots were stripped and reprobed with 
antibodies recognising the proteins irrespective of their phosphorylation status (STAT3, STAT1, 
STAT5, ERK1/2, p38 and Akt). Depicted blots are representative for three independent experiments. 
 
 
The cells were lysed and SDS-PAGE followed by Western blotting was performed 
analysing the tyrosine phosphorylation sites of STAT3, STAT1 and STAT5 (Fig. 22). 
Moreover, double phosphorylation motifs of the MAPKs (ERK1/2 and p38) and the 
important serine (pS473) phosphorylation of Akt were analysed. 
As already observed using other IL-6-type cytokines, the intensity of STAT3 
phosphorylation is already maximal, when cells are treated with 10 ng/ml rOSM. 
Clear phosphorylations of STAT1, STAT5, ERK1/2 and p38 are already detectable at 
this cytokine concentration (10 ng/ml), but an rOSM induced Akt phosphorylation 
requires higher concentrations of the polypeptide (≥50 ng/ml). While the serine 
phosphorylation of Akt cannot be detected using lower concentrations of rOSM, 
STAT1, STAT5, ERK1/2 and p38 phosphorylation levels are even more elevated with 
increasing cytokine levels. Especially the levels of phospho-STAT5 and phospho-p38 
are continuously augmented by increasing rOSM concentrations. Taken together, 
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rOSM mimics the human homologue by activating each of the analysed signalling 
pathways (compare chapter 4.4.2).  
 
4.4.2 Rat OSM is able to initiate cell signalling in rat, human and murine cells 
 
After determining the rOSM induced pathways in rat cells, its signalling capacities 
and cross-species activities in comparison to hLIF, hOSM and mOSM have been 
analysed. Therefore hepatoma cell lines from human, mouse and rat origin (HepG2, 
Hepa1c1c7, JTC-27) were utilised. All three cell lines were stimulated with human, 
murine or rat OSM (10 ng/ml) as well as human LIF (10 ng/ml) for 15 min (Fig. 23). 
The applied OSMs are able to induce individual signalling pattern in cells of their own 
species. Comparable to hLIF, hOSM, mOSM and rOSM induce the phosphorylation 
of STAT3, STAT1 and ERK1/2 in JTC-27 cells (Fig. 23, left panel) with partially 
different intensities. An activation of p38 or Akt in JTC-27 has not been observed 
upon stimulation with the indicated cytokine concentrations (data not shown, 
compare Fig. 22). As also shown previously in rat cardiac myocytes and fibroblasts, 
mOSM can indeed induce signal transduction on rat cells. Interestingly, the mOSM 
and rOSM induced STAT3 and ERK1/2 phosphorylations in JTC-27 cells show very 
similar strength, but rOSM mediates a clearly stronger STAT1 phosphorylation (Fig. 
23, compare lanes 4 and 5). In murine cells (Hepa1c1c7, middle panel) hLIF and 
hOSM initiate STAT3, STAT1 and ERK1/2 phosphorylation with similar potentials, 
while mOSM and rOSM induce a much stronger ERK1/2 phosphorylation. However, 
compared with other cells STAT1 and ERK1/2 phosphorylation levels are rather weak 
in Hepa1c1c7 cells.  
In sharp contrast to murine OSM, rat OSM is able to stimulate the human hepatoma 
cell line HepG2 (right panel). It induces clear tyrosine phosphorylation of STAT3, and 
a weak phosphorylation of STAT1 is also initiated. However, rOSM fails to distinctly 
activate ERK1/2. Notably, hLIF also fails to induce ERK1/2 phosphorylation and 
strongly mimics rOSM behaviour in human cells. Regarding these aspects, rOSM 
shows more similarity to hLIF than to hOSM on human cells (Fig. 23, compare lanes 
12, 13 and 15). In contrast, rOSM and mOSM behave identically on murine cells 
(lanes 9 and 10). Taken together, rOSM can stimulate rat, murine and human cells. 
On rat cells, it activates similar pathways as hOSM on human cells (STAT3, STAT1, 
STAT5, ERK1/2 and at higher concentrations p38 and Akt, see Fig. 22). The 
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additional hOSM induced phosphorylations of STAT5, p38 and Akt in HepG2 cells 
are shown in figure 23B. Interestingly, hLIF is not able to induce p38 and Akt 
phosphorylation in these cells (an extremely weak STAT5 phospho-signal can be 
detected). Rat OSM also does not induce any of these pathways in HepG2 cells 
(data not shown).  
 
 
Figure 23: rOSM induces distinct signalling pathways on rat, murine and 
human cells 
A, JTC-27 (left panel), Hepa1c1c7 (middle panel) and HepG2 (right panel) cells were stimulated with 
10 ng/ml hLIF, hOSM, mOSM or rOSM for 15 min. Phosphorylation levels of STAT3 (pY705), STAT1 
(pY701) and ERK1/2 (pT202/pY204) were detected via Western blot analysis. The blots were stripped 
and reprobed with antibodies recognising the proteins irrespective of their activation status (STAT3, 
STAT1, ERK1/2 and tubulin). Depicted blots are representative for three independent experiments. B, 
HepG2 cells were stimulated with 10 ng/ml hLIF, hOSM, mOSM or rOSM for 15 min. Phospho-levels 
of STAT5 (pY694), p38 (pT180/pY182) and Akt (pS473) were detected via Western blot analysis. After 
stripping, the membranes were reprobed with the respective, total protein recognising antibodies 
(STAT5, p38, Akt and tubulin). Western blots shown are representative for three independent 
experiments. 
 
 
4.4.3 Rat OSM signals via the LIFR/gp130 (type I) and the OSMR/gp130 (type II) 
receptor complex on rat cells 
 
After determining the signalling pathways induced by hOSM, mOSM and rOSM on 
rat, murine and human hepatoma cells, the used receptor complexes were 
characterised. To analyse the participation of the rLIFR for rOSM signalling, the LIFR 
was blocked by the antagonist LIF-05. This protein represents a mutated variant of 
human LIF in which the binding site for the LIFR (site 3) is unmodified, while the 
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binding site for gp130 (site 2) is destroyed. LIF-05 still binds to the LIFR, but acts as 
a strong LIF antagonist by preventing gp130-LIFR-heterodimerisation254. The 
antagonistic activity of LIF-05 is presented in figure 24. The induced signalling of hLIF 
(lanes 3 and 4) and hOSM (lanes 5 and 6) is strongly reduced in the presence of the 
LIFR antagonist. 
 
 
 
Figure 24: rOSM signals through LIFR/gp130 and OSMR/gp130 complexes: 
Blockade of the rLIFR through LIF-05  
JTC-27 were preincubated with LIF-05 (50 ng/ml, 30 min) and subsequently stimulated with 10 ng/ml 
hLIF, hOSM, mOSM and rOSM for 15 min. The phosphorylation intensities of the indicated proteins 
were detected via Western blot analysis. The membranes were stripped and reprobed with antibodies 
recognising the proteins irrespective of their activation status (STAT3, STAT1, ERK1/2 and tubulin). 
Phosphorylation intensities were quantified by chemiluminescence analysis (right panel) and 
normalisation to loading controls. Shown are the means (n=3) with standard error of mean (SEM). * 
p<0.05, ** p<0.01 untreated vs. LIF-05-pretreated sample. 
 
 
The dramatic decrease indicates that, equivalent to hOSM behaviour on murine cells, 
hOSM exclusively utilises the rLIFR/rgp130 (type I) receptor complex. In contrast, the 
activation of STAT3 and STAT1 following rOSM stimulation is barely decreased in 
the presence of LIF-05 (Fig. 24, lanes 9 and 10) supporting the hypothesis, that 
rOSM is able to signal via the gp130/OSMR complex. Surprisingly the rOSM 
mediated ERK1/2 activation is even increased in the presence of LIF-05. According 
to the results of the NRCM and NRCFB, no inhibitory effect of LIF-05 can be 
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observed, when JTC-27 were treated with mOSM indicating an exclusive 
rOSMR/rgp130 (type II receptor complex) activation by the murine cytokine.  
Furthermore, RNA interference studies using siRNA specifically silencing the rat 
OSMR were performed in JTC-27 cells (Fig. 25A and B). Transient siRNA 
transfection of JTC-27 rat hepatoma cells targeting the rat OSMR resulted in 80% 
reduction of OSMR mRNA expression (Fig. 25A). 
 
 
 
Figure 25: rOSM signals through LIFR/gp130 and OSMR/gp130 complexes: 
Silencing the rOSMR through use of siRNA 
A, JTC-27 were transfected with control or rOSMR siRNA or left untransfected. Transfection 
efficiencies were analysed by semiquantitative RT-PCR (bottom) and quantitative real time RT-PCR 
(top). B, Untransfected, control siRNA and rOSMR siRNA transfected JTC-27 were treated with 10 
ng/ml hLIF, hOSM, mOSM and rOSM for 15 min. Lysates were subjected to Western blot analysis 
using antibodies specific for the indicated proteins. The blots were stripped and reprobed with 
antibodies recognising the proteins irrespective of their phosphorylation status and with an α-tubulin 
antibody. Phosphorylation intensities were quantified by chemiluminescence analysis and 
normalisation to loading controls. hOSM activation level was set to 100%. Shown are the means (n=3) 
with standard error of mean (SEM). * p<0.05, ** p<0.01, *** p<0.001 OSMR siRNA vs. control siRNA. 
 
 
Stimulation with hLIF guaranteed the specificity of the rOSMR knockdown, because 
LIFR/gp130 signalling is not impaired by rOSMR siRNA. LIF induces similar 
phosphorylation levels of STAT1, STAT3 and ERK1/2 in OSMR siRNA transfected, 
control siRNA transfected or untransfected cells (Fig. 25B, compare lanes 2, 7 and 
12). An interesting result was observed in OSMR siRNA transfected JTC-27 cells 
treated with rOSM: the phosphorylation of STAT3 and STAT1 in response to rOSM is 
not significantly affected by rOSMR knockdown (Fig. 25B, lanes 5, 10, 15 and 
quantification). However, a clear reduction in ERK1/2 phosphorylation intensity 
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(approximately 50%) is observed in OSMR knockdown cells (Fig. 25B, lanes 5, 10 
and 15). In sharp contrast, all mOSM induced signalling pathways (STAT3, STAT1, 
ERK1/2) are impaired by approx. 80% in JTC-27 transfected with rOSMR siRNA in 
comparison to untransfected cells (lanes 4, 9 and 14, quantification). This exactly 
correlates with the knockdown efficiency of the rOSMR (reduction of 80%, Fig. 25A). 
In contrast, hOSM signalling is not attenuated by the knockdown of the rat OSMR 
(lanes 3, 8 and 13). Taken together, these results strongly suggest that rOSM, unlike 
mOSM, but similar to hOSM, is able to utilise two receptor complexes, the type I 
(LIFR/gp130) and the type II (OSMR/gp130) receptor complex on rat cells. OSM from 
murine origin exclusively uses the type II receptor complex, while human OSM 
signals via the type I receptor complex on rat cells. 
 
4.4.4 Rat OSM on murine cells: Higher preference for the type II OSMR receptor 
 
Next, the signalling preferences of rOSM on murine hepatoma cells (Hepa1c1c7) 
were determined. As previously shown in figure 23, rOSM is able to induce signal 
transduction in Hepa1c1c7. Human OSM also mediates signalling on murine cells, 
but is known to exclusively use the type I (mLIFR/mgp130) receptor complex on 
mouse cells74, 75. To analyse, if rOSM only uses the type I receptor complex on 
murine cells too, LIFR mediated signalling was again blocked using the mutein LIF-
05 (see 4.4.3, Fig. 24). As shown in figure 26, the blockade of LIFR strongly reduces 
the LIFR/gp130 induced phosphorylation of STAT3, STAT1 and ERK1/2 by hLIF and 
hOSM (Fig. 26, lanes 3, 4, 5 and 6). In contrast, no decrease of the mOSM or rOSM 
induced phosphorylations can be observed in the presence of LIF-05 (lanes 7, 8, 9 
and 10). This is a clear proof that rOSM based signalling in mouse cells, in contrast 
to hOSM mediated signalling, does not exclusively rely on the type I receptor 
complex (gp130/LIFR).  
Hepa1c1c7 cells were additionally treated with siRNA targeting murine OSMR 
mRNA. Thereby similar knockdown efficiencies as in rat JTC-27 (Fig. 25A) cells were 
achieved (Fig. 27A, panel 4, mOSMR protein, Fig. 27B, quantification of mOSMR 
levels). Equivalent reductions were determined for the mOSMR mRNA by semi-
quantitative RT-PCR (data not shown). The analysis of the cytokine initiated 
signalling pathways in presence or absence of mOSMR siRNA clearly shows, that 
phosphorylations induced by hLIF as well as hOSM are not significantly reduced in 
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the presence of the mOSMR siRNA (Fig. 27A, compare lanes 2, 7 and 12 for hLIF, 
lanes 3, 8 and 13 for hOSM). However, mOSM and rOSM induced ERK1/2 
phosphorylation is almost completely abrogated by the knockdown of the mOSMR 
(Fig. 27A, third panel, lanes 4, 5, 9, 10, 14 and 15). Moreover, the mOSM induced 
STAT1 tyrosine phosphorylation also seems to be mostly/exclusively mediated by the 
type II receptor complex since it is severely impaired upon mOSMR knockdown (Fig. 
27A, second panel, lanes 4, 9 and 14). 
 
 
 
Figure 26: rOSM mainly signals via the type II receptor complex in murine cells: 
LIFR blockade using LIF-05 
Murine hepatoma cells (Hepa1c1c7) were preincubated with 50 ng/ml LIF-05 for 30 min and 
subsequently treated with 1 ng/ml hLIF, 10ng/ml hOSM, 10ng/ml mOSM or 10ng/ml rOSM for further 
15 min. The phosphorylation intensities of the indicated proteins were detected via Western blot 
analysis. The membranes were stripped and reprobed with antibodies recognising the proteins 
irrespective of their activation status (STAT3, STAT1, ERK1/2 and tubulin). Phosphorylation intensities 
were quantified by chemiluminescence analysis (right panel) and normalisation to loading controls. 
hOSM activation level was set to 100%. Shown are the means (n=2) with standard error of mean 
(SEM).  
 
 
The results of STAT1 phosphorylation upon rOSM stimulation are rather ambiguous, 
as a partial, but not significant decrease of the already weak phospho-signal is 
observed in the presence of the mOSMR siRNA. Part of the STAT1 signal seems to 
be mediated by LIFR/gp130 heterodimers, although rOSM actually does not potently 
induce STAT1 phosphorylation in these cells. Similar to the results of the STAT1 
activation, the STAT3 tyrosine phosphorylation following mOSM treatment is strongly 
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reduced in mOSMR siRNA transfected Hepa1c1c7 (Fig. 27A, lanes 4, 9 and 14, first 
panel). The rOSM induced STAT3 phosphorylation is also partly abrogated in 
mOSMR siRNA transfected Hepa1c1c7 cells, but clearly stronger STAT3 
phosphorylation is maintained than after mOSM stimulation (lanes 5, 10 and 15 of the 
first panel) indicating that both receptor complexes might potentially be involved.  
 
 
 
Figure 27: rOSM mainly signals via the type II receptor complex in murine cells: 
Silencing the murine OSMR using specific siRNA 
A, Hepa1c1c7 were transfected with control or mOSMR siRNA or left untransfected. Untransfected, 
control and mOSMR siRNA transfected Hepa1c1c7 cells were treated with 10 ng/ml hLIF, hOSM, 
mOSM and rOSM for 15 min. Lysates were subjected to Western blot analysis using antibodies 
specific for the detection of STAT3 (pY705), STAT1 (pY701), ERK1/2 (pT202/pY204) and protein 
levels of the OSMR. The blots were stripped and reprobed with antibodies recognising the proteins 
irrespective of their phosphorylation status and with an α-tubulin antibody. Phosphorylation intensities 
were quantified by chemiluminescence analysis and normalisation to loading controls. hOSM 
activation level was set to 100%. Shown are the means (n=4) with standard error of mean (SEM). * 
p<0.05, ** p<0.01 and *** p<0.001 OSMR siRNA vs. control siRNA. B, Corresponding quantification of 
mOSMR protein levels normalised to tubulin. Control siRNA was set to 100%. Shown are the means 
(n=4) with standard error of mean (SEM). *** p<0.001 OSMR siRNA vs. control siRNA. 
 
 
4.4.5 Rat OSM utilises the type I receptor complex on human cells 
 
After characterizing the rOSM receptor preferences on rat and murine cells, human 
HepG2 hepatoma cells were used to determine the receptor usage of the cytokine on 
human cells. Therefore, equivalent experiments as performed before in Hepa1c1c7 
and JTC-27 cells (4.4.4 and 4.4.3) have been carried out. Again, the LIFR based 
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signalling was suppressed using LIF-05. Blockade of the human LIFR by LIF-05 
completely inhibits the rOSM induced STAT3 and STAT1 tyrosine phosphorylation 
(Fig. 28, lanes 9 and 10). Unlike hOSM that is known to signal via both human 
receptor complexes, no rescue of the rOSM and the hLIF mediated signalling occurs, 
if the LIFR is blocked (Fig. 28A, compare lanes 3, 4, 5, 6, 9 and 10). As described 
above, murine OSM is not able to elicit signalling on human cells. Unlike the situation 
in rat or murine cells, rat OSM exclusively signals via the type I receptor complex on 
human cells. There is no hint for any hOSMR activation by rOSM. In chapter 4.4.6 
the clear evidence for this hypothesis is shown by using Ba/F3 cells expressing only 
hOSMR/hgp130.  
 
 
Figure 28: rOSM signals via the type I receptor complex in human cells: 
Blockade of the hLIFR via LIF-05 
Human hepatoma cells (HepG2) were preincubated with LIF-05 (50ng/ml, 30 min). Afterwards the 
cells were treated with 10 ng/ml hLIF, hOSM, mOSM or rOSM for 15 min. The phosphorylation 
intensities of the indicated proteins were detected via Western blot analysis. The membranes were 
stripped and reprobed with antibodies recognising the proteins irrespective of their activation status 
(STAT3, STAT1, ERK1/2 and tubulin). Phosphorylation intensities were quantified by 
chemiluminescence analysis and normalisation to loading controls. hOSM activation level was set to 
100%. Shown are the means (n=2) with standard error of mean (SEM).  
 
 
Vice versa, silencing the human OSMR using specific hOSMR siRNA (Fig. 29A, 
panel 4, hOSMR protein, Fig. 29B, quantification of hOSMR levels) does not 
negatively influence rOSM induced signalling (Fig. 29A, lanes 5, 10 and 15 of panel 1 
and 2). In contrast STAT1 and ERK1/2 phosphorylations in response to hOSM are 
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strongly decreased in the presence of OSMR siRNA confirming that LIFR/gp130 
based signalling alone is not able to maintain the activation of these pathways. The 
phosphorylation of STAT3 is also significantly decreased in OSMR siRNA transfected 
cells, but the degree of inhibition is less severe compared to STAT1 and ERK1/2. 
Taken together, rOSM exclusively utilises the hLIFR/hgp130 type I receptor complex 
on human cells, thereby mimicking neither murine nor human OSM.  
 
 
 
Figure 29: rOSM signals via the type I receptor complex in human cells: 
Silencing the hOSMR via specific OSMR siRNA 
A, HepG2 were transfected with control or hOSMR siRNA or left untransfected. Untransfected, control 
and hOSMR siRNA transfected HepG2 cells were exposed to 10 ng/ml hLIF, hOSM, mOSM or rOSM 
for 15 min. Cell lysates were used for Western blot analysis and phosphorylation levels of STAT3 
(pY705), STAT1 (pY701), ERK1/2 (pT202/pY204) and protein levels of the OSMR were detected. 
After stripping membranes were reprobed with antibodies recognising the proteins irrespective of their 
phosphorylation status and with an α-tubulin antibody. Phosphorylation intensities were quantified by 
chemiluminescence analysis and normalisation to loading controls. hOSM activation level was set to 
100%. Shown are the means (n=3) with standard error of mean (SEM). * p<0.05, ** p<0.01 and *** 
p<0.001 OSMR siRNA vs. control siRNA. B, Corresponding quantification of hOSMR protein levels 
normalised to tubulin. Control siRNA was set to 100%. Shown are the means (n=3) with standard error 
of mean (SEM). ** p<0.01 OSMR siRNA vs. control siRNA. 
 
 
4.4.6 Confirmation of the rat OSM receptor usage on human cells using stably 
transfected Ba/F3-hOSMR/hgp130 cells 
 
To corroborate the rather surprising finding that rOSM might solely use the 
LIFR/gp130 type I receptor complex on human cells, proliferation assays were 
carried out in stably transfected Ba/F3 cells expressing only hOSMR and hgp130. For 
this purpose, the cells were treated with different concentrations of hOSM and rOSM 
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for 48 h. As shown in figure 30, Ba/F3 cells expressing hOSMR and hgp130 (type II 
receptor complex) proliferate in a dose dependent manner in response to hOSM. 
Already concentrations of 0.8 ng/ml hOSM are sufficient to induce measurable Ba/F3 
proliferation. At concentrations of 20 to 100 ng/ml hOSM the proliferation response is 
saturated (Fig. 30, red curve). 
 
 
Figure 30: rOSM is not able to induce proliferation of hOSMR/hgp130 
expressing Ba/F3 cells 
Stably transfected Ba/F3 cells expressing hOSMR and hgp130 were treated with different 
concentrations of hOSM and rOSM (0.0064 – 100 ng/ml cytokine) for 48 h. To evaluate the 
proliferation rate, the WST-1 reagent was subsequently added to the cell suspension and Ba/F3 cells 
were incubated for additional 4 h. The shown values represent means (± SEM) of the measured 
absorbance at 450 nm minus absorbance at 660 nm. The means with SEM were calculated from three 
independent experiments.  
 
 
In sharp contrast to hOSM, rOSM is unable to induce proliferation of the cells even at 
a concentration as high as 100 ng/ml which is ten times the amount used in 
experiments before (Fig. 30, green line). This clearly proves that the human type I 
receptor complex is activated by the cytokine, while the human type II receptor 
complex is not. 
 
4.4.7 Confirmation of the finding that rOSM signals through the rat type I and 
the rat type II receptor complex using stably transfected Ba/F3 cells 
 
Since LIF-05 or rat OSMR siRNA were not able to fully abrogate LIFR based 
signalling or OSMR transcription, respectively, in rat JTC-27 cells (see section 4.4.3), 
we decided to additionally analyse the receptor usage of rOSM on stably transfected 
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Ba/F3 cells. In contrast to cells naturally expressing rgp130, rOSMR and rLIFR, these 
cells have the clear advantage of synthesising only the desired receptor combination 
(rLIFR-rgp130 or rOSMR-rgp130). Therefore, rOSMR, rLIFR and rgp130 were cloned 
from total RNA isolated from the rat hepatoma cell line JTC-27 and subcloned into a 
vector containing a bidirectional tet-responsive promoter upstream of two multiple 
cloning sites (pBO)255. After inserting either the rOSMR and rgp130 combination or 
the rLIFR and rgp130 combination, the sequenced vectors (@164: pBO-rgp130-
rOSMR and @166: pBO-rgp130-rLIFR) were singly electroporated into Ba/F3 cells 
already expressing the doxycycline inducible reverse tet-responsive transcriptional 
activator (rtTA). After selecting the cells with hygromycin and geneticin (G418), the 
expression of the respective receptor combination was induced by 0.5 µg/ml 
doxycycline (24 h). RNA was isolated and upon stimulation the cells were lysed to 
analyse the cytokine induced pathways. The resulting RNAs were used to confirm the 
expression of rgp130, rOSMR, rLIFR, while mGAPDH served as control (Fig. 31A). 
All transfected cells express rgp130 mRNA independent of the doxycycline induction, 
what might result from a leakiness of the promoter. The Ba/F3-rgp130-rOSMR cells 
additionally express rOSMR mRNA, however, similarly independent of doxycycline. 
The LIFR expression in Ba/F3-rgp130-rLIFR seems to be slightly increased upon 
doxycycline treatment, since more LIFR mRNA is produced in the presence of the 
antibiotic. However, the leakiness of the promoters is completely irrelevant for the 
analysed receptor preferences. As a precautionary measure, all induced signalling 
pathways were determined in the presence of doxycycline. For Western blot 
analyses, the cells were treated with 10 ng/ml hLIF, 20 ng/ml hOSM, mOSM or 
rOSM, respectively, for 15 min. The cell lysates were examined performing 
quantitative Western blot analysis detecting STAT3 (pY705), STAT1 (pY701) and 
ERK1/2 (pT202/pY204) phosphorylation levels. As shown in Fig. 31B (upper panel), 
in Ba/F3 cells expressing rgp130 and rOSMR STAT3, STAT1 and ERK1/2 are 
exclusively phosphorylated in response to mOSM or rOSM stimulation. Human LIF or 
hOSM fail to activate any analysed pathway. This is the clear proof that only mOSM 
and rOSM can utilise the rat OSMR/gp130 (type II) receptor complex among the 
analysed cytokines (Fig. 31B, lanes 4 and 5 of the upper panel). In sharp contrast, in 
Ba/F3 cells expressing rgp130 and rLIFR STAT3, STAT1 and ERK1/2 are exclusively 
phosphorylated in response to hLIF, hOSM and rOSM, while mOSM fails to induce 
any signalling pathway (Fig. 31B, lower panel, lanes 2, 3 and 5). Thus rOSM, just like 
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hLIF and hOSM, is able to signal via the rLIFR/rgp130 (type I) receptor complex. 
Comparable to the results shown in 4.4.3 (hOSM, mOSM and rOSM stimulation of 
JTC-27 cells), OSM from murine origin is not capable of utilising the rat OSM type I 
receptor complex.  
 
Figure 31: rOSM signals via the cloned rat type I and type II receptor complex 
A, Ba/F3 cells (wt (wildtype), selected pool of cells expressing rgp130/rOSMR or rgp130/rLIFR) were 
cultured on 6 well plates (conditions, see 3.3.1). After reaching 80% confluency, one well of Ba/F3-
rgp130-rOSMR and Ba/F3-rgp130-rLIFR each was treated with 0.5 µg/ml doxycycline for 24 h. Total 
RNA was isolated using the RNeasy Mini Kit. RT-PCR was performed using the indicated primers and 
the Verso 1-Step RT-PCR Kit. B, Ba/F3 cells expressing either rOSMR/rgp130 or rLIFR/rgp130 were 
cultured on 24 well plates to a density of 2 x 105 cells per well. The expression of the respective 
receptors was induced 24 h before addition of the cytokines. The cells were treated with 10 ng/ml hLIF 
or 20 ng/ml hOSM, mOSM or rOSM for 15 min. The phosphorylation intensities of the indicated 
proteins were detected via Western blot analysis. The membranes were stripped and reprobed with 
antibodies recognising the proteins irrespective of their activation status (STAT3, STAT1, ERK1/2 and 
tubulin). Activation determined for rOSM was set to 100%. Shown are the means (n=3 for STAT1 and 
ERK, n=6 for STAT3) with standard error of mean (SEM). * p<0.05, ** p<0.01, *** p<0.001 untreated 
vs. cytokine-treated sample, # p<0.05, ## p<0.01, ### p<0.001 for rOSM vs. either hLIF/hOSM or 
mOSM. 
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The results from Ba/F3 cells expressing the rat type I or type II OSM receptor 
complex provide clear evidence that rOSM is able to signal through both receptor 
complexes in a human OSM-like manner, that is clearly divergent from the murine 
homologue. 
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5 Discussion 
5.1 Classification of the hypertrophic potential of IL-6-type cytokines  
 
Cardiac hypertrophy is a crucial element of the protective cardiac remodelling upon 
pathological insults. However, in some cases cardiac hypertrophy can result in the 
development of a severe heart insufficiency. Initial processes of cardiac hypertrophy 
cause an increase of muscular mass as a compensatory reaction to altered 
conditions. The long term growth of cardiac myocytes, however, has rather harmful 
side effects. Such modifications contribute to a loss of myocardial contractility and 
primary plasticity, a scenario in which the primary compensatory response converts 
to a maladaptive reaction267. The experiments performed within this study highlight 
the hypertrophic influence of oncostatin M (OSM) in comparison to related IL-6-type 
cytokines on neonatal rat cardiac myocytes (NRCM). Within the first part of the 
results it has been shown that hOSM and mOSM as their related IL-6-type cytokines 
hLIF, hCT-1 and hIL-6 combined with hsIL-6R are able to induce an elongated 
phenotype (eccentric hypertrophy) of NRCM which results in cell growth of 
approximately twice the size of untreated cells. Although overexpression of STAT3 in 
transgenic mice has been shown to be sufficient to initiate cardiomyocyte 
hypertrophy in vitro227 and in vivo268, IL-6-type cytokines so far have not been 
considered as therapeutic targets in anti-hypertrophy approaches. To analyse, if 
different IL-6-type cytokines induce diverse kinds of hypertrophy based on their 
property to initiate not only redundant STAT3 phosphorylation, but also activation of 
different sets of MAPKs, further STATs, Akt and additional proteins involved in other 
hypertrophic pathways, we decided to perform a comparison of the hypertrophic 
potentials, the induced signalling pathways and the induction of hypertrophy 
enhancing mRNAs. The role of OSM was of central importance, as no publications 
determining the hypertrophic potential of the cytokine existed at that time. In contrast, 
several studies were already available showing the hypertrophic potential of LIF, IL-6 
and CT-1194-197, 199-205, 210. In addition to NRCM, we also analysed the same signalling 
pathways and hypertrophy enhancing mRNAs in neonatal rat cardiac fibroblasts 
(NRCFB) to determine the involvement of this second cardiac cell type in the 
development of cardiac hypertrophy.  
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It has to be mentioned that the hypertrophic network comprises several ligand-
receptor interactions and downstream pathways. Besides the IL-6-type cytokine-
gp130-axis, Na+/H+ channels, Na+/Ca2+ channels, insulin-like growth factor receptors, 
L-type Ca2+ channels and G protein coupled receptors like adrenergic receptors, 
angiotensin receptors and endothelin receptors play important roles in the 
development of cardiac hypertrophy269. The functions of many of these participating 
proteins have been analysed in recent years. In this study a potential interaction 
between IL-6-type cytokines and the renin-angiotensin system has been 
corroborated in more detail. 
 
5.1.1 Hypertrophic potential of oncostatin M in relation to different heart 
relevant IL-6-type cytokines 
 
Primary neonatal rat cardiomyocytes represent the most common and most 
frequently used in vitro model to determine cardiomyocytic hypertrophy. The primary 
culture of NRCM was already established 30 years before, in 1982270, and until today 
it is the routinely used cell based system for basic cardiovascular research. The 
difficulties of NRCM preparation are to achieve high purity of myocyte cultures and to 
maintain the quality of such cultures by exact standardisation of preparation and 
culture conditions. Especially the analysis of induced signalling pathways places high 
demands on a freshly isolated primary cell culture. A number of cardiomyocyte cell 
lines (H2C9271, HL-1272 or AC16273) have been established within the past four 
decades which express specific cardiomyocyte markers (e.g. sarcomeric α-actinin or 
cardiac myosin heavy chain)271-273 and seem to display a comparable hypertrophic 
potential as their primary counterparts274, 275. However, these cell lines have been 
described to develop the tendency to dedifferentiate272, 276 rendering them 
inappropriate for reproducible results. We therefore decided to work with primary 
NRCM. 
Supported by the group of Prof. Dr. Stefan Engelhardt (until October 2008 RVZ, 
Würzburg, now TU Munich), we have analysed cytokine induced cardiac hypertrophy 
using their established high content screening (HCS) technique257. This approach 
was originally developed to screen pools of siRNA or miRNA transfected 
cardiomyocytes on a multiwell plate format in an automated way277-280. The great 
advantage of the technique is the exclusion of remaining non-cardiomyocytes from 
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the cell size analysis, while cardiomyocytes are fully included, based on the criterion 
“expression of sarcomeric α-actinin”257. Therefore, cellular contaminants like cardiac 
fibroblasts are not counted, thus clearly increasing the quality of the results. The 
second advantage of the HCS is the automation of cell size analysis allowing the 
investigation of high numbers of NRCM (up to 3 x 103 cells per 96 well) within a few 
hours, while almost every cell on each well is acquired by the analysis. Jentzsch et 
al. have plausibly demonstrated that experimentally induced cell size alterations are 
comparably detectable by a manual microscopy/quantification method and the HCS 
method257, 281-283. As a positive control we have used the α1-adrenergic ligand PE, 
which is well known as a classic hypertrophy inducing adrenergic agonist. The results 
shown in figure 6 of the presented thesis display that PE serves as appropriate 
positive control for NRCM hypertrophy. Although the HCS method allows the 
generation of unbiased and highly reproducible data sets, the method still needs to 
be strictly controlled. Hence, all segmentation data have been visually compared to 
the pure microscopy data to exclude any errors made by the software (e.g. two cells 
that are wrongly considered as one big cell).  
After adapting the HCS method from the Engelhardt group, we first analysed the 
hypertrophic potential of OSM in relation to hLIF, hCT-1 and hIL-6 (± hsIL-6R). As 
shown in figure 6, hOSM and mOSM have hypertrophic potentials comparable to 
those of hLIF, hCT-1 and hIL-6/hsIL-6R. Slight differences, however, can be 
observed between the various IL-6-type cytokines indicating that the analysed 
cytokines partially stimulate different receptor complexes. A direct comparison 
between OSM, LIF, CT-1 and IL-6 regarding hypertrophic responses of NRCM has 
never before been published, but some studies analysing the hypertrophic potential 
and/or induced pathways of single cytokine(s) exist. First, our data regarding LIF 
emphasize the strong hypertrophy inducing role of this cytokine and confirm its ability 
to initiate the activation of the STAT3/STAT1, Akt and ERK1/2 pathways in NRCM 
(Fig. 7, 10). This is perfectly in line with previous studies, that have shown that LIF 
induces gp130, STAT3 and STAT1 tyrosine phosphorylation resulting in hypertrophic 
responses of rodent cardiomyocytes284, 285. Matsui et al. further suggested an 
autocrine/paracrine role of this IL-6-type cytokine in the heart, as they found LIF 
mRNA to be expressed by cardiomyocytes as well as by non-cardiomyocytes285. Our 
own data also demonstrate that LIF mRNA expression is induced by hLIF and IL-
6/sIL-6R activity in NRCM (Fig. 13) and NRCFB (Fig. 17A). The observation that LIF 
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was the strongest hypertrophic stimulus among the tested IL-6-type cytokines might 
be due to the fact that STAT3 as well as Akt and ERK1/2 are phosphorylated in 
response to LIF. As previously mentioned, each of these phosphorylations is involved 
in the hypertrophic response of cardiomyocytes146-148. Another aspect that has to be 
discussed in this context is the high affinity of human LIF to the murine and obviously 
also to the rat LIFR. For rat cells this phenomenon has not been shown in previous 
studies, however, it is well known that hLIF binds the mLIFR with 100-500-fold higher 
affinity compared to mLIF36. Due to this affinity difference Huyton et al. might have 
preferred to use human LIF instead of murine LIF to crystallise the cytokine in 
complex with the mLIFR (D1-D5)286. This strong affinity also seems to be true for the 
interaction between hLIF and the rLIFR/rgp130 complex and might therefore be an 
accurate explanation for the observed differences between hLIF and hOSM induced 
signalling (Fig. 7 and 10).  
As already mentioned, hOSM can only activate the type I receptor complex 
(LIFR/gp130) of murine cells74, thus precisely mimicking LIF. Within the presented 
thesis we have shown in several experiments (Fig. 9, 15, 24, 31 and additional, not 
presented data) that the same receptor use (rLIFR/rgp130 type I complex) is also 
true for rat cells. Moreover, we could exclude any participation of the rat OSMR in 
hOSM signalling (Fig. 9, 15, 24 and 31). Since hLIF and hOSM induce signalling 
using the same rat receptor complex, the stronger phosphorylations of STAT3, 
STAT1, STAT5, ERK1/2, p38 and Akt in response to hLIF compared with hOSM, 
shown in figure 10, indicate that only hLIF but not hOSM has an extremely high 
affinity for the rat LIF receptor. Dose-response experiments comparing hLIF and 
hOSM might clarify this hypothesis in the future. Although the observed 
phosphorylations of the hypertrophy relevant proteins STAT1, ERK1/2 and Akt are 
clearly weaker in response to hOSM than to hLIF, the third strongest NRCM 
hypertrophy inducer among the analysed IL-6-type cytokines, however, is hOSM. 
This might be due to the strong STAT3 tyrosine phosphorylation probably 
representing the most important IL-6-type cytokine induced pro-hypertrophic 
pathway191. This hypothesis is strengthened by the findings that hCT-1 potently 
promotes NRCM hypertrophy, which - as also shown in older studies195, 227, 287 - 
mainly induces the phosphorylation of STAT3 and only to a minor extent of STAT1 
and ERK1/2 (Fig. 8). Taken together, all analysed LIFR/gp130 heterodimer activating 
cytokines induce hypertrophy, mainly through STAT3 phosphorylation. 
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The activation of OSMR/gp130 heterodimers through mOSM also causes NRCM 
hypertrophy (Fig. 6). Although the hypertrophic potential of murine OSM seems to be 
milder than the LIFR based hypertrophy, the mOSM induced phosphorylations of 
STAT3, STAT1, ERK1/2 and Akt rank between the hOSM and hLIF induced 
phosphorylation intensities (Fig. 10). This is an interesting finding, because the 
mOSM associated induction of NRCM hypertrophy is less severe than the one 
induced by hLIF or hOSM (Fig. 6). One might therefore anticipate that mOSM cannot 
activate additionally required, but here not analysed, signalling pathways or that it 
simultaneously induces hypertrophy antagonising signals. For example, it has been 
shown that the association of SHP2/Gab1 and the resulting ERK5 activation play a 
major role in LIF induced hypertrophy217, 288, 289. Takahashi et al. contend that ERK5 
is even the major hypertrophy causing pathway induced by CT-1218. However, in our 
hands the activation of ERK5, at least in response to LIF or OSM, could not be 
detected (data not shown). Moreover, the observed differences cannot be explained 
by differential initiation of feedback inhibitors like SOCS1, SOCS3 or SHP2, because 
hLIF, but not mOSM, even induces the highest mRNA expression levels of SOCS1 
and SOCS3 as well as the strongest SHP2 tyrosine phosphorylation of all tested 
cytokines (Fig. 14). Although it has recently been shown that OSM is able to induce 
myocyte hypertrophy and is an important mediator of cardiomyocyte dedifferentiation 
and remodelling198, 290, the entirety of OSM induced signalling pathways in 
cardiomyocytes was not analysed or shown in these studies. Notably, we have 
determined that mOSM is able to induce STAT3, STAT1, STAT5, ERK1/2, Akt and 
p38 phosphorylation in a hLIF-like manner, though STAT1 and STAT5 tyrosine 
phosphorylations are clearly weaker (Fig. 10). Anyway, STAT5 phosphorylation is not 
considered to directly mediate cardiomyocyte hypertrophy, although it has been 
shown that STAT5a is activated in ischemia/reperfusion experiments and mediates 
the mRNA expression of angiotensinogen291. As described in the next sections, the 
link between the IL-6-type cytokines and the renin-angiotensin system is considered 
to be one of the most cardiomyocyte hypertrophy promoting cellular networks. 
Nevertheless, also STAT3 phosphorylation (in response to CT-1) has been shown to 
induce angiotensinogen expression in NRCM292, what might partially relativise the 
exclusiveness of the STAT5 mediated expression of angiotensinogen. Why the 
hypertrophic response following mOSM stimulation is weaker than the hypertrophic 
responses to hOSM or hCT-1 remains unclear, however. Most likely the less 
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pronounced pro-hypertrophic character of mOSM is closely connected with the 
comparatively weak induction of IL-6 mRNA and the negative regulation of LIF mRNA 
expression (Fig. 13). In contrast to mOSM, hLIF induces an increase of LIF mRNA 
and provokes higher IL-6 mRNA levels (particularly at early time points) in NRCM. 
Both of the endogenously synthesised cytokines (especially LIF) are likely able to 
maintain previously induced (exogenic) NRCM hypertrophy. Furthermore, the 
different effects of mOSM and hOSM cannot be explained by the additionally 
detected mOSM mediated p38 phosphorylation, because this signalling pathway 
seems to be more pro-hypertrophic than anti-hypertrophic293, and hLIF also mediates 
the phosphorylation of this MAPK (Fig. 10).  
Contrary to the rLIFR ligands hLIF, hCT-1 and hOSM, classical IL-6 signalling via the 
membrane-bound IL-6R and gp13011 is not capable of inducing hypertrophy (Fig. 6) 
or the related, typical signalling pathways in NRCM (e.g. STAT3, see Fig. 10). This is 
a rather interesting finding, because many studies have focused on the hypertrophic 
actions of pure IL-6 (classical IL-6 signalling294). As shown by Sano et al. the 
upregulation of IL-6 (induced by ATII activity), that actually activates cardiomyocytes 
to hypertrophy, is based on a complex regulatory network. Cardiac fibroblasts seem 
to be involved in this process, since cardiac myocytes only express marginal levels of 
AT-1 receptors, rendering them rather unresponsive to ATII260. The same is also true 
for the IL-6R260. Therefore, Sano et al. postulate that the described ATII induced 
hypertrophic effects might be mainly mediated by parallel LIF and CT-1 induction. 
These observations lead to the conclusion, that the abundantly expressed LIFR and 
gp130 are responsive mediators for the fibroblast-cardiomyocyte-ATII-IL-6-type 
cytokine hypertrophy promoting interplay. As shown in our results, IL-6 without its 
soluble α-receptor, the IL-6R, is indeed not able to signal on NCRM or to induce 
measurable NRCM hypertrophy (Fig. 10 and 6).  
Notably, IL-6 trans-signalling (mimicked through stimulation with hIL-6/hsIL-6R, see 
Fig. 10) is required and leads to cardiomyocyte hypertrophy (Fig. 6 and 7). In this we 
clearly agree with Hirota et al. who have shown several years ago, that only the 
stimulation with IL-6 and sIL-6R induces hypertrophy in cardiomyocytes199. As 
described above the hypertrophic effects of IL-6 trans-signalling seem to be mainly 
mediated via STAT3 activation, since the activations of STAT1 and ERK1/2 are 
rather weak and Akt phosphorylation cannot be detected (Fig. 10). IL-6/sIL-6R 
thereby closely resembles the activities of CT-1. It has to be noted that the induction 
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of endogenous IL-6 and LIF likely contributes to the pro-hypertrophic phenotype of 
hIL-6/sIL-6R treatment (Fig. 8). Moreover, the participation of regulatory miRNAs and 
further hypertrophy supporting proteins cannot be excluded. 
5.1.2 The analysis of IL-6-type cytokine target genes in NRCM suggests a 
potential autocrine amplification loop 
 
NRCM treated with mOSM, hLIF and hIL-6/hsIL-6R transcribe a specific pattern of 
target genes that can possibly contribute to the development and persistence of 
cardiomyocyte hypertrophy. As shown in figure 13, analysis of a selected panel of 
potential target genes revealed that mOSM, hLIF and hIL-6/sIL-6R mediate varyingly 
strong, persistent IL-6 mRNA induction. Moreover, hIL-6/hsIL-6R or LIF stimulation of 
NRCM cultures causes the upregulation of endogenous LIF mRNA, an attribute of 
these two cytokines that is not shared by mOSM. In sharp contrast, mOSM signalling 
negatively influences LIF mRNA levels, a regulation that is even intensified after 12 
or 24 h, respectively. The observation that cardiac myocytes (and fibroblasts) are 
able to produce LIF and IL-6 (partially by an autoinductive process and without any 
additional stimulus), and that this secretion causes hypertrophy, was initially 
described by Ancey and colleagues197, 295. Furthermore, there are several studies 
showing that IL-6 secretion is induced by ATII, adrenergic receptor activation (e.g. by 
isoproterenol) or IL-1β treatment260, 296-298. Moreover, Ng et al. have shown that IL-1β 
induces a delayed STAT3 activation in NRCM causing a LIF-like hypertrophic 
phenotype. They could show that this secondary STAT3 phosphorylation (already 
appearing after 60 min) occurs via ERK/p38 involvement, but it was not clear, if any 
intermediate IL-6-type cytokine expression was induced or not299.  
However, it has not been shown until now that IL-6-type cytokines can induce their 
own expression in cardiomyocytes. This is indeed a finding with far reaching 
consequences for the IL-6-type cytokine exposed heart. Once induced, LIF or IL-6 
are likely able to maintain the hypertrophic actions of the primarily applied stimulus. 
On the other hand, mOSM shares the capacity of inducing Il6 transcription with the 
related cytokines IL-6 and LIF (Fig. 13). The induction of the IL-6 expression is a 
feature of OSM that was already observed previously in other cell types. Several 
groups have described that OSM is able to promote IL-6 secretion of hepatocytes via 
C/EBP activation8, 300, 301. This induction was also described for murine fibroblasts302, 
human synovial fibroblasts303, vascular smooth muscle cells304, human endothelial 
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cells305, human astrocytes306-309 and murine mammary epithelial cells237, 310. Our own 
data from rat hepatoma cells (JTC-27) that were stimulated with mOSM show also a 
strong upregulation of IL-6 and the IL-6R (data not shown), completely in line with the 
published data. In contrast to our findings in JTC-27 hepatoma cells, NRCM do not 
significantly upregulate the IL-6R expression in response to mOSM, hLIF or IL-6 
(data not shown). As already mentioned, under basal conditions NRCM do also not 
express sufficient IL-6R molecules to directly respond to pure IL-6 (Fig. 6 and 10). 
These data are in line with the study of Sano et al.260, in which they have 
demonstrated that NRCM express no significant amounts of the IL-6R. This fact is 
unfortunately ignored by many groups and complicates the understanding of the IL-6 
expression and its impact on hypertrophy. It can, however, not be excluded that the 
low levels of the receptor are sufficient to promote or maintain hypertrophy over time. 
Nonetheless, we believe that in NRCM the actions of LIF and OSM might be more 
important for the development/persistence of hypertrophy. This hypothesis is 
supported by a study of Fuchs et al. demonstrating that deletion of the Il6 gene in 
mice has neither a beneficial nor a harmful influence on left ventricular remodelling, 
function or infarct size209.  
A further induced target that likely contributes to the pro-hypertrophic actions of the 
analysed cytokines is the OSMR. All tested cytokines, mOSM, hLIF and hIL-6/sIL-6R 
cause the significant upregulation of the rat Osmr gene transcription (Fig. 13).  
Intriguingly, this is a prolonged activity that leads to elevated rOSMR mRNA levels 
also after 12 or 24 h of stimulation. So far, the upregulation of the OSMR has only 
been described for OSM itself in human kidney tissue samples311 and pulmonary 
fibroblasts165.  
Nevertheless, it has to be mentioned that -unlike the IL-6R- the OSMR mRNA levels 
under basal conditions are sufficient to allow clearly detectable mOSM mediated 
signalling. This can be read off the activated signalling pathways, induction of target 
gene transcription and initiation of hypertrophy. Since it is known that OSM 
stimulation results in a ligand dependent internalisation of the OSMR/gp130 receptor 
complex165, the OSM-induced enhanced transcription of the OSMR might play a role 
in restoring the internalised OSMR molecules. Nevertheless, it is possible that the 
observed OSMR upregulation prepares the cells for later OSM impacts by increasing 
the sensitivity of the cells to the cytokine. Notably, so far we could not detect the 
induction of OSM mRNA following hIL-6/sIL-6R, hLIF or mOSM stimulation of NRCM 
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or NRCFB (data not shown) indicating that a mOSM induced hypertrophy is not the 
result of an autocrine OSM loop. Which stimulus might lead to OSM secretion 
remains to be determined. It is, however, well known that OSM is released by 
neutrophils, monocytes and T-cells43, 58, 65, 66, which can be found in the heart in 
pathophysiological conditions such as ischemia/reperfusion or myocardial 
infarction312, 313. Moreover, Kubin et al. have demonstrated that patients suffering 
from dilated cardiomyopathy show strongly elevated OSM levels and resulting 
signalling. Interestingly, this cytokine seems to mediate the dedifferentiation of 
cardiomyocytes and an upregulation of stem cell markers thus initially improving 
cardiac function after myocardial infarction, what was also shown in a mouse model 
of myocardial infarction. While the first phase of OSM induced cardiac remodelling 
seems to be beneficial for the cardiac function, the extended dedifferentiation of 
cardiomyocytes by OSM clearly impairs the cardiac performance198.  
 
5.1.3 The response of NRCFB to IL-6-type cytokines: a contribution to 
hypertrophy 
 
As described before for NRCM, mOSM or hIL-6/hsIL-6R stimulation strongly 
increases the transcription of the Il6 gene in NRCFB. The induction mediated by IL-6 
trans-signalling (i.e. via IL-6/sIL-6R, in contrast to classical IL-6 signalling via IL-6 
binding to the membrane bound IL-6R) is, however, unequally stronger than the 
mOSM initiated upregulation of the cytokine’s mRNA levels (16-fold mRNA induction 
after 3 h mOSM vs. 204-fold mRNA induction after 3 h hIL-6/hsIL-6R, Fig. 17A). 
Notably, this observed disparity is not described in literature until now. Additionally, 
the cardiac Il6 transcription in response to OSM or IL-6/sIL-6R has not yet been 
shown. Fredj et al. have established a cardiac myocyte/fibroblast co-culture model, 
where they could clearly show, that ATII (produced from cardiac myocytes) induces 
IL-6 secretion by cardiac fibroblast subsequently causing hypertrophy of myocytes in 
a paracrine manner314. However, it is completely unclear whether pathological 
cardiac hypertrophy mediated/maintained by IL-6-type cytokines is always initiated by 
ATII or other non-IL-6-type cytokine family members.  
In line with the mRNA induction, we have observed increased rIL-6 concentrations in 
the supernatants of mOSM and hIL-6/hsIL-6R stimulated NRCFB (Fig. 17B) 
demonstrating that the cytokine is truly secreted from these cells. It has to be 
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mentioned again, that it is unlikely that IL-6 is the major mediator of hypertrophy in 
this scenario, as cardiac myocytes express only marginal IL-6R levels. The same is 
true for NRCFB (Fig. 15 and 16). Therefore, other family members have to be 
involved in the hypertrophic response, because the application of antagonising anti-
gp130 antibodies decreases the observed hypertrophy much stronger than the 
application of respective anti-IL-6 antibodies314. Furthermore, it cannot be excluded 
that the inhibitory influence of antagonising IL-6 antibodies is dependent on sIL-6R in 
the fetal calf serum used for the culture medium.  
In equivalent co-culture systems, it was shown that cardiac myocytes/fibroblasts are 
able to produce CT-1287, and exogenous CT-1 treatment can induce cardiac fibroblast 
proliferation via cross-talk with the endothelin system315. Therefore, besides IL-6, CT-
1 might also play a major role in cardiac fibroblast proliferation/fibrosis development 
and transmission of hypertrophic signals to cardiomyocytes.  
Our own data suggest that besides IL-6 and CT-1, LIF might be secreted by NRCFB, 
since we observed an upregulation of LIF mRNA levels in response to 3 h hIL-6/sIL-
6R stimulation. However, induction of Lif transcription appears to be rather transient, 
because this upregulation was mostly aborted after 18 h of hIL-6/sIL-6R treatment 
(Fig. 17A). In contrast to cardiomyocytes, not much is known about the role of LIF in 
cardiac fibroblasts. Wang et al. have shown that LIF stimulation can inhibit the 
differentiation of cardiac fibroblasts into myofibroblasts, along with a decrease of 
collagen production and matrix metalloproteinase (MMP) activity316. Moreover, it has 
been shown that cardiac fibroblasts in co-cultures with myocytes produce LIF (and 
endothelin simultaneously) and that LIF, just like CT-1, can act in trans on 
cardiomyocytes inducing a typical IL-6-type cytokine induced hypertrophic 
phenotype317. Logically, the production of LIF by NRCFB can consequently induce Lif 
and Il6 gene transcription in NRCM (Fig. 13). While mOSM decreases the 
transcription of Lif in NRCM (Fig. 13), it has no effect on LIF mRNA levels in NRCFB 
(Fig. 17A).  
Besides regulating the expression of their own gene (e.g. IL-6) or that of a related 
family cytokine gene (LIF), IL-6 trans-signalling and mOSM signalling additionally 
mediate the gene expression of some of the IL-6-type cytokine receptors. Particularly 
the OSMR expression is strongly elevated (Fig. 17A). While the induction of OSMR 
mRNA following mOSM stimulation is transient and almost terminated after 18 h, the 
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OSMR mRNA induction in response to IL-6/sIL-6R stimulation is even increased after 
18 h.  
In addition to the OSMR mRNA induction through mOSM or hIL-6/sIL-6R, that was 
previously observed in NRCM too (chapter 5.1.2), we have detected a statistically 
significant twofold increase of IL-6R mRNA after 3 h IL-6 trans-signalling in NRCFB 
(Fig. 17A). This is in line with data from hepatocytes that were also described to 
upregulate the IL-6R in response to IL-6 stimulation301. In contrast to HepG2 cells 
that additionally elevate the IL-6R expression in response to OSM300, however, we 
could not detect any augmented IL-6R levels in NRCFB after mOSM stimulation 
indicating that this might be a cell type specific regulation. The enhanced Il6r 
transcription in NRCFB in response to IL-6/sIL-6R might be of increased interest 
since –in case the increase is sufficient to allow translation into IL-6R protein- it would 
make NRCFB responsive to IL-6 signalling in the absence of soluble alpha-receptor, 
i.e. classical signalling in contrast to trans-signalling could occur. Unfortunately, we 
were unable to investigate IL-6R protein expression since no rat specific IL-6R-
antibody was available and the antibodies detecting murine or human IL-6R did not 
cross-react with the rat protein. 
Under pathological conditions, however, two possibilities exist maybe allowing IL-6 
signalling and IL-6 induced hypertrophy, respectively, in these cells: 1) sIL-6R, 
delivered from serum or produced by a third cell type (e.g. invading leukocytes), does 
complete the trans-signalling requirements for IL-6, 2) very low membrane bound IL-
6R protein levels still exist which, upon long term stimulation by secreted IL-6, might 
be sufficient to promote hypertrophic response over time. As already mentioned, the 
CT-values of the IL-6R in both cell types, NRCM and NRCFB, are extraordinarily high 
and therefore not on a typical “expression level”, but also not on a comparable “no 
expression level”. Hirota et al. have shown several years earlier how harmful a strong 
parallel expression of IL-6 and the IL-6R can be. Mice transgenic for IL-6 and the 
membrane-bound IL-6R and therefore overexpressing both proteins develop a strong 
myocardial hypertrophy, while none of the mice transgenic either for IL-6 or the IL-6R 
alone has a comparable phenotype199. This indicates that indeed IL-6 trans-signalling 
is required for the induction of cardiac hypertrophy.  
In addition to the OSMR and IL-6R, a transient upregulation of the LIFR can be 
detected in response to IL-6 trans-signalling and mOSM stimulation (Fig. 17A). Upon 
availability of specific antibodies future studies will have to clarify whether appropriate 
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increase in LIFR protein expression takes place allowing stronger or more sensitive 
signalling of cardiac fibroblasts under pathological conditions. The induction of the 
LIFR in response to OSM has previously been shown only in human pulmonary 
fibroblasts and epithelial cells165.  
As the renin-angiotensin system is a major mediator of hypertension and known to 
cross-talk with IL-6-type cytokines in cardiac hypertrophy318, we decided to 
corroborate this cross-talk in more detail. Angiotensin II is a potent vasoconstrictor 
and, as already mentioned, plays an important role in the development of cardiac 
hypertrophy by initiating the expression of IL-6 by cardiac fibroblasts260, 296.  
In this study we could show that reciprocally, IL-6 or OSM induce a clear prolonged 
upregulation of the angiotensin I converting enzyme (ACE I) mRNA in NRCFB (Fig. 
18). ACE I is the key enzyme for the ATII synthesis catalysing the conversion of the 
decapeptide angiotensin I into the active octapeptide angiotensin II319, 320. Therefore, 
IL-6-type cytokines induce critical components of the renin-angiotensin system that 
additionally amplify hypertrophic effects. While ATII induces IL-6 secretion of cardiac 
fibroblasts226, IL-6 or OSM probably initiate the upregulation of cardiac ACE I that 
increases the local concentrations of bioactive ATII. In the presence of exogenous 
ATI and sIL-6R this cross-talk could possibly result in an enclosed autocrine IL-6-ATII 
loop. 
What accessorily fits into this idea is the observed strong upregulation of the 
important ATII utilised angiotensin II receptor 1 alpha (AT1α) in response to mOSM 
or hIL-6/sIL-6R stimulation of NRCFB (Fig. 18). Contrary to the ACE I expression, a 
prolonged Agtr1a gene (encoding for the AT1α protein) induction was only observed 
in response to IL-6 trans-signalling. Indeed, it was shown several years ago that 
cardiomyocyte specific overexpression of the human AT1α is sufficient to induce 
cardiac hypertrophy and remodelling in mice263. These findings are consistent with 
results from hypertensive rats that also develop cardiac hypertrophy. In such rats the 
AT1α mRNA and protein levels have been found to be significantly upregulated264, 
while the angiotensin II receptor type 2 (AT2) levels have not been significantly 
altered265. Moreover, AT1α has been shown to be upregulated after myocardial 
infarction allowing ATII to promote ventricular remodelling in the infarcted heart266. 
The simultaneous upregulation of AT1α and ACE I represents a crucial cardiac event 
that is connecting the hypertrophic side of the IL-6-type cytokines with the 
hypertensive/hypertrophic axis of the renin-angiotensin system.  
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5.1.4 Kinetics of IL-6/sIL-6R and mOSM regulated gene expression differs 
substantially in NRCFB 
 
Comparison of OSM and IL-6 mediated signalling and gene expression in NRCM and 
NRCFB clearly shows that the duration of their stimulatory potential differs strongly. 
The IL-6 trans-signalling induced expression of the OSMR and IL-6 itself in NRCFB is 
clearly more prolonged than upon mOSM stimulation (Fig. 17A, OSMR and IL-6 
mRNA levels). As already mentioned in the results section, the obvious decrease in 
IL-6 expression upon IL-6/sIL-6R stimulation after 18h stimulation is only due to the 
fact that the –fold increase is related to the corresponding untreated control. Since IL-
6 is apparently constitutively released by NRCFB in culture295, also the CT values for 
untreated NRCFB decrease (higher IL-6 mRNA levels). Interestingly, the variation in 
signalling persistence upon IL-6 vs. OSM was not observed in NRCM, in which both 
target mRNAs are induced and remain expressed on a significantly increased level 
even after 12 and 24 h, irrespective of the used stimulus (Fig. 13). 
To further scrutinise the differences in signalling persistence, we compared the short 
time (1-60 min) signalling and the long time (2-48 h) signalling with focus on 
phospho-STAT3, phospho-STAT1 and phospho-ERK1/2. While in NRCM no 
significant differences in signalling duration between both stimuli exist (Fig. 19, 1-60 
min and Fig. 20, 1-48 h), a definite difference between mOSM and hIL-6/sIL-6R 
induced STAT3 and STAT1 phosphorylation is observed between 12 and 48 h in 
NRCFB. Interestingly, hIL-6 trans-signalling induces a clearly prolonged activation of 
STAT1 and STAT3, in contrast to mOSM. This is either due to an intermediate 
cytokine expression or due to a less efficient initiation of the feedback inhibition 
machinery in response to IL-6. However, Stross et al. have shown that classic IL-6 
signalling is even more sensitive to SOCS3 inhibition than OSM signalling in human 
HepG2 and murine embryonic fibroblast321. Moreover, it has already been described 
that SOCS3 induction has a much stronger negative influence on IL-6-type cytokine 
signalling than SOCS1322. As mOSM induces slightly stronger STAT1 and STAT3 
tyrosine phosphorylation (Fig. 16 and 19) and SOCS3 is a direct target of activated 
STAT3 as well as SOCS1 of activated STAT1323, a more potent activation of the 
inhibition machinery after mOSM is rather comprehensible. This discrepancy could 
potentially explain the faster signalling shutdown upon mOSM stimulation. 
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Nevertheless, the differential SOCS3 induction is most likely not the only reason for 
the observed prolonged IL-6 trans-signalling in NRCFB.  
In this study we identified C/EBPβ (formerly known as nuclear factor for IL-6, NF-IL6) 
and C/EBPδ as potential candidates for the differential induction of Il6 transcription 
by IL-6 and OSM. The mRNA levels of both transcription factors are strongly 
upregulated in NRCFB correlating with the induced levels of IL-6 mRNA (Fig. 21). 
The C/EBP transcription factors are known to play important roles in cell proliferation, 
cell differentiation, inflammation and metabolism, but a hypertrophy stimulating role of 
C/EBPβ and C/EBPδ, as indicated in this thesis, is rather novel. Until now, the 
induction of members of this transcription family in response to IL-6-type cytokines 
was mainly observed in epithelial cells, hepatocytes, adipocytes and haematopoietic 
cells231-233, 240, 241, 324, 325. C/EBPβ and C/EBPδ are capable of inducing IL-6232, 233 
potentially mediating an autocrine IL-6-STAT3-C/EBP-IL-6-loop. The potential 
occurrence of an autocrine IL-6 loop demonstrates how important the cellular 
inhibition machinery is. Represented by SOCS proteins, PIAS proteins, 
phosphatases (e.g. SHP2) and receptor internalisation, these molecular brakes play 
important roles in the prevention of overshooting signalling. The prolonged induction 
of C/EBPδ might be an indirect result of an inefficient signalling inhibition. Previous 
studies have already shown that the initial C/EBPδ induction is driven by STAT3 
activity, while a prolonged and constitutive induction is mainly mediated by 
autoregulation235, 239-241, 326. Regarding the results from NRCFB (Fig. 19, 20 and 21), 
it is obvious that mOSM, compared with hIL-6/sIL-6R, induces lower levels of both 
C/EBP mRNAs (Fig. 21). Therefore, it might fail to reach a threshold to activate the 
already mentioned C/EBP autoregulation necessary to induce prolonged IL-6 
transcription. Importantly, we have found no upregulated OSM mRNA levels in 
NRCFB. Thus, any participation of newly synthesised OSM can certainly be 
excluded.  
What might also play a role for the strong difference between both cytokines is the 
fact that IL-6 induces LIF mRNA upregulation, while mOSM does not regulate Lif 
transcription in these cells (Fig. 17A). As shown in Fig. 16, LIF is indeed able to 
mediate signalling in NRCFB, however, not with the potential observed in NRCM. 
This is the result of the low LIFR expression in NRCFB (Fig. 15). In NRCM, LIF 
induces a similar C/EBPβ and C/EBPδ mRNA upregulation as OSM (Fig. 21). Due to 
the comparable C/EBP mRNA induction and the stronger STAT3 activation, LIF is 
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even able to mediate higher initial IL-6 mRNA levels than mOSM. Interestingly, the 
downregulation of Il6 transcription in NRCM following hLIF treatment occurs 
synchronously to the decrease of C/EBPβ and δ levels indicating a direct correlation. 
Furthermore, this downregulation seems to be in line with the strong initial SOCS1 
and SOCS3 upregulation in response to hLIF (Fig. 14). Intriguingly, mOSM that 
initially induces less IL-6 mRNA expression in NRCM (also correlating with C/EBP 
levels) promotes a longer maintenance of IL-6 and C/EBP mRNA levels than hLIF, 
likely via less SOCS induction and weaker SHP2 activation (Fig. 14). 
In contrast to NRCFB, in NRCM hIL-6 trans-signalling is only able to induce slightly 
higher C/EBPβ and C/EBPδ mRNA levels than OSM or LIF (Fig. 21). However, the 
hIL-6/hsIL-6R mediated upregulation of both transcription factors (in combination with 
other transcription factors) is sufficient to allow the strongest Il6 gene induction, 
compared to all other used IL-6-type cytokines. This is a rather surprising finding, 
since hIL-6 plus sIL-6R clearly represents the weakest stimulus on signalling level 
among all tested IL-6-type cytokines in NRCM. So far, we have no substantiated 
explanation for the differential regulation of C/EBP gene expression by various IL-6-
type cytokines in NRCM and NRCFB. One possible mechanism explaining the 
observed discrepancy is a differential methylation status of the C/EBP promoters in 
both cell types leading to a partial reduction of gene expression. This mechanism 
was previously described in cancer cells and can be responsible for different 
transcription efficiencies241, 327. Besides promoter methylation, additional mechanisms 
can be involved in the regulation of C/EBPs. The levels of C/EBP regulation include: 
Translation of either active or inactive C/EBPβ versions (LAP and LIP)231, 
phosphorylation at various phospho-sites231 and the promoter binding of additional 
transcription factors like CREB236, 328 or Runx329. Nevertheless, it has been published 
that the transcriptional induction (primarily via STAT3 activity at the nucleus) of the 
C/EBPs is the most important regulatory level in controlling the activity of these 
transcription factors231. It remains to be elucidated, if the intense IL-6 mRNA 
induction in NRCFB is only the result of the high level Cebpb and Cebpd gene 
induction (maybe in combination with weak SOCS expression), or if further 
mechanisms are involved. 
When comparing NRCM and NRCFB one obvious result attracts attention: While 
induced C/EBPβ mRNA levels were approximately comparable in both cardiac cell 
types, the transcriptional upregulation of C/EBPδ in NRCFB is unequally higher than 
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in NRCM. This is not only true for IL-6 trans-signalling, but also for mOSM induced 
C/EBPδ expression. The underlying molecular mechanism that is responsible for this 
difference remains to be defined. However, this imbalance could serve as further 
explanation for the differential IL-6 induction since both transcription factors might 
form heterodimeric complexes potentiating their transcriptional activity. Nonetheless, 
this hypothesis has to be substantiated in future. Several studies have shown that, 
with exception of C/EBPζ, all other C/EBP family members can form such 
heterodimeric complexes with a respective other family member232, 233, 330-339. As also 
described for STAT heterodimers, this mechanism provides the opportunity to 
expand and diversify the amount of responsive target genes.  
Altogether, these results suggest that hIL-6 trans-signalling in NRCFB strongly 
initiates C/EBPβ and C/EBPδ expression causing IL-6 upregulation, which in turn 
induces C/EBP upregulation and thereby potentially initiates a vicious circle. In the 
context of cardiomyocyte hypertrophy this regulation exhibits a rather harmful 
mechanism that can be considered to maintain hypertrophy for an indefinite time. As 
noted before, NRCFB slightly upregulate their IL-6R expression as well, a result that 
was exclusively observed upon IL-6/sIL-6R treatment (Fig. 17A). Unfortunately, 
secondary stimulation experiments in NRCFB failed, within which we tried to confirm 
IL-6 binding to the newly synthesised IL-6R by secondary pure rat IL-6 stimulation of 
IL-6/sIL-6R pretreated NRCFB.  
 
5.2 Characterisation of the rat OSM receptor complex 
 
As previously mentioned, human OSM and murine OSM significantly differ in the 
usage of their receptors. While hOSM is able to bind and signal via the human type I 
(LIFR/gp130) and type II (OSMR/gp130) receptor complex26, 27, 73, mOSM is only 
capable of binding to the murine type II (OSMR/gp130) complex, because it lacks 
specific affinity sites for the LIFR74. Moreover, cross-species experiments from 
human cells using mOSM and from murine cells treated with hOSM have shown that 
mOSM is not able to initiate any signalling on human cells, while hOSM exclusively 
utilises the murine type I (LIFR/gp130) receptor complex74, 75. Solid information on 
receptor usage of the OSM variants on rat cells has not been published so far. Since 
our previous studies on the hypertrophic potential of IL-6-type cytokines were 
performed using rat cardiac cells treated with hOSM or mOSM, we first analysed the 
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receptor usage of hOSM and mOSM on these cells using the LIFR specific 
antagonist LIF-05254. Later on, when rat OSM became available two years ago, first 
experiments with the new cytokine on human and rat hepatoma cells demonstrated 
clear differences between rOSM and the closely related mOSM. For this reason, we 
decided to characterise the receptor binding and signalling properties of rOSM. More 
specifically, we analysed the receptor usage by classic stimulation experiments in 
hepatoma cells from rat, murine and human origin, LIFR blockade experiments by the 
use of LIF-05, RNA interference experiments targeting the respective OSMR and 
finally by generation of stably transfected Ba/F3 cells either expressing gp130/OSMR 
or gp130/LIFR.  
 
5.2.1 Only rat OSM signals through the rat LIFR/gp130 (type I) and the rat 
OSMR/gp130 (type II) receptor complex 
 
So far, only one research group had made the effort to use OSM from rat origin for 
their experiments with rat cells51. Even in recent studies, within which the role of 
OSM in rat models of human diseases has been determined, OSM from human340-342 
or murine343-346 origin has been used.  
First, we analysed the receptor usage of both OSM variants in NRCM (Fig. 9) and 
NRCFB (Fig. 14). Using the specific LIFR antagonist LIF-05, we clearly could show 
that, analogously to murine cells, hOSM exclusively signals through the rat 
LIFR/gp130 type I complex, while mOSM uses the rat type II OSMR/gp130 receptor 
complex, as it does in murine cells too. In NRCFB, which barely express LIFR, the 
obtained results are absolutely unambiguous: Pretreatment with LIF-05 completely 
abrogates hOSM (and hLIF) signalling in NRCFB, while the antagonist has no 
influence on mOSM induced signalling pathways. Experiments in NRCM indicate that 
mOSM might have a very low affinity for the rLIFR since pretreatment of the cells with 
LIF-05 leads to a slightly reduced STAT3 and STAT1 tyrosine phosphorylation 
(chapter 4.1.4, Fig. 9). This hypothesis might be supported by experiments by Walker 
et al. showing that mOSM stimulates bone formation in Osmr–/– mice347. 
Consequently, the authors postulate that mOSM utilises the mLIFR in osteoblasts. 
However, the presented data regarding the activated signalling pathways are not 
entirely convincing. Furthermore, with focus on all experiments in rat hepatoma cells 
(JTC-27), reduction of mOSM mediated signalling upon LIF-05 treatment was never 
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observed (Fig. 24). Therefore, an alternative and more likely explanation is a 
detectable LIF-05 induced downregulation of signalling pathways activated by 
continuously secreted cytokines (Fig. 9, compare lane 1 and 2). As already 
described, NRCM are able to produce IL-6-type cytokines like LIF, CT-1 and IL-6 that 
are important for cell survival and functionality of these cells, thus serving as 
myokines295. Out of these only LIF and CT-1 signal via the LIFR and, therefore, might 
be responsible for the activation of signalling pathways under basal culture 
conditions. Indeed, the existence of this continuous stimulation by endogenous 
cytokines only becomes apparent when LIF-05 is used, since untreated cells 
normally serve as negative control. Moreover, the decrease of basal signalling can be 
observed in all LIF-05 experiments performed with NRCM. Our data from NRCM, 
NRCFB, JTC-27, Hepa1c1c7 and Ba/F3 cells expressing either rgp130/rOSMR or 
rgp130/rLIFR clearly demonstrate the exclusive type II receptor usage of mOSM and 
its inability to bind to the type I receptor (at least in the concentration used). This is 
completely in line with a study of Lindberg et al. who also attested that mOSM has no 
affinity to the LIFR/gp130 receptor complex74. Moreover, it is possible that, upon 
binding to the LIFR, the antagonist induces internalisation and maybe also co-
internalisation of other receptors in close vicinity (e.g. gp130), independent of the 
typical ligand induced mechanism. This hypothesis would also explain the difference 
between NRCM and NRCFB, because NRCFB clearly express more gp130 
(compare Fig. 11 and 15), therefore remaining unaffected by this effect. Notably, the 
strong negative influence of LIF-05 on hOSM signalling is comparable in both cardiac 
cell types indicating that hOSM exclusively signals through the rat LIFR/gp130 type I 
complex. Moreover, OSMR siRNA experiments in JTC-27 cells served as second line 
of evidence for the definition of the OSM receptor usage. In these cells the reduction 
of OSMR expression levels to 20% by siRNA knockdown results in total inhibition of 
mOSM induced signalling, while hOSM mediated STAT3, STAT1 and ERK 
phosphorylation remains completely unaffected (Fig. 25). Therefore, it can be 
concluded that mOSM utilises the OSMR/gp130 type II receptor complex on cells 
from rat origin.  
With the availability of commercially produced rOSM in 2010, we have set out to 
characterise the receptor usage of this OSM variant. First, the LIFR blockade 
experiments in JTC-27 cells have clearly demonstrated that rOSM does not 
exclusively signal via the rat type I (rLIFR/rgp130) receptor complex, since STAT3 
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and STAT1 phosphorylations are almost completely unaffected upon LIF-05 
treatment (Fig. 24). Notably, we observe an even increased ERK1/2 phosphorylation 
in the presence of LIF-05 what might indicate that the rOSMR/rgp130 complex has 
more potential to initiate MAPK signalling. In contrast, JTC cells expressing only 20% 
of the OSMR after siRNA transfection show a strong decrease of rOSM induced 
ERK1/2 activation, while STAT1 and STAT3 phosphorylations remain mostly 
unaffected (Fig. 25). On the one hand, this clearly implies that rOSM is able to utilise 
the type I and the type II receptor complex, since blocking the LIFR or knocking down 
the OSMR has almost no influence on the rOSM induced STAT3/STAT1 
phosphorylations. On the other hand, both experiments argue for a higher ERK 
activation potential of the OSMR/gp130 receptor complex in comparison to the 
LIFR/gp130 complex. This might be due to the ability of the type II receptor complex 
to recruit SHP2 to gp130137 and Shc to the OSMR141. In contrast, the type I receptor 
complex is only able to recruit SHP2, since the LIFR also recruits SHP2138. However, 
this correlation has to be verified in further studies.  
The final evidence confirming our hypothesis, that rOSM uses both receptor 
complexes, has been obtained from Ba/F3 cells expressing either the type I 
(rgp130/rLIFR) receptor complex or the type II (rgp130/rOSMR) receptor complex 
(Fig. 31). While mOSM is exclusively able to signal via the rat type II receptor 
complex, and hOSM solely utilises the rat type I receptor complex, the rat ortholog 
mediates the phosphorylation of STAT3, STAT1 and ERK1/2 via both receptor 
complexes. This is analogous to the receptor usage of human OSM in human cells26, 
73 and differs strongly from murine OSM74. A fourth OSM variant was cloned several 
years ago, namely bovine OSM. While this cytokine has been shown to activate the 
type I (LIFR/gp130) receptor complex in murine cells348, no characterisation of the 
cytokine was performed using bovine cells. Thus, it is not clear whether the protein is 
able to bind the type I and/or the type II receptor complex on bovine cells.  
 
5.2.2 Rat OSM predominantly signals via the type II receptor complex on 
murine cells and via the type I receptor complex on human cells 
 
As previously mentioned, hOSM is capable of inducing signalling in murine cells 
through binding to LIFR/gp130 heterodimers74, while mOSM utilises the murine type 
II receptor complex74, 75. This is completely in line with our data from murine 
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Hepa1c1c7 hepatoma cells (and murine Hepa1-6 hepatoma cells, data not 
presented), shown in figure 26 and 27. 
Since the mode of action and receptor usage of rOSM on murine cells were 
completely unknown, Hepa1c1c7 cells were stimulated with the cytokine, with or 
without LIF-05 pretreatment (Fig. 26), or after transfection with siRNA targeting the 
mOSMR (Fig. 27). Similarly to our observations in JTC-27 cells, LIF-05 pretreatment 
has no negative influence on rOSM mediated signalling in Hepa1c1c7. This indicates 
that, in Hepa1c1c7 cells, the OSMR/gp130 type II complex is able to rescue the LIF-
05 caused blockade of the LIFR/gp130 type I receptor complex. In contrast to JTC-
27, a clear decrease of the STAT3 phosphorylation in response to rOSM was 
observed upon OSMR silencing in Hepa1c1c7. Nevertheless, this reduction is not as 
strong as in response to mOSM. Moreover, the rOSM induced STAT1 
phosphorylation, that is already weak in untreated cells, is not significantly decreased 
in the presence of OSMR siRNA indicating that the murine type I receptor complex 
might be utilised by rat OSM too. Ba/F3 cells expressing the murine type I or type II 
OSM receptor complex, respectively, would provide the ultimate evidence for the 
receptor usage of rOSM on murine cells.  
In line with data from previous publications23, 73, the results from human HepG2 
hepatoma cells indicate that mOSM has no signalling potential on human cells (Fig. 
28 and 29), while hOSM uses the human type I and type II receptor complex (Fig. 28-
30). Interestingly, OSM from rat origin is indeed able to stimulate human cells, but 
exclusively utilises the human type I receptor complex on HepG2 cells (Fig. 28 and 
29). Experiments, in which we used Ba/F3 cells expressing the human type II 
(OSMR/gp130) receptor complex, have clearly shown that rOSM is not able to induce 
proliferation of these cells by activating the type II receptor complex (Fig. 30). Thus, 
the receptor usage of rOSM on human cells represents the exact reverse cross-
species specificity to the receptor usage of hOSM on rat cells, since both OSM 
variants only utilise the type I receptor complex on cells from the respective foreign 
species.  
 
5.2.3 Possible reasons for the human OSM-like receptor usage by rat OSM 
 
To our surprise, rOSM represents itself more homologous to hOSM than to mOSM 
with regard to its receptor preference. This fact is even more astonishing, when the 
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sequence identities of murine, rat and human OSM are compared. While rOSM and 
mOSM share approximately 60% identical amino acids, the alignment of rOSM and 
hOSM highlights only 49% sequence identity (EBLOSUM62 Matrix, Gap penalty: 
10.0, Extension penalty: 0.5). The described difference in receptor preferences, 
however, would have suggested a higher homology of rOSM to hOSM than to 
mOSM. 
 
Figure 32: Differences in the BC loop of human, murine and rat OSM might be 
responsible for the unequal receptor usage.  
A, Structures of mOSM (amino acids 25-205 of NP_001013383.1, orange) and rOSM (amino acids 26-
207 of NP_001006962.1, green) were modelled using the solved crystal structure of human OSM 
(PDB entry code: 1EVS, red) as template. SWISS-MODEL-Server349-351 was used for molecular 
modelling and PyMOL (DeLano, W.L. (2002) The PyMOL Molecular Graphics System. DeLano 
Scientific, San Carlos, CA, USA) for graphical presentation and structural overlay. B, Sequence 
alignment of murine, rat and human OSM. The sequential alignment was generated using a fold 
algorithm (ProHit package, ProCeryon Biosciences GmbH, Salzburg, Austria). Asterisks indicate 
identical amino acid residues in all three species. Helical regions are accentuated through black 
boxes, and interhelical loops are marked by blue bars. Black bars illustrate amino acids/regions that 
are part of the site 3 (binding site for the LIFR/OSMR)42, 256, 286, 352 in the human cytokine, while red 
bars highlight amino acids/regions that are important for gp130 binding (site 2)256.  
 
 
Nevertheless, sheer sequence alignments frequently fail to explain protein 
differences or similarities and are thereby not suitable to interpret the found 
phenomenon. A study analysing the binding sites of CNTF to the LIFR has indicated 
that there are rather large interfaces between the LIFR and the LIFR binding cytokine 
(CNTF)352. This interacting region of the cytokine, the so-called site 3, consists of 
three structural entities: 1) Amino acid residues of the C-terminal A helix extending 
into the N-terminus of the AB loop, 2) amino acid residues of the BC loop and 3) 
amino acid residues of the C-terminal end of the CD loop reaching into the N-
terminus of the D helix (Fig. 32B, amino acids contributing to the site 3 are marked by 
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black bars). Moreover, the crystal structure of hLIF in complex with the mLIFR 
identified the following residues as essential for LIF-LIFR binding: Pro-51 and Phe-52 
(C-terminus of helix A), Phe-156 and Lys-159 (N-terminus of the D helix)286. While 
corresponding amino acids to Pro-51 and Phe-52 are completely absent in all OSM 
variants, Phe-156 and Lys-159 are not only present in all OSM (including mOSM) 
variants, but can be found in every potential LIFR interacting IL-6-type cytokine (LIF, 
OSM, CT-1, NP, CNTF and CLC). By combining this information with sequence 
comparisons of all three OSM variants, we conclude that differences in the BC loop 
might be responsible for the observed species divergence. As shown in figure 32A 
(hOSM, red structure), the BC loop of crystallised hOSM seems to contain a unique 
feature, a short inter-BC-helix.  
Structural modelling of mOSM and rOSM on the basis of the crystal structure of 
hOSM as template using the SWISS-MODEL-Server349-351 as well as overlaying the 
proposed structures using PyMOL (DeLano, W.L. (2002) The PyMOL Molecular 
Graphics System. DeLano Scientific, San Carlos, CA, USA) revealed important 
findings: First, neither mOSM nor rOSM seem to feature such an inter-BC-helix. 
Second, mOSM has been found to contain an extremely short BC loop, while this 
loop is substantially longer in hOSM and rOSM (Fig. 32A and B). Whether this region 
is definitely essential to allow high affinity binding of OSM to the LIFR has to be 
verified in future by performing mutagenesis experiments (e.g. insertion of the rat 
OSM BC loop into murine OSM). Successful identification of the important residues 
and mutagenesis of mOSM into a human- or rat-like variant would finally allow a 
reliable use of murine cells or mice as adequate model systems. Only a type I and II 
receptor complex binding OSM is accurate to mimic hOSM activity, a fact that should 
no longer be neglected.  
 
5.2.4 Consequences of the use of non-human-like OSM model organisms 
 
As already described, murine OSM lacks the ability to signal via both OSM receptor 
complexes. This difference to human or rat OSM does not remain without 
consequences. OSM is mostly expressed by neutrophils, macrophages, dendritic 
cells and activated T-cells43, 58, 65, 66. High expression levels of the cytokine were 
found in various inflammatory diseases54-57, and the receptor complexes of OSM, 
LIFR/gp130 (type I receptor complex) and OSMR/gp130 (type II receptor complex), 
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are widely expressed. However, up to date the physiological function of OSM is still 
controversially discussed. Hence, pro- as well as anti-inflammatory activities have 
been attributed to the cytokine. For example, administration of recombinant human 
OSM to LPS treated mice induces a strong decrease of LPS mediated TNFα 
secretion, and a prolonged survival of the animals can be observed. In accordance 
with the suppressed inflammatory progress, the degree of joint destruction in these 
mice is reduced, indicative of an anti-inflammatory activity of OSM353. On the other 
hand, intra-articular injection of adenovirus encoded murine OSM mediates a 
rheumatoid arthritis-like phenotype in mice354, clearly representing a pro-inflammatory 
effect of the cytokine. Furthermore, administration of murine OSM neutralising 
antibodies strongly attenuates the symptoms of collagen and pristane induced 
arthritis355 also arguing for a strong pro-inflammatory role of the protein. Similar 
information was collected in a study showing that the inhalation of adenoviral 
particles encoding for murine OSM results in exacerbated infiltration of eosinophils 
into the lung tissue of infected mice60. One possible explanation for these highly 
controversial findings might originate from the fact that OSM from different species 
was used, while all experiments were performed utilising mouse cells or mice, 
respectively. Interestingly, in the study attributing an anti-inflammatory role to OSM, 
recombinant human OSM was injected into mice353. In contrast, the studies arguing 
for a more pro-inflammatory role of OSM made use of recombinant murine OSM60, 
354, 355. As already mentioned, human OSM exclusively binds to the type I 
(gp130/LIFR) receptor complex on murine cells, while murine OSM exclusively 
activates the murine type II (gp130/OSMR) receptor system. Indeed, a recently 
published study describing the phenotypes of mice overexpressing bovine, human 
and murine OSM after retroviral gene transfer confirms this receptor usage and 
demonstrates that mice overexpressing bovine or human OSM display a LIF-like 
phenotype. On the other hand, it has been shown that mice overexpressing murine 
OSM develop a completely different phenotype348. Astonishingly, and in contrast to 
all previously published in vivo studies using retro- or adenovirally encoded murine 
OSM60, 354, these mice display a rather mild phenotype including lymph node 
enlargement, splenic white pulp atrophy and thymic atrophy348. Nevertheless, it 
cannot be excluded that this rather mild phenotype is due to the cloning or 
expression strategy, respectively, used by Juan et al. in their study. In contrast to the 
two studies from Langdon et al. who used processed mOSM (Ala24-Arg206) lacking 
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the N-terminal signal peptide and the C-terminal propeptide27, 59, 354, Juan and 
colleagues overexpressed mOSM, bOSM and hOSM as entire proteins (e.g. Met1-
Ala263 of mOSM) by using respective primers to generate cDNA348. Interestingly, 
Linsley et al. have shown several years ago that the non-processed hOSM form has 
the same receptor binding activity as the processed hOSM, but is 5- to 60-fold less 
active in growth inhibition assays68. In sharp contrast, mOSM that still contains the C-
terminal propeptide seems to have no measurable activity, since supernatants of 
COS cells secreting C-terminally untruncated mOSM have no growth stimulatory 
effect on DA-1 cells, while C-terminally truncated mOSM strongly mediates the 
growth of DA-1 cells356. Thus, it is possible that these mOSM overexpressing mice 
produce an fully or partially inactive form of the cytokine, what finally might explain 
the rather mild phenotype of these mice. Notably, all in vitro studies within which 
human primary cells as well as human cell lines were treated with hOSM indicate 
exacerbated inflammatory gene expression56, 59-64. Because of such divergent results 
and given by the fact that mOSM (on murine cells) cannot correctly reflect the human 
situation, the newly characterised rat OSM offers a more accurate and human-like 
alternative.  
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6 Future Prospects 
6.1 Analysis of the hypertrophic potential of rat OSM 
 
As shown in the result section (4.4), on cells of rat origin rOSM is the only OSM 
variant able to correctly mimic the signalling potential of hOSM on human cells. This 
is due to the capability of rOSM to utilise the rat type I and type II receptor complex, 
just as hOSM on human cells. Furthermore, mOSM exclusively utilises the rat type II 
(gp130/OSMR) receptor complex, while hOSM signals through the exclusive use of 
the rat type I (gp130/LIFR) complex. However, when the hypertrophy project started, 
within which the hypertrophic potential of several IL-6-type cytokines in heart cells 
was analysed, rOSM was not yet commercially produced and the differential receptor 
usage of the OSM orthologs was still unknown. Therefore, the experiments in 
neonatal rat cardiomyocytes and fibroblasts were initially performed using mOSM 
and hOSM. Preliminary data (not shown) comparing the mRNA levels of IL-6, OSMR 
and AT1α upon mOSM and rOSM stimulation indeed indicate that rOSM induces a 
stronger upregulation of these hypertrophy supporting target genes in comparison to 
mOSM. Therefore, hypertrophy assays in response to rOSM treatment will show, 
whether rOSM is a stronger hypertrophy inducer compared to other IL-6-type 
cytokines. Since hLIF/hOSM induce hypertrophy of NRCM utilising LIFR/gp130 
heterodimers and mOSM mediates hypertrophic responses via OSMR/gp130 
heterodimers, the double receptor complex binding cytokine rOSM is considered to 
mediate even stronger myocardial hypertrophy. Additional preliminary data (not 
shown) indicate that rOSM is able to mediate IL-6 expression in NRCFB. Notably, the 
IL-6 protein levels after 5 and 20 h cytokine treatment (data not shown) suggest, that 
IL-6 expression in response to rOSM treatment is highly induced and occurs earlier 
than the mOSM induced IL-6 secretion. Further experiments are required to confirm 
these preliminary data, but it is likely that rOSM has the strongest hypertrophy 
supporting influence on NRCM and NRCFB among LIFR and OSMR utilising 
cytokines, because both receptor complexes are activated.  
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6.2 Analysing the influence of AT1α and ACE induction 
 
The results shown in 4.2.4 demonstrate that mOSM as well as hIL-6/sIL-6R induce 
increased mRNA levels of AT1α and ACE in NRCFB. Since AT1α represents the 
important angiotensin II receptor mediating cardiac hypertrophy, vasoconstriction and 
aldosterone synthesis357, its upregulation by IL-6-type cytokines might be of 
increased interest. Furthermore, the overexpression of this receptor is sufficient to 
induce cardiac hypertrophy263. First, it has to be verified in future experiments, 
whether NRCFB have a higher responsiveness to ATII due to the finding that AT1α 
expression is increased by OSM or IL-6. In addition, this elevated AT1α expression 
might be crucial for maintaining cross-talk with IL-6-type cytokines. As already 
mentioned, ATII seems to be able to induce the secretion of IL-6 in heart tissue 
which, as an effector, mediates cardiac hypertrophy296. Therefore, we might observe 
an increased IL-6 secretion of NRCFB after prestimulating the cells with OSM or IL-
6/sIL-6R, respectively, and later treatment with ATII. This would confirm the 
increased ATII responsiveness of these cells and also indicate that the expression 
levels of AT1α are crucial for the described cross-talk.  
ACE represents a further potential protein of the renin-angiotensin system that seems 
to contribute to IL-6 type cytokine induced hypertrophy. The enzyme catalyses the 
conversion of the mostly inactive angiotensin I to the highly active angiotensin II. 
Whether ACE is truly released from NRCFB has to be confirmed in future 
experiments. The experimental setup to analyse the expression of ACE on protein 
level will be as follows: Stimulation of NRCFB with OSM or IL-6/sIL-6R in the 
presence of angiotensin I. Meanwhile, ACE can be directly detected via ELISA. In 
addition, it is possible to detected the enzymatic conversion to ATII by ELISA. 
Thereby, the amount of produced ATII serves as indirect readout of the existing ACE 
concentrations.  
Furthermore, we want to analyse, if other components of the renin-angiotensin 
system such as angiotensinogen and renin are upregulated by IL-6-type cytokines in 
heart cells at later time points. Already performed experiments determining mRNA 
levels of angiotensinogen and renin upon 18 h stimulation with OSM, LIF or IL-6/sIL-
6R did not show a significant upregulation in NRCFB. On the other hand, it has been 
shown that the cardiac-restricted expression of renin, angiotensinogen and resulting 
ATII can be induced under special conditions (e.g. stretch induced adaptive 
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responses in cardiac fibroblasts and myocytes)358. This local availability of all 
important renin-angiotensin components in the heart is called intracardiac renin-
angiotensin system. This local system can generate active ATII without participation 
of the liver (produces angiotensinogen) or kidney (synthesises renin). Further 
analyses at different time points are required to verify whether some other 
components of the renin-angiotensin system are upregulated upon IL-6-type cytokine 
treatment. Interestingly, mOSM and hIL-6 were already described to potently 
suppress the renin transcription in the murine kidney and in immortalised renin 
producing renal tumor cells of murine origin359, 360. Regarding OSM, one of central 
questions will be whether this transcriptional regulation is only true for mOSM 
exlusively utilising the murine/rat type II receptor complex or also for rOSM signalling 
through the rat/murine type I and the type II receptor complex. Since our 
corresponding experiments in NRCFB and NRCM were performed using mOSM, the 
regulation of renin also will be analysed upon rOSM stimulation. It will be interesting if 
the renin expression is suppressed in the heart as well, because this decrease would 
finally cause attenuation of the ATII synthesis and the described IL-6-ATII-cross-talk. 
Furthermore, the examination of alternatively spliced angiotensin receptors and 
respective enzymes will complete the analyses. The exact expression analysis of 
angiotensinogen and renin in NRCFB or NRCM would be of great interest, since an 
enclosed ATII-IL-6-type cytokine-loop would probably explain the rather harmful 
longterm effects of the cytokine family during development of heart failure.  
 
6.3 Validating the hypertrophic potential of IL-6 in vivo 
 
One of the most important questions in future studies will be, if systemic sIL-6R levels 
are sufficient to allow prolonged IL-6 trans-signalling in the heart. Since we could 
demonstrate that neither NRCM hypertrophy nor the typical signalling pathways are 
induced by pure IL-6 treatment (classic IL-6 signalling), it would be interesting, if sIL-
6R serum levels are partly responsible for cardiac hypertrophy in vivo. Hirota et al. 
have shown several years ago that mice overexpressing hIL-6 and hIL-6R develop 
myocardial hypertrophy, while mice exclusively overexpressing hIL-6 or hIL-6R do 
not199. These data are fully consistent with our in vitro data. However, it cannot be 
excluded that e.g. intravenous application of murine IL-6 has similar effects as those 
observed in the double transgenic mice. Systemic overrepresentation of IL-6 might 
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have a completely different phenotype than the locally restricted cardiospecific 
overexpression of IL-6, because sIL-6R would be continuously present in the serum. 
Since IL-6 binds to the IL-6R with very low affinity (Kd = 5.5 nM), it is possible that 
local overexpression of hIL-6 alone is not sufficient to induce hypertrophy (a local 
event), while circulating sIL-6R together with increased concentrations of IL-6 would 
allow the induction of myocardial hypertrophy under pathophysiological conditions. 
Therefore, it might be of special interest to determine the hypertrophic role of IL-6, 
OSM and LIF in an in vivo model in the presence and absence of soluble gp130 or 
an IL-6R neutralising antibody (equivalent to tocilizumab used to antagonise the hIL-
6R). As tocilizumab is already used for the treatment of rheumatoid arthritis and 
systemic juvenile idiopathic arthritis, this antibody would possibly be beneficial for the 
treatment of cardiac hypertrophy. Indeed, recent publications studying 
polymorphisms of the human IL-6R in patients also postulate a beneficial effect of 
tocilizumab application to treat coronary heart disease361, 362.  
Furthermore, the generation of a conditional cardiomyocyte and/or cardiofibroblast 
specific gp130 (membrane bound and soluble) knockout mouse or rat would be an 
ambitious goal in the future. Unfortunately, the conditional gp130 knockout mice 
described by Betz et al. only showed about 20-30% effectiveness of the knockout in 
the heart and high levels of soluble gp130 were generated by floxing the exon 
encoding for the transmembrane region363. The gp130 knockout mice described by 
Hirota et al. are ventricular myocyte specific, but still produce sgp130214. Thus, the 
observed myocardial abnormalities that interestingly share similarities to IL-6 type 
cytokine induced hypertrophy (thinning of the ventricular walls, decreased myocyte 
diameter and dilated cardiomyopathy in response to pressure overload), are difficult 
to assess.  
 
6.4 Determining the roles of C/EBPs during hypertrophy 
 
Our results shown in 4.3 suggest the participation of C/EBPβ and C/EBPδ in 
prolonging the IL-6/sIL-6R induced hypertrophy. This might be due to an 
autocrine/paracrine loop of IL-6, STAT3 and C/EBPs between NRCFB and NRCM. 
Interestingly, the strong induction of IL-6 mRNA and protein levels obviously 
correlates with the previously mediated upregulation of C/EBPβ and C/EBPδ. The 
different levels of C/EBPβ and C/EBPδ might also explain why mOSM treatment is 
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not able to induce an equivalent prolonged IL-6 secretion in NRCFB in comparison to 
hIL-6 trans-signalling. Further experiments are required to finally prove the correlation 
of C/EBP levels and IL-6 levels. RNA silencing will be the appropriate method to 
determine the participation of both transcription factors in future. Furthermore, since 
several phosphorylation sites of C/EBP are known to increase or decrease the 
transcriptional activity, we will have to examine the phosphorylation status of the 
proteins by Western Blot or mass spectrometry. In the case of C/EBPβ, the ratio of 
LIP and LAP has to be analysed additionally, as LAP is the active form of C/EBPβ, 
while LIP decreases the transcription of C/EBPβ target genes. 
 
6.5 Cloning of a human- and rat-like murine OSM  
 
As demonstrated in 4.4 and discussed in 5.2, mOSM/mOSMR complexes cannot 
correctly mimic the interaction of hOSM with its two receptor complexes. While 
mOSM cannot utilise any receptor complex on human cells, it exclusively signals via 
the type II receptor complex on murine and rat cells. Depending on the LIFR and 
OSMR expression of a respective cell, the consequences of the different receptor 
usage can strongly alter the cell’s response to OSM. Preliminary data of OSM 
induced hypertrophic genes in rat neonatal cardiomyocytes and initiated antiviral 
target genes in rat fibroblasts (data not shown) already indicate that the double 
receptor usage of rOSM truly increases activation of some signalling pathways 
(STAT1, STAT5, p38 and Akt) resulting in transgression of threshold levels required 
to induce gene transcription364 (and not presented data). In both cell types the 
observed differences in mOSM and rOSM responses are much more significant than 
in JTC-27 (see 4.2) indicating that the expression levels of LIFR, OSMR and gp130 
might be different. 
For these reasons and to further analyse the pathophysiological effects of OSM in 
vivo, the cloning of a murine OSM variant utilising the type I and type II receptor is 
indispensable. We therefore recommend the replacement of the mOSM BC loop by 
that of rat OSM and human OSM. These altered mOSM variants could be used for 
stimulation of Ba/F3 cells stably expressing either the murine type I or type II receptor 
complex. As we consider the BC loop of hOSM and rOSM to be the critical region 
contributing to site III (site of LIFR binding), these muteins are expected to bind to 
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both receptor complexes. In contrast to native mOSM or hOSM, they could serve as 
adequate cytokines in murine models of human diseases.  
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7 Summary 
Interleukin-6 (IL-6), oncostatin M (OSM), leukaemia inhibitory factor (LIF) and 
cardiotrophin-1 (CT-1) are members of the IL-6-type cytokine family that is 
characterised by sharing the common receptor subunit gp130. While the involvement 
of these polypeptides in cell differentiation, cell survival, proliferation, apoptosis, 
inflammation, haematopoiesis, immune response and acute phase reaction has 
already been demonstrated, the description of their role in development and 
progression of cardiac hypertrophy is still rather limited and partially controversial. 
For OSM, its modulatory functions on cells of cardiac origin were completely unclear 
at the time this study was initiated. A model has been postulated that declares the 
transient expression of IL-6-type cytokines as protective (e.g. an after myocardial 
infarction), while a continuous cardiac secretion of these proteins seems to be rather 
harmful for the heart.  
 
Within the first part of the study (results 4.1, 4.2 and 4.3) it was shown that OSM 
induces hypertrophy of primary neonatal rat cardiomyocytes (NRCM), just as its 
related cytokines LIF, CT-1 and hIL-6/hsIL-6R (hsIL-6R, human soluble IL-6 
receptor). Regarding the hypertrophic potentials the LIFR/gp130 utilising cytokines 
(hLIF, hOSM and hCT-1) are stronger inducers than the OSMR/gp130 utilising 
mOSM. Human IL-6/hsIL-6R which signals via a gp130 homodimer has the weakest 
hypertrophic effect. The thorough analysis of typical signalling pathways initiated by 
IL-6-type cytokines revealed that STAT3 phosphorylation at Y705 seems to be the 
most important hypertrophy promoting pathway, since it is the only activated 
signalling molecule common to all analysed cytokines. In addition and in contrast to 
published work, we clearly demonstrate that classical IL-6 signalling (upon pure IL-6 
treatment) has no hypertrophic effect on cardiomyocytes, because they lack sufficient 
amounts of the membrane-bound IL-6R. This is also true for neonatal rat cardiac 
fibroblasts (NRCFB). Since these cells can also influence cardiac hypertrophy, 
signalling pathways and target genes were additionally examined in NRCFB in 
response to OSM, LIF and IL-6/sIL-6R. One of the key findings of this thesis is the 
selective change in expression of cytokines and receptors of the IL-6 family in both 
cell types upon IL-6-type cytokine stimulation. Out of the analysed receptor mRNA 
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levels, particularly the OSMR expression is promoted by OSM, LIF and IL-6/sIL-6R. 
Only minor changes occurred in mRNA levels of gp130, LIFR and IL-6R. Analysis of 
the cytokine genes revealed that IL-6 expression is strongly enhanced in NRCM and 
NRCFB, most notably upon IL-6/sIL-6R stimulation. Furthermore, LIF mRNA is 
upregulated by IL-6/sIL-6R and LIF stimulation. OSM, however, suppresses the 
transcription of Lif. A striking difference between NRCM and NRCFB is the fact that 
the target gene induction in NRCM is of similar duration upon mOSM and hIL-6/hsIL-
6R treatment, while hIL-6/hsIL-6R is capable of promoting the induction of OSMR 
and IL-6 significantly longer in NRCFB.  
By searching for transcription factors or intermediate cytokines which could be 
responsible for this difference, a strong correlation between increased Il6 
transcription and amount of mRNA levels for C/EBPβ and C/EBPδ was observed in 
response to IL-6/sIL-6R stimulation. Interestingly, mOSM also mediates the induction 
of C/EBPβ and δ, but the initiation is significantly less efficient than in response to IL-
6/sIL-6R. Therefore, we assume that mOSM stimulation fails to reach threshold 
values required for a prolonged IL-6 secretion. Since we additionally observe a slight 
IL-6R mRNA upregulation in NRCFB, we assume that the combination of IL-6, LIF, 
C/EBPβ, C/EBPδ and IL-6R expression might be responsible for the observed 
different kinetics with which IL-6 and OSM stimulate NRCFB. 
In addition to the aforementioned proteins, members of the renin-angiotensin system 
seem to support the IL-6-type cytokine mediated hypertrophy. While we did not find 
any of these genes to be significantly regulated in cardiomyocytes upon IL-6-type 
cytokine stimulation, we were able to show a significant increase of the angiotensin 
converting enzyme (ACE) and the angiotensin II (ATII) receptor type 1α (AT1α) 
mRNA in NRCFB upon OSM or IL-6/sIL-6R treatment. Since it has already been 
shown that angiotensin II vice versa induces IL-6 expression in NRCM and NRCFB, 
this enhanced expression of AT1α and ACE could be of crucial interest for the 
hypertrophy supporting phenotype.  
 
The second part of the presented work (results 4.4) dealt with the characterisation of 
the receptor complexes of rat OSM that became available as recombinant protein at 
this time. The central question of this analysis was, whether rOSM, just like mOSM, 
only binds the type II (OSMR/gp130) receptor complex or is able to utilise the type II 
and type I (LIFR/gp130) receptor complex, exactly as hOSM. Using different 
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experimental approaches (knock-down of the OSMR expression by RNA 
interference, blocking of the LIFR by LIF-05, an antagonistic LIF variant, and 
generation of stably transfected Ba/F3 cells expressing the newly cloned rat 
OSMR/gp130 or LIFR/gp130 receptor complex) we can clearly show that rat OSM 
surprisingly utilises both, the type I and type II receptor complex. Therefore it closely 
mimics the human situation. Furthermore, rOSM displays cross-species activities and 
stimulates cells of human (HepG2) as well as murine origin (Hepa1c1c7). Its 
signaling capacities closely mimic those of human OSM in cell types of different 
origin in the way that strong activation of the JAK/STAT, the MAP kinase as well as 
the PI3K/Akt pathways can be observed. Therefore, the results obtained in the last 
section of this thesis clearly suggest that rat disease models would allow evaluation 
of the relevance of OSM for human biology much better than murine models. 
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8 Zusammenfassung 
Interleukin-6 (IL-6), Oncostatin M (OSM), Leukämie inhibierender Faktor (LIF) und 
Cardiotrophin-1 (CT-1) sind Mitglieder der IL-6-Typ Zytokin-Familie, welche durch die 
gemeinsame Nutzung der Rezeptoruntereinheit gp130 charakterisiert ist. Während 
eine Beteiligung dieser Polypeptide bei Zelldifferenzierung, Zellüberleben, 
Proliferation, Apoptose, Entzündung, Hämatopoese, Immunantwort und Akut-Phase-
Reaktion bereits gezeigt wurde, ist die Beschreibung ihrer Rolle bei der Entstehung 
und dem Fortschreiten der kardialen Hypertrophie deutlich limitierter und teilweise 
auch kontrovers. Die Wirkungsweise von OSM auf Zellen kardialen Ursprungs war zu 
jener Zeit, in welcher diese Arbeit begonnen wurde, noch gänzlich unklar. Es wurde 
bereits ein Modell postuliert, nach dem die kurzzeitige Expression dieser Zytokine 
(z.B. nach einem Herzinfarkt) schützend wirkt, während eine andauernde kardiale 
Sekretion dieser Proteine eher schädlich für das Herz zu sein scheint. 
 
Innerhalb des ersten Teils der Arbeit (Ergebnisse 4.1, 4.2 und 4.3) konnte gezeigt 
werden, dass OSM wie auch seine verwandten Zytokine LIF, CT-1 und hIL-6/hsIL-6R 
(hsIL-6R, humaner löslicher IL-6 Rezeptor) Hypertrophie-induzierend auf primäre 
neonatale Ratten-Kardiomyozyten (NRCM) wirkt. Hinsichtlich ihres hypertrophen 
Potentials sind die Zytokine, welche über LIFR/gp130 signalisieren (hLIF, hOSM und 
hCT-1), die stärkeren Induktoren im Vergleich zu mOSM, welches den OSMR/gp130 
Rezeptorkomplex bindet. Die Stimulation mit humanem IL-6/hsIL-6R, welches mit 
Hilfe von gp130 Homodimeren signalisiert, hatte hingegen die schwächste 
hypertrophe Wirkung. Unsere genaue Analyse der typischen IL-6-Typ Zytokin 
vermittelten Signalwege enthüllte die Phosphorylierung von STAT3 an Y705 als 
offenkundig wichtigsten Hypertrophie-fördernden Weg, da es das einzige 
Signalmolekül ist, das von allen analysierten Zytokine aktiviert wird. Zusätzlich dazu 
konnten wir auch zeigen, dass klassisches IL-6 signalling (nach purem IL-6) keinen 
hypertrophen Einfluss auf NRCM hat, da diesen Zellen ausreichende Mengen des 
membranständigen IL-6R fehlen. Diese Beobachtung steht in klarem Kontrast zu 
bereits publizierten Arbeiten. In den ebenfalls untersuchten neonatalen Ratten-
Kardiofibroblasten (NRCFB) verhält es sich, was den IL-6R angeht, genauso wie in 
NRCM. Da auch diese Zellen eine kardiale Hypertrophie mit beeinflussen können, 
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wurden in ihnen die gleichen Signalwege und Zielgene nach Stimulation mit OSM, 
LIF und IL-6/sIL-6R untersucht. Die selektive Expressionsregulation von Zytokinen 
und Rezeptoren der IL-6-Familie in beiden Zelltypen nach IL-6-Typ Zytokin 
Stimulation ist hierbei einer unserer wichtigsten Befunde. Innerhalb der untersuchten 
Rezeptor-mRNAs wird speziell die OSMR Expression von OSM, LIF und IL-6/sIL-6R 
induziert. Bezüglich der gp130, LIFR und IL-6R Level waren hingegen nur geringe 
Veränderungen zu detektieren. Innerhalb der Analyse der Zytokin-Gene konnten wir 
in NRCM und NRCFB eine starke IL-6-Expression beobachten, welche besonders 
nach IL-6/sIL-6R Stimulation induziert wird. Des Weiteren regulieren LIF und IL-6/sIL-
6R auch die LIF mRNA Level hoch. OSM supprimiert die Lif Transkription hingegen. 
Ein gravierender Unterschied zwischen NRCM und NRCFB besteht darin, dass die 
mOSM und hIL-6/hsIL-6R vermittelte Geninduktion in NRCM von vergleichbarer 
Dauer ist, wohingegen hIL-6/hsIL-6R die OSMR und IL-6 Expression in NRCFB 
deutlich länger induziert.  
Bei der Suche nach Transkriptionsfaktoren oder intermediären Zytokinen, welche für 
diesen Unterschied verantwortlich sein könnten, beobachteten wir nach IL-6/sIL-6R 
Stimulation eine deutliche Korrelation zwischen der Il6-Transkription und den mRNA 
Mengen von C/EBPβ und C/EBPδ. Auch OSM ist in der Lage beide 
Transkriptionsfaktoren zu induzieren, jedoch viel ineffizienter als IL-6/sIL-6R. Wir 
vermuten deshalb, dass mOSM einen bestimmten Schwellenwert, der für die 
verlängerte IL-6 Sekretion benötigt wird, nicht erreicht. Da wir zusätzlich noch eine 
schwache Zunahme der IL-6R mRNA in NRCFB beobachten konnten, gehen wir 
davon aus, dass die Expression von IL-6, LIF, C/EBPβ, C/EBPδ und IL-6R für die 
unterschiedlichen Kinetiken, mit denen IL-6 und OSM NRCFB stimulieren, 
verantwortlich sein dürfte.  
Zusätzlich zu den erwähnten Proteinen scheinen auch Mitglieder des Renin-
Angiotensin-Systems die IL-6-Typ Zytokin vermittelte Hypertrophie zu unterstützen. 
Während in NRCM keines dieser Gene durch IL-6-Typ Zytokin-Stimulation reguliert 
wurde, konnten wir in NRCFB eine deutlich gesteigerte mRNA Induktion des 
Angiotensin konvertierenden Enzyms (ACE) und des Angiotensin II (ATII) Typ 1α 
Rezeptors (AT1α) detektieren. Da schon gezeigt wurde, dass Angiotensin II reziprok 
die IL-6 Expression in NRCM und NRCFB induziert, könnte diese verstärkte 
Synthese von AT1α und ACE von größter Bedeutung für den Hypertrophie-
unterstützenden Phänotyp sein.  
Zusammenfassung 
 
148 
Der zweite Teil der Arbeit (4.4) beschäftigte sich mit der Charakterisierung der 
Rezeptorkomplexe des Ratten-OSM, das damals erstmals als rekombinantes Protein 
erhältlich wurde. Die zentrale Frage hierbei bestand darin, ob rOSM wie mOSM nur 
den Typ II (OSMR/gp130) Rezeptorkomplex bindet, oder wie das hOSM sowohl den 
Typ II als auch den Typ I (LIFR/gp130) Rezeptorkomplex benutzen kann. Mit Hilfe 
unterschiedlicher experimenteller Strategien (knock-down der OSMR Expression 
durch RNA-Interferenz, LIFR-Blockade durch die antagonistische LIF-Variante LIF-
05, und die Generierung von stabil transfizierten Ba/F3-Zellen, welche die hierzu 
klonierten OSMR/gp130 oder LIFR/gp130 Rezeptorkomplexe der Ratte exprimieren) 
konnten wir eindeutig zeigen, dass Ratten-OSM überraschenderweise beide 
Rezeptorkomplexe benutzt. In dieser Hinsicht verhält sich das Zytokin also wie das 
humane Homolog. Des Weiteren besitzt Ratten-OSM Kreuz-Spezies-Aktivität und 
stimuliert humane (HepG2) und murine Zellen (Hepa1c1c7). Das Signal-Potential von 
rOSM ist dem von humanem OSM auf Zellen unterschiedlichen Ursprungs sehr 
ähnlich. Das Zytokin ist befähigt JAK/STAT, MAP Kinase und PI3K/Akt Signalwege 
potent zu aktivieren. Deshalb deuten die Daten des zweiten Teils dieser Arbeit darauf 
hin, dass Krankheitsmodelle in Ratten die Evaluierung der Relevanz des OSM für die 
humane Biologie deutlich besser widerspiegeln würden als murine Modelle.  
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